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Two diverse works regarding DNA-Drug Interaction are presented here. The 
first portion deals with covalent interactions between compounds that are derivatives 
of heterocyclic aza-enediynes and DNA (conventional Watson-Crick base paired 
double stranded DNA) and the second is related to non-covalent interactions of these 
compounds with G-quadruplex DNA.  
 xii
The aza-enediynes have been studied for their ability to undergo aza-variants 
of the Bergman and Myers cyclizations, and the potential role of the ensuing 
diradicals in DNA cleavage chemistry. The aza-Myers-Saito cyclization of aza-enyne 
allenes that are derived from base-promoted isomerization of skipped aza-enediynes 
has been recently reported. In the first part of the dissertation, the synthesis and DNA 
cleavage chemistry of a series of pyridinium skipped aza-enediynes (2-alkynyl-N-
propargyl pyridine salts) are reported.  Efficient DNA cleavage requires the presence 
of the skipped aza-enediyne functionality, and optimal DNA cleavage occurs at basic 
pH. An optimized analog containing a p-methoxyphenyl substituent was prepared.  
Studies with radiolabeled DNA duplexes reveal that this analog generates non-
selective frank DNA strand breaks, via deoxyribosyl 4’-hydrogen atom abstraction, 
and also leads to oxidation of DNA guanine bases. This is the first report of enediyne-
like radical-based DNA cleavage by an agent designed to undergo an alternative 
diradical-generating cyclization.    
The second part is based upon the growing evidence for G-quadruplex DNA 
structures in genomic DNA and the presumed need to resolve these structures for 
replication. A prototypical replicative helicase - SV40 large T-antigen (T-ag), a 
multifunctional protein with duplex DNA helicase activity is shown to also unwind 
G-quadruplex DNA structures.  A series of G-quadruplex-interactive agents, 
particularly perylene diimide derivatives, is explored for inhibition of T-ag duplex 
and G-quadruplex DNA unwinding activities, and it is revealed that certain perylene 
diimides are both potent and selective inhibitors of the G-quadruplex DNA helicase 
 xiii
activity of T-ag.  Surface plasmon resonance and fluorescence spectroscopic G-
quadruplex DNA binding studies of these T-ag G-quadruplex helicase inhibitors have 
been carried out, demonstrating the importance of attributes in addition to binding 
affinity for G-quadruplex DNA that may be important for inhibition. The 
identification of potent and selective inhibitors of the G-quadruplex helicase activity 
of T-ag provides tools for probing the specific role of this activity in SV40 
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DNA, the master blueprint, is pivotal to the function of cells and is a very 
important drug target; however, in terms of its chemistry (e.g., structure) DNA is 
almost undifferentiated between normal cells and abnormal cells. In cancer 
chemotherapy, we generally rely on the rapid and unregulated cell division and 
metabolism of cancer cells to distinguish them from the healthy cells. However, every 
day, new research emerges helping us understand the differences in molecular 
biology between the two cell types in greater detail, and how these differences would 
allow us to target cancer cells more selectively.  
Even before the elucidation of double-stranded DNA structure, there was a 
drug that targets DNA. Nitrogen mustard (mechlorethamine)1 was the first drug 
approved for clinical use (clinical trial in 1942; FDA approval in 1949) in cancer 
treatment and ushered the era of modern chemotherapy. This first modern 
chemotherapeutic agent is a DNA–interacting agent, modifying DNA by covalently 
binding to the nucleic acid. Currently, many more medicines that act by interacting 
with DNA are playing a huge role in the clinic.  
It was not until April 1953, when Watson and Crick determined the double 
helical structure of DNA 2, 3 and 50 years subsequent to that the sequencing of the 
human genome was announced. The growth of knowledge in the science of nucleic 
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acids has been tremendous; however, there are several areas that still need to be 
explored.  
Besides the Watson-Crick base pair motif in duplex DNA structures, there are 
a variety of higher–order polynucleotide structures. One of the most important, which 
is the focus of nucleic acid-drug design, is G-quadruplex DNA, a structure of whose 
building block is the G-tetrad, a planar array of four guanines with Hoogsteen 
hydrogen bonds.  The story began in 1910 when Bang4 reported guanylic acid gel 
formation, and in the early 1960s Gellert et al. proposed a tetrameric arrangement of 
guanines based on crystallography5 and strengthened by circular dichroism6 and 
infrared7 spectroscopic data. The biological significance of G-quadruplex DNA has 
initially focused on its roles at the telomere.8, 9 Besides telomeres, putative 
quadruplex sequences are predicted throughout the human genome; as many as 
376,000 potential quadruplexes could exist,10 and scientists now believe that G-
quadruplex DNA is also involved in the regulation of gene expression. Moreover, a 
fast growing number of G-quadruplex-interacting proteins are continually being 
discovered. Today, G-quadruplex DNA is one of several targets for anticancer drug 
design. In addition to G-quadruplex structures, several proteins that interact with G-
quadruplex DNA (e.g., telomerases, helicases.) are also attractive targets for drug 
design.  
In this dissertation I will present two diverse works of medicinal chemistry in 
the field of DNA-drug interactions. The first portion deals with compounds that 
covalently interact with and modify conventional Watson-Crick base paired double 
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stranded DNA. The second deals with non-covalent interactions of compounds with 
G-quadruplex DNA.  
The first part of the dissertation will deal with double-stranded DNA cleavage 
arising from interaction with pyridinium-based heterocyclic skipped aza-enediynes 
(chapter 1 - chapter 3). The work commences with the synthesis of pyridinium-based 
heterocyclic skipped aza-enediynes and then structural-based optimization based on 
their ability to cut plasmid DNA. AZB037, the most effective DNA cleavage agent in 
the series was further investigated to better elucidate it’s mechanism of action. 
Detailed studies show that two different mechanisms play a role in DNA breakage. 
One is consistent with hydrogen atom abstraction and the other is consistent with 
guanine oxidation. The first half of chapter 1 provides a general picture of DNA 
damage, and some examples of the means of injury to DNA. The other half of this 
chapter discusses enediynes, aza-enediynes and related cycloaromatizations as well as 
the research Kerwin’s group has focused on in the previous decade, leading up to the 
work that I initiated. Chapters 2 and 3 are focused on my research, the results and 
experimental parts, respectively. 
The second portion of this dissertation is concerned with G-quadruplex (non-
covalently) binding agents. I have used SV40 large T antigen (T-ag) helicase to study 
the effects of a variety of G-quadruplex interactive agents (chapter 4 - chapter 6).  
Chapter 4 gives an overview of G-quadruplex, telomeres, telomerases and helicases 
leading up to the effort to develop anti-cancer agents based on these concepts and 
ends with the examples of selectivity of G-quadruplex interactive agents. Chapter 5 
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and 6 are focused on my work. Firstly, G-quadruplex DNA unwinding activity of T-
ag is shown to be robust and comparable to duplex helicase activity of T-ag. Then, a 
number of G-quadruplex interactive agents were investigated as inhibitors of both G-
quadruplex and duplex DNA unwinding activities of T-ag. Some perylene diimides 
were shown to be potent and selective inhibitors of G-quadruplex DNA unwinding 
activities of T-ag. In collaboration with Mireya Rodriguez and Dr. Wendi M. David, 
binding studies on G-quadruplex binding ligands were performed to explain the 
inhibition of G-quadruplex and duplex DNA T-antigen helicase activities. It was 
demonstrated that in addition to binding affinity, other aspects of G-quadruplex-
interactive agents may be important for effective inhibition of T-ag G-quadruplex 
helicase.  
Finally, this dissertation is completed with a conclusion and proposed future 
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Chapter 1                                                                            
DNA Cleavage, Enediynes and Aza-enediynes 
DNA damage: Jekyll and Hyde  
DNA damage in the context of cancer can be one of two categories, either 
causative or therapeutic. In order to carry on the correct genetic code and to produce 
functional proteins, the accuracy of transcription processes and reliable repair systems 
are very important. DNA damage such as nucleobase modification can generate errors 
in replication leading to mutations which can be associated with cancer. On the other 
hand, damaging DNA is one strategy for fighting cancers. DNA damaging agents are 
one of a large group of chemotherapeutics currently used clinically in cancer 
chemotherapy. Moreover, radiation therapy for cancer also injures cancer cells by 
damaging their genetic material. Nevertheless, in this instance, we will be dealing 
with the therapeutic aspect of this dichotomy. 
The nucleotides in the genetic biopolymers possess a variety of reactive 
regions, such as nucleobases, phosphates and sugars, for DNA damaging agents to 
alkylate, oxidize, or hydrolyze. Besides oxidative damage to DNA, which is 
considered as a major pathway for DNA damage and plays a key role in mutagenesis 




DNA alkylation is the reaction of electrophiles with a nucleophilic site on 
DNA. Heterocyclic nucleobases are the most common targets for electrophiles and 
they generally do not produce direct DNA-strand scission, but can lead to DNA 
cleavage under alkaline condition. Deglycosylation of the alkylated nucleotides forms 
abasic sites which, when followed by phosphate elimination give rise to strand 
scission.  The final products are a 3’ fragment oligodeoxyribonucleotide of the 
original strand containing a terminal 5’-phosphate and a 5’ fragment 
oligodeoxyribonucleotide of the original strand containing a terminal  3’-phosphate, 























































Scheme 1-1 DNA cleavage after the formation of an abasic site 
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Another class of DNA damaging reactions is reaction of radicals with DNA, 
which can abstract a hydrogen atom from the sugar backbone and give rise to either 
direct, or frank, DNA strand breaks or alkaline labile lesions. Radicals can also 
perform hydrogen atom abstraction or addition with the nucleobases. Generally, 
radical associated DNA cleavage gives no sequence selectivity, for instance, hydroxyl 
radicals; however, non-Gaussian DNA cleavage patterns may be seen from non-
diffusible carbon radicals, in which their selectivity usually comes from a specific-
DNA binding moiety of those particular molecules.  
DNA damage derived from hydrogen atom abstraction 
For radical related DNA damage via hydrogen atom abstraction, some 
examples of the more common sites of DNA damage that have been well studied will 
be discussed, these sites are the deoxyribose H-1’, H-4’ and H-5’ positions (Figure 1-
1). Moreover, these sites are pertinent to naturally occurring enediynes such as 
























Abstraction of H-1’ 
Examples of agents that give rise to hydrogen atom abstraction at C-1’ include 
Cu(OP2),4, 5, 6, 7  Mn-TMPyP48, 9, 10 and natural enediynes, e.g., neocarzinostatin,11, 12 
calicheamicin,13, 14 dynemicin A,15, 16 C-1027.17  In a double stranded B-DNA, H-1’ is 
deeply embedded in the minor groove and the least accessible among deoxyribose 
hydrogen atoms.18, 19 In the case of neocarzinostatin, after abstraction of H-1’, the 
addition of molecular oxygen to C-1’ radical can occur to yield peroxyl radical. The 
reduction of peroxide radical gives to rise 2-deoxyribonolactone and free base.20, 21 
Base treatment, e.g., hot piperidine, of this abasic site leads to DNA strand scission,22, 
23 resulting in methylene lactone sugar portion, 3’ fragment oligodeoxyribonucleotide 
of the original strand containing a terminal 5’-phosphate and 5’ fragment 




















































Scheme 1-2  H-1’ abstraction pathway for DNA strand scission 
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Abstraction of H-4’ 
The abstraction of H-4’ can be observed by a variety of DNA-damaging 
agents, such as hydroxyl radical, natural enediynes, and bleomycin.24 The 4’ 
hydrogen atom is thought to be very accessible in double stranded B-form DNA.19, 25  
The products from C-4’ radicals resulting from hydrogen atom abstraction are 4’-
hydroxylated abasic site (alkali-labile site) and 3’-phosphoglycolate (frank strand 
break).   The C-4’ radicals react with molecular oxygen and give rise to the 
peroxide,26 which, in the presence of thiol, then gets converted to the hydroperoxide, 
and the hydroperoxide product generates frank strand break via Criegee 
rearrangement. Following hydrolysis the final products obtained are 5’-phosphate 
terminal DNA fragment,  3’-phosphoglycolate DNA fragment and base propenal.27 
Alternatively, in the presence of reducing agent, C-4’ radical can be hydroxylated and 
generate a 4’-hydroxylated abasic site.28, 29 Elimination yields strand cleavage with 
5’-phosphate terminus and an alkaline labile intermediate, 4’-keto-1’-aldehyde-
terminal strand. Base treatment would give rise to a DNA strand with a 3’-phosphate 
terminus.30 Nevertheless, the 3’-phosphoglycolate terminated DNA fragments serves 
as the signature of H-4’ abstraction products. With 5’-radiolabeled DNA fragments, 
the 3’-phosphoglycolate terminal product can be readily detected by high resolution 
PAGE, in which this particular product posses slightly faster gel mobility with respect 



































































































Scheme 1-3  H-4’ abstraction pathway for DNA strand scission as carried out in the 




Abstraction of H-5’ 
H-5’ abstraction can be generated by neocarzinostatin,33 C1027,17, 34 hydroxyl 
radical,18 and Mn-TMPyP4.10 The H-5’ is a major site of H atom abstraction leading 
to DNA cleavage by natural enediynes including neocarzinostatin.  The C-5’ radical 
reacts with molecular oxygen to yield the peroxide which when subjected to 
subsequent reactions yields the 5’-nucleoside aldehyde and 3’-phosphate ending 
DNA fragment. Upon alkaline treatment, the 5’-terminal aldehyde containing DNA 
fragment produces a 5’-terminal phosphate DNA fragment, free base and furfural. 
The production of furfural, which can be detected by HPLC, can be used as a 















































Scheme 1-4  H-5’ abstraction pathway for DNA strand scission 
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There are several reviews focused on DNA strand scission initiated by radical 
reactive species, for instance, Pogozelski W.K. and Tullius, T.D., 1998,36 Burrows 
C.J. and Muller, J.G. 1998,37  and Greenberg, MM 1998.38   
Oxidation of guanine nucleobase    
DNA oxidation is probably the largest contributor to DNA damage, and can 
result in damage to all four nucleobases and deoxyriboses introducing base mutation, 
DNA strand breakage and disrupting enzymatic processes. Oxidative DNA 
modification is involved in many pathophysiological processes, including cancers. 
There are many different oxidative DNA modifications described,39, 40, 41  yet, the 
main one is the formation of 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxo-dG). 
Guanine is the most easily oxidized among DNA bases.42, 43 After one electron 
oxidation, deprotonation of the oxidation product rapidly occurs giving rise to 
deoxyguanine radical cation lession.44 Hydration and a further one-electron oxidation 
of this nucleobase radical cation intermediate generates the 8-oxo-dG  lesion in the 
DNA strand.45  Single oxygen could also perform one-electron chemistry and give 
rise to 8-oxo-dG.46 The formation of 8-oxo-dG can also be accomplished by other 
means, for instance, the addition of hydroxyl radicals to C8 position of guanine 
nucleobase, which is a major product of DNA damage by hydroxyl radicals.47 
Although, 8-oxo-dG is an earmark of DNA oxidation, this lesion is prone to further 
oxidation. The oxidative decomposition of 8-oxo-dG residues yields the 
guanidinohydantoin which is prone to deglycosylation.48 The detection of 8-oxo-dG 
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can be accomplished by HPLC with an electrochemical detector.49 Furthermore, in 
the presence of an oxidant or molecular oxygen, treatment of 8-oxo-dG with a base 
such as hot piperidine leads to DNA strand cleavage.50, 51 Alternatively, the reduction 
of 8-oxo-dG hydration product yields 2,6-diamino-5-formamidino-4-hydropyrimidine 






































































Several agents are capable of causing DNA damage via a radical based 
mechanism. The enediynes belong to a class of agents that have been extensively 
studied for their anticancer properties arising from a radical based DNA cleavage 
mechanism. 
The naturally occurring enediyne antitumor antibiotics contain two acetylenic 
groups conjugated to double bond [(Z)-3-ene-1,5-diyne] which can undergo a 
Bergman cyclization to form a diradical intermediate, 1,4-didehydrobenzene.53, 54 The 
diradical species can abstract a hydrogen atom from the deoxyribose sugar backbone 
of DNA, resulting in DNA strand scission.33, 55 The naturally occurring enediynes are 
very potent antitumor agents, for instance, calicheamicin is more than 8000 times 
more potent that adriamycin,  and over 1000-fold more potent than mitomycin C and 
vincristine in the mice model.56 The naturally occurring enediyne antitumor 
antibiotics are biosynthesized by Actinobacteria, e.g., Micromonospora, 
Actinomadura, and Steptomyces, as well as tunicate ascidians, which are in symbiosis 
with Micromonospora sp. Based on the ring size of the enediyne core, these natural 
endiynes can be grouped into two classes, naturally occurring, 9-membered ring 
enediynes (Figure 1-2), e.g., neocarzinostatin, the first described enediyne 
antibiotic,57, 58 kedarcidin,59, 60, 61 C-1027,62, 63, 64 maduropepetin,65  and N1999A266  
and naturally occurring, 10-membered ring enediynes (Figure 1-3), e.g., 
calicheamicin γ1I,67, 68, 69 esperamicin,70, 71 dynemicin A,72, 73 namenamicin,74 
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shishijimicin75  and uncialamycin.76 With the exception of N1999A2,66 members of 
the 9-membered ring enediynes are chromoproteins comprising of an enediyne 
chromophore and an apoprotein which non-covalently binds and stabilizes the 
chromophore; while the 10-membered ring enediynes are relatively more stable and 























































































































































































Unfortunately, these enediyne antitumor antibiotics are extremely toxic and 
nonspecific in their activity, which makes them very harmful to healthy cells and 
limits their clinical use. Several research groups in this area, however, have focused 
on achieving selectivity for cancer cells and simplifying the complexity of natural 
enediyne antitumor antibiotics. For instance, poly(styrene-co-maleic acid)-conjugated 
neocarzinostatin was approved  in Japan for treatment of hepatoma,77 gemtuzumab 
ozogamicin (Mylotarg®) , a CD33 monoclonal antibody-calichemycin conjugate was 
approved in United State for treating acute myeloid leukemia.77, 78, 79, 80, 81, 82, 83  
The mechanism of action of endiyne antitumor antibiotics is based on 
electronic rearrangement of enediyne core moiety. The (Z)-3-ene-1,5-diyne reactive 
core undergoes cycloaromtization such as a Bergman cyclization to form a diradical 
intermediate. The diradical species can abstract a hydrogen atom from the 
deoxyribose sugar backbone of DNA, resulting in DNA strand scission.53, 54, 84 
Generally, DNA cleavage by naturally occurring enediynes begins with the 
recognition of and binding to DNA. This process is aided by the DNA binding 
domains of the molecules, e.g., the naphthoate of neocarzinostatin, the carbohydrate 
side chains of calicheamicin and esperamicin, or anthracycline portion of dynamycin. 
Binding is followed by the activation of enediynes toward electronic rearrangements 
(Bergman or Myers-Saito cyclization). The cycloaromatization gives rise to 
diradicals, which are the reactive species and finally, abstraction of hydrogen atoms 
from DNA leading to DNA strand scission.  
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The natural endiyne antitumor antibiotics, such as, calicheamicin and 
esperamicin, contain an allylic methyl trisulfide moiety which acts as a trigger to 
initiate aromatization to generate a diradical species of enediyne core. Beginning with 
bioreductive activation of the allylic trisulfide to a thiolate anion, followed by 
Michael addition of the thiolate, the structural rigidity from the bridgehead double 
bond is eliminated permitting the Bergman cyclization of the enediyne and generating 
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Scheme 1-6  Bioactivation of calicheamicin 
 
In the case of dynemicin A, which contains an epoxide and anthraquinone unit, the 
triggering mechanism involves a redox mediated activation and opening of the 
epoxide.  First, the reduction of anthraquinone to hydroquinone takes place and 
rearrangement to open the epoxide gives a semiquinone methide. Further protonation 
leads to quinone alcohol which relieves ring strain and reduces distance between the 
 22
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Scheme 1-7  Bioactivation of dynemicin A 
 
In the case of chromoproteins such as C-1027, the apoprotein not only 
specifically targets the chromophores to DNA but also protects it from premature 
degradation. These chromophores are not stable when unbound to the apoprotein.62, 86 
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Upon exposure to DNA, a cycloaromatization occurs, generating biradicals and 
resulting in DNA cleavage.  
Since neocarzinostatin is comprised of a different conjugate core system, activation of 
neocarzinostatin arises from a different mechanism that begins with nucleophilic 
attack by a thiol group (e.g., glutathione) and subsequent epoxide ring opening to 
generate an enyne cumulene. Then, cycloaromatization of  an enyne cumulene 














































Among enediyne antitumor antibiotics, the DNA cleavage chemistry of the 
neocarzinostatin chromophore has been extensively documented especially by 
Goldberg’s research group at Harvard medical school.  The diradical reactive species 
can abstract hydrogen atoms from the sugar backbone at the minor groove, resulting 
in a single stranded break or double stranded cleavage. The single-stranded break is 
mainly via a H-5’ abstraction by the C6 center of the diradical species, which occurs 
mostly at T residues. 91 In contrast, the double stranded DNA scissions are sequence 
specific, AGC•GCT or AGT•ACT (cleavage site underlined), and involve the 5’, 4’ 
or 1’ hydrogen atom abstractions by radical centers at C2 and C6 of diradical 
species.11 The lesion at AGC•GCT site contains a pyrimidinic abasic site caused by 
H-1’ abstraction leading to the formation of 2-deoxyribonolactone at C residue; on 
complementary strand, 5’-GCT-3’, H-5’ abstraction yields frank stand break via the 
formation of a 5’-nucleotide aldehyde. On the other hand, the lesion at AGT•ACT, 
either H-4’ abstraction (89% of the lesion) or H-5’ abstraction (11% of the lesion) 
occurs at T residue of 5’-AGT-3’. The H-4’ abstraction results in either a 4’-
hydroxylated abasic site generation or a 3’-phosphoglycolate-terminated fragment. 
On the complementary strand, 5’-ACT-3’, strand cleavage occurs at the T residue due 





Bergman cyclization and Myers-Saito cyclization 
The cycloaromatizations of enediynes occurs by a process that was first 
described by Robert Bergman,93 generating diradicals, which lead to DNA cleavage. 
This reaction, known as the Bergman cyclization is also the basis of the mechanism 
of action for several synthetic derivatives of enediynes. Alternatively, Myers-Saito 
cyclization which is the rearrangement of the enyne allene system was inspired by 
neocarzinostatin chromophore. 
In 1972, Jones and Bergman reported the thermal cycloaromatization of (Z)-
hex-3-ene-1,5-diyne to 1,4-didehydrobezene, a transformation now commonly called 
the Bergman cyclization. the p-benzyne diradical may abstract hydrogen atoms from 
suitable hydrogen atom donors or may undergo a retro-Bergman cyclization.93 The 
cyclization of (Z)-hex-3-ene-1,5-diyne to 1,4-didehydrobezene is an endothermic 
process with an activation energy of 32 kcal/mol as reported by Bergman93 and 28.33 




























In 1989, Myers’s group and Saito’s group independently reported the 
cyclization of Z-1,2,4-heptatrien-6-yne (enyne-allenes) undergoing Myers-Saito 
cyclization (C2-C7) cyclization to α,3-didehydrotoluene diradical which abstracts 
hydrogen atoms from hydrogen atom donors  such as 1,4-dicyclohexadiene.87, 89  This 
process is exothermic by 15 kcal/mol and the half life of (Z)-1,2,4-heptatrien-6-yne is 















Scheme 1-10  Myers-Saito cyclization 
 
Thermolysis of (Z)-1,2,4-heptatrien-6-yne demonstrated the polar character of 
the Myer-Saito cyclization intermediate; in methanol this reactive intermediate is 
trapped to form methyl benzyl ether in addition to phenylethanol. It was proposed that 
methyl benzyl ether product was formed via a zwitterionic intermediate. Later, 
Carpenter’s group suggested that enyne allene directly forms the zwitterions and then 






















Scheme 1-11  Myers-Saito cyclization (C2-C7) from thermolysis of (Z)-1,2,4-
heptatrien-6-yne 
  
Later on, in 1995, Schmittel and co-workers96, 97, 98, 99 and others100, 101 
reported an alternate cyclization of enyne allenes in which joins positions C2 and C6  










Scheme 1-12  Schmittel cyclization 
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In addition to lacking the aromaticity of the Schmittel cyclization product, 
computational studies demonstrated that Schmittel cyclizations have much higher 
activation barriers than Myers-Saito cyclizations (about 10 kcal/mol, ∆G‡ = 25 vs. 35 
kcal/mol).102  However, enyne allenes may favor Schmittel cyclization when radical 
stabilizating substituents such as aryl or bulky alkyl groups are introduced at terminal 
alkyne position. Other factors like steric effects103, 104 or ring strain effects104 also 
affect the relative barriers of the Myers-Saito cyclization and Schmittel cyclization. 
Aza-enediynes and aza-Bergman cyclization 
David and Kerwin in 1997, reported a new variation of enediynes, the 3-aza-
enediynes (C,N-dialkynyl imines); these aza-enediynes undergo an aza-Bergman 
cyclization to 2,5-didehydropyridine diradical intermediates. However, the diradical 
intermediate, 2,5-didehydropyridine, could not be trapped; instead, (Z)-β-alkynyl 
acrylonitrile, derived from the retro-aza-Bergman rearrangement, was the exclusive 








Scheme 1-13  Aza-Bergman Cyclization 
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A sp2-nitrogen substituted in the enediyne core disturbs π-delocalization as 
compared with enediyne, and nitrogen also decreases repulsion of the in plane π-
orbital in the transition state. These facilitate the cycloaromatization of aza-enediynes. 
Moreover, computations suggest that the barrier for the aza-Bergman cyclization is 
lower than the barrier for the Bergman cyclization,106 and the barrier for the ring 
opening reaction of 2,5-didehydropyridine, the retro-aza-Bergman rearrangement, to 
the thermodynamically stable (Z)-β-alkynyl acrylonitrile is also low.107 In order to 
access the diradical intermediate, the retro-aza-Bergman reaction must be prevented. 
Upon the protonation of the nitrogen, the retro-aza-Bergman rearrangement of the 
2,5-didehydropyridinium to the nitrilium is more difficult than in the case of 2,5-
didehydropyridine.108 This also means that the protonation of didehydropyridines may 
facilitate hydrogen abstraction.109 Moreover, calculations have indicated that 
protonation of the nitrogen causes the aza-Bergman rearrangement to be less 
exothermic compared to the non-protonated case.106 
Research on aza-enediynes in Kerwin’s research group continued with Feng 
and co-workers studying a series of 6-unsubstituted and 6-triisopropylsilyl substituted 
1-phenyl-4-aryl-3-aza-hex-3-ene-1,4-diynes. Both aza-enediynes undergo aza-
Bergman reaction, but rapidly undergo retro-aza-Bergman rearrangement to obtain β-








Ar = Ph,  4-(OMe)Ph,  2-(OMe)Ph  
Scheme 1-14  Rearrangement of aza-enediyne to β–alkynyl acrylonitrile 
Nevertheless, Chen and co-workers documented the detection of small 
amounts of pyridine products by GC/MS in the thermolysis of the aza-enediyne under 
acidic conditions.106 
Aza-enyne allenes and aza-Myers-Saito cyclization 
Also from Kerwin’s research group, Feng and co-workers synthesized skipped 
aza-enediynes (C-alkynyl-N-allenyl imines) that isomerizes to the corresponding aza-
enyne allene under basic conditions. The aza-enyne allene could not be purified, 
because cyclization occurs readily at subambient temperatures; in the presence of 1,4-
cyclohexadiene, this aza-enyne allene undergo an aza-Myers-Saito cyclization 
resulting in 6-phenyl-3-picoline and other products corresponding to the trapping of 

















Scheme 1-15  Cyclization of aza-enyne allene 
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Heterocyclic skipped aza-enediyne  
To apply the aza-Myers-Saito cyclization to the design of potential DNA 
cleavage agents, both the potential hydrolytic lability and the stereochemical 
isomerization of the imine double bond were addressed by incorporation of this 
moiety into a heteroaromatic ring. The Kerwin lab has previously reported the 
preparation and DNA cleavage properties of two different series of such heterocyclic 
skipped aza-enediynes.112, 113, 114 First, the benzothiazolium series, exemplified by 
AZB005, serve as electrophiles, leading to DNA adducts that undergo guanosine-
specific cleavage after piperidine/heat treatment.112, 113 Interestingly, in this series, the 
presence of a skipped aza-enediyne functionality, such as, AZB004, is not required 
for the G-selective cleavage activity; the N-methyl benzothiazolium triflate AZB004 









Figure 1-4  Benzothiazolium aza-enediynes 
 
Secondly, the benzimidazole system, exemplified by AZB017 showed 
supercoiled DNA cleavage activity, while AZB001 and AZB006, which lack the 
skipped aza-enediyne functionality, do not show any appreciable cleavage.112 The 
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benzimidazole skipped aza-enediyne derivative AZB017 forms DNA adducts leading 











Figure 1-5  Benzimidazole aza-enediyne and benzimidazolium aza-enediynes 
 
The difference in the covalent DNA interactions in the benzothiazolium and 
benzimidazolium series demonstrates that the identity of the heterocyclic system can 
have a pronounced effect on the DNA cleavage chemistry; however, in neither case is 
there evidence for DNA cleavage involving hydrogen-atom abstraction from the 
DNA backbone, as would be expected for an aza-Myers-type cyclization process.  
Nevertheless, with heterocyclic skipped-aza-enediynes, 4-aza-3-ene-1,6-
diynes, different DNA cleavage mechanisms are feasible,  this core structure might 
isomerize to the aza-enyne allene (Scheme 1-16, B) which may undergo cyclization 
analogous to aza-Myers-Saito or aza-Schmittel cyclization and produce reactive 
diradical intermediates (Scheme 1-16, C or D). The direct addition of DNA, serving 




































Scheme 1-16  Proposed reaction pathway of DNA cleavage by aza-enediynes  
 
In conclusion, the skipped aza-enediyne incorporated heterocyclic system 
displays a potential of being customizable, since the difference in heterocyclic 
framework obviously gives different character in DNA breakage properties. We 
believe that modulation of the heterocyclic framework will be a tool to optimize the 
generation of diradicals by the cyclization of heterocyclic skipped aza-enediynes and 
direct the lead candidate towards better DNA cleavage agents. Moreover, it is also 
significant to understand how this particular group of compounds does react with 
DNA and, if the free radical is generated by cyclization, how they behave with the 
oligonucletides in an aqueous environment.  
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Here, in the Kerwin Lab, I present the synthesis of DNA cleavage chemistry 
of pyridinium-based skipped aza-enediynes, and demonstrate that, for this 
heterocyclic system, efficient DNA cleavage requires the presence of the skipped aza-
enediyne functionality and that optimal DNA cleavage is observed for an analogue 
bearing a p-methoxyphenyl group on the pyridinium 2-alkyne substituent. Detailed 
studies on this analog show that DNA cleavage occurs through hydrogen-atom 
abstraction from the DNA backbone and oxidation of guanine bases. To the best of 
our knowledge, this is the first report of radical-based DNA cleavage by compounds 
designed to undergo diradical-generating cyclization reactions akin to the Bergman, 
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Chapter 2                                                                            
DNA Cleavage Chemistry of Pyridinium-Based Heterocyclic Skipped         
Aza-Enediynes 
 
The interest of  the enediyne Bergman cyclization (Scheme 1-9) continues 
because of its fundamental role in the mechanism of DNA cleavage by natural and 
designed anticancer agents.1, 2  The p-benzyne diradical intermediates generated by 
these thermal cyclizations are capable of abstracting hydrogen atoms from the 
deoxyribose backbone of DNA, leading to DNA strand cleavage and ultimately cell 
death.3 Inspired by the proposed enyne cumulene cyclization of neocarzinostatin, 
Myers and Saito independently proposed an analogous diradical-generating 
cyclization (C2-C6) of enyne allenes (Scheme 2-1).4, 5, 6 The Myers-Saito cyclization 
also gives rise to products corresponding to the trapping of an ionic intermediate, 
formulated as the zwitterion, particularly when these cyclizations are carried out in 
polar solvents such as methanol (Scheme 2-1).4, 5, 6 A different diradical-generating 
C2-C6 cyclization of enyne allenes was first reported by Schmittel et al (Scheme 2-1).7  
Enyne allenes that have been designed to undergo either Myers-Saito8, 9 or Schmittel 
cyclizations10, 11 have been shown to cleave DNA. In the case of enyne allenes that 
undergo Myers-Saito cyclizations, G-selective DNA cleavage has been observed, 
which has been proposed to arise either from electrophilic attack on the DNA by the 










Scheme 2-1  Myers-Saito (C2-C7), and Schmittel (C2-C6) Diradical-Generating 
Cyclizations 
 
Diradical-generating cyclizations analogous to Bergman, Myers-Saito and 
Schmittel cyclizations have been proposed for DNA cleavage applications of hetero-
enediynes or hetero-enyne allenes. These heteroatom variants of the Bergman and 
Myers-Saito cyclizations may have advantages over the all-carbon systems in the 
design of DNA cleavage agents because of their inherently lower cyclization barriers 
which had been demonstrated in Kerwin’s lab14, 15, 16   and the possibility of 
modulating the reactivity of the resultant diradical through protonation in the acidic 
tumor environment.17 When some of these heteroatom variant cyclizations are 
allowed to proceed in organic solvents, products corresponding to the trapping of 
diradical intermediates are observed,16, 18, 19, 20, 21, 22, 23, 24  the ability of hetero-
enediynes or hetero-enyne allenes to effect DNA cleavage in aqueous solution has not 
been widely demonstrated, and in the few cases where DNA cleavage has been 
observed, it is not clear that this proceeds through hydrogen-atom abstraction or by 






















Recently, Kerwin’s research group reported aza-Myers-Saito cyclization of a 
C-alkynyl-N-propargyl imines (skipped aza-enediynes) to α-5-didehydropicoline 
diradical through the intermediate aza-enyne allene (Scheme 1-15). To apply this aza-
Myers cyclization to the design of potential DNA cleavage agents, I prepared a new 
series of heterocyclic skipped aza-enediynes by incorporating the skipped aza-
enediyne into pyridinium- heterocyclic framework and studied their DNA cleavage 
chemistry. 
Synthesis of pyridinium-based skipped aza-enediynes.  
 
A series of pyridine-based skipped aza-enediynes 17a-h were synthesized by 
Sonogashira coupling30, 31 of 2-bromopyridines 12a or 12h with a variety of terminal 
acetylenes to afford the 2-alkynyl pyridines 16a-h, which were subjected to alkylation 
with propargyl triflate32 to afford the skipped aza-enediynes (Scheme 2-2 and Table 
2-1). A number of related pyridinium compounds were also prepared by 
propargylation of pyridines lacking a 2-alkynyl substituent (19-21, Scheme 2-2) and 
by methylation of selected 2-alkynyl pyridines (18a, 18d, and 18e, Scheme 2-2 and 
Table 2-1). All final pyridinium triflate salts were isolated as hygroscopic solids that 
were purified by either washing with cold ether or recrystallization. These salts were 
characterized by 1H and 13C NMR, low- and high-resolution mass spectrometry, and 











































12a. R = H, X  = Br
12h. R = Me, X = Br
13.   R = H, X = H
14.   R = H, X = CH2CH2Ph
15.   R = H,  X = CF2
X = H, CF3, or 
      CH2CH2PH
19.  X = H (88%)
20.  X = CH2CH2Ph (5%)
21.  X = CF2 (37%)
for 16, 17, and 18
      
a.  R = H, R' =  H 
b.  R = H, R' =  TMS 
c.  R = H, R' =  TIPS 
d.  R = H, R' =  Ph                    
e.  R = H, R' =  4 -CF3-C6H4
f.   R = H, R' =  4 -(OCH3)-C6H4   [AZB037]
g.  R = H, R' =  3,4,5-(OCH3)3-C6H2 




Scheme 2-2  Synthesis of pyridinium skipped aza-enediynes related compounds
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b 58 64 NAc 
c 34 34 NAc 
d 30 72 97 
e 19 49 98 
f 25 68d NAc 
g 63 54 NAc 
h 
 
50 66 NAc 
 












Supercoiled DNA cleavage studies 
 
An initial evaluation of the DNA cleavage ability of the synthesized 
pyridinium skipped aza-enediynes and related compounds were carried out using 
supercoiled DNA cleavage assays. It was expected that the propargyl/allene 
isomerization required for subsequent aza-Myers-Saito cyclization of these skipped 
aza-enediynes would occur more readily at higher pH; therefore, DNA cleavage 
assays were performed at both pH 7 and 8. After agarose gel electrophoresis, the 
amounts of supercoiled, nicked relaxed, and linear DNA products were determined; a 
representative gel is shown for compound 17f [AZB037] (Figure 3-1). To quantify 
the DNA cleavage activity of these compounds, at least three individual experiments 
for each compound at each pH were performed and results are reported as the average 
EC25, the concentration of compounds required to produce 25% normalized DNA 



















Figure 2-1  Supercoiled DNA cleavage by AZB037. Supercoiled ФX174 phage DNA 
(50 µM base pairs) was incubated alone (lane CTR) or with 0.1, 1, 10, 50, 100, and 
500 µM 17f [AZB037] in 50 mM Tris buffer at pH 8 and 13% (v/v) DMSO for 12 h 
at 37 ºC and analyzed by gel electrophoresis (1% agarose, ethidium bromide stain). 
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     Compound 
 
 
  pH 7 










16f ndb > 100 
17b 4.6 ± 1.5 9.8 ± 2.3 
17c 23.0 ± 5.2 23.5 ± 6.5 
17d 15.5 ± 1.5 10.5 ± 1.5 
17e 21.5 ± 8.5 11.5 ± 1.5 
                  17f [AZB037] 6.8 ± 1.7 1.8 ± 1.0 
17g 28.0 ± 3.0 16.1 ± 1.2 
17h 16.5 ± 0.5 16.5 ± 0.4 
18a 37.8 ± 5.2 39.0 ± 3.0 
18d > 100 > 100 
18e > 100 > 100 
19 ndb > 100 
20 > 100 > 100 
21 
 
39.5 ± 3.5 44.3 ± 7.3 
aConcentration of the compound required to effect 25% normalized DNA cleavage, 




All of the pyridinium skipped aza-enediynes examined effect significant 
single-stranded DNA nicking at concentrations in the low micromolar range (Table 2-
2). With the exception of the two silyl-substituted analogues 17b and 17c, the DNA 
cleavage by the pyridinium skipped aza-enediynes is between 1.5 and 3.8 times more 
efficient at pH 8 than pH 7. Examination of the series 17d, 17e and AZB037, in 
which substitution on the 2-phenylethynyl moiety is varied, demonstrate a modest 
electronic effect on the DNA cleavage activity. The electron-donating p-
methyoxyphenyl-substituted analogue AZB037 is the most active DNA cleavage 
agent in this series, followed by the phenyl analogue 17d, which is slightly more 
active than the p-trifluoromethylphenyl analogue 17e. However, increasing the 
number of methoxy groups from one to three, as in 3,4,5-trimethoxyphenyl analogue 
17g, does not result in increased DNA cleavage activity over AZB037. The origin of 
these substituent effects may involve a balancing of electronic effects or a steric 
preference about the 2-ethynyl substituent. In either case, the p-methoxyphenyl 
analogue AZB037 is not only the most effective DNA cleavage agent within this 
pyridinium series, it is also a more effective DNA cleavage agent than any of the 
previously reported heterocyclic skipped aza-enediynes.27, 28 Besides, the presence of 
all three forms of DNA (supercoiled form I, nicked relaxed form II, and linear form 
III) was observed at one or more concentrations of the skipped aza-enediynes 17d,e,g 
and AZB037; however, statistical analysis33 showed that the double-stranded DNA 
cleavage activity of these compounds was less than 5% of their single-stranded DNA 
nicking activity. 
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The DNA cleavage results summarized in Table 2-2 demonstrate that the 
skipped aza-enediyne functionality is generally required for efficient DNA cleavage 
activity. With two exceptions, none of the compounds that lack the skipped aza-
enediyne functionality demonstrates any appreciable DNA cleavage activity. The N-
methyl-2-ethynyl pyridinium salt 18a shows weak DNA cleavage activity, as does the 
N-propargyl-2-trifluoromethyl pyridinium salt 21. None of the other N-methyl 
pyridinium salts (18d and 18e) or N-propargyl pyridinium salts (19 and 20) examined 
cleaved DNA to any appreciable degree at concentrations up to 100 µM, the highest 
concentration examined. 
The propensity of 2-ethynyl pyridinium salts to undergo nucleophilic addition 
has been noted.34 We found that the N-propargyl-2-ethynyl compound 17a was 
unstable in nucleophilic solvents such as methanol, which precluded its evaluation in 
these DNA cleavage assays. On the basis of these observations, it is likely that the N-
methyl-2-ethynyl pyridinium triflate 18a acts as an electrophile toward DNA, leading 
to DNA cleavage in this assay. The 2-trifloromethyl-N-propargyl pyridinium salt 21 
also displays DNA cleavage activity, although only at concentrations approximately 
twice as high as the weakest DNA cleaving skipped aza-enediyne. N-Propargyl 
pyridinium salts can also undergo nucleophilic attack.35 To probe the nature of the 
supercoiled DNA cleavage because of AZB037 and 21 in more detail, inhibitor 
studies were carried out. While the DNA cleavage by both AZB037 and 21 were 
inhibited by equimolar dithiothreitol (DTT) (35% and 70% inhibition, respectively) 
(Figure 2-2A), only the DNA cleavage by 21 was inhibited by NaN3 and KBr (Figure 
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2-2B). The sensitivity of 21 to the presence of nucleophiles such as KBr may indicate 
that the DNA cleavage by this compound proceeds through a different mechanism 










































































































Figure 2-2  Effect of inhibitors on the supercoiled DNA cleavage by AZB037 (A) 
and 21 (B).  Supercoiled ФX174 DNA (50µ M base pairs) was incubated with 
500 µM 21 and 25 µM AZB037 and various concentrations of mercaptoethanol 
(MCE), dithiothreitol(DTT), NaN3, KBr, and glycerol (pH 8, 50 mM Tris buffer, 13% 
v/v DMSO, 24 h at 37 °C) and analyzed by gel electrophoresis (1% agarose, ethidium 
bromide stain). The percent inhibition of DNA cleavage is shown for each 
concentration of inhibitor, expressed as a ratio of inhibitor concentration to DNA 
























Investigation of the DNA cleavage mechanism of pyridinium skipped aza-
enediyne 
 
Pyridinium skipped aza-enediyne-mediated DNA cleavage leads to sequence-
independent, frank-strand breaks and G-selective cleavage after piperidine/heat 
treatment.  
The pyridinium salt AZB037 demonstrates the most pronounced, pH-
dependent supercoiled DNA cleavage activity of the heterocyclic skipped aza-
enediynes examined; thus, this compound was selected for further studies. The 
sequence  and/or base preference and nature of the DNA cleavage was examined 
using 229 base-pair singly 5’-32P-labeled duplex DNA oligonucleotide, prepared as 
previously described.36 Incubation of the labeled DNA with AZB037 in Tris buffer at 
pH 7 for 16 h at 37 ºC followed by gel electrophoresis of the DNA products reveals a 
sequence-independent DNA cleavage that does not require post-incubation 
piperidine/heat treatment (Figure 2-3A). DNA cleavage reactions that were treated 
with 10% piperidine at 95 ºC for 15 min prior to electrophoresis show, in addition to 
an enhancement in the non-sequence selective cleavage, a more pronounced, G-
selective cleavage pattern (Figure 2-3B). Under these conditions, the sequence-
independent, frank DNA cleavage by AZB037 is significant at concentrations of 50 
µM and higher, whereas concentrations of AZB037 as low as 1 µM result in 
significant DNA cleavage after piperidine/heat treatment. The frank DNA strand 
cleavage by AZB037 occurs slowly over a period of hours; significant frank DNA 
cleavage is seen after 1-2 h, with a maximum in frank DNA cleavage after 12 h in the 
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presence of 250 µM AZB037 (Figure 2-4).  As expected, compound 16d, lacking of 
skipped aza-enediyne moiety, which does not cleave supercoiled DNA (vide supra), 
also does not produce any DNA cleavage products when incubated with the 5’-
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Figure 2-3 Cleavage of 5’-labeled DNA by pyridinium triflate AZB037 leads to 
sequence-independent, frank-strand scission and G-selective cleavage after 
piperidine/heat treatment. Singly 5’-32P-labeled double-stranded DNA (L151, 229 bp) 
was incubated with 0, 1, 10, 50, 100, 250, and 500 µM AZB037 (lanes 0-6) in 50 mM 
Tris buffer at pH 7 and at 37 ºC for 16 h. (A) Samples were subjected to 
phenol/chloroform extraction and EtOH precipitation, followed by gel 
electrophoresis. (B) Samples were treated the same as in A  but heated at 90 ºC for 15 
min in 10% piperidine before gel electrophoresis. Lanes G, GA, and CT are Maxam-
































Figure 2-4  Time-course for the frank and piperidine-heat-dependent DNA cleavage 
by AZB037. Double-stranded, 5’-32P-labeled DNA (L151, 229 bp) was incubated 
with 250 µM AZB037 in 50 mM Tris buffer at pH 8 and at 37 ºC for 0 (lanes 1, 7), 1 
(lanes 2, 8), 2(lanes 3, 9), 6 (lanes 4, 10), 12 (lanes 5, 11), and 24 h (lanes 6,12) and 
analyzed by electrophoresis (lanes1-6), or treated with hot piperidine (90 ºC for 15 
min) prior to electrophoresis. Lanes G, GA, and CT are Maxam-Gilbert sequencing 
reaction products. 
1    2    3     4    5     6    7     8     9   10   11   12 G    GA  CT
GCGGA CTACG CCATA AAA
GAGGA ATGCG TAGAC ACGCC
CGTG




Figure 2-5  DNA cleavage by 17d but not 16d. Double-stranded , 5’-lable DNA 
(R378, 229 bp) was incubated with 500 µM 16d or 17d in 10 mM tris buffer pH 7, at 
37 ºC. Sample were extracted with chlorofrom/phenol, subjected to ethanol 
precipitation, and treated with 10% piperidine (95ºC, 15 min) prior to electrophoresis. 
Lane 1 and 4 are controls in the absence of add compound. Lane 2 and 3 are reaction 
mixtures incubated with 16d for 1 and 2 h, respectively; Lane 5 and 6 are reaction 
TTCCGCTAATTCAA
GCCCG GAGAA 





   1    2    3     4    5    6   G   GA CT    
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mixtures incubated with 17d for 1 and 2 h, respectively. Lane G, GA and CT are 
Maxam-Gilbert sequencing reaction products. 
The DNA cleavage because of AZB037 is not light-dependent.  
Separate DNA cleavage reactions were carried out in the presence of AZB037 
(50 µM) in the dark and under irradiation with a sun lamp for 2 h. As shown in Figure 
2-6, the DNA cleavage proceeds equally well under both conditions. Similarly, no 
difference was noted when supercoiled DNA cleavage assays were carried out in the 



























Figure 2-6 DNA cleavage because of AZB037 does not require light. Singly 5’-32P-
labeled double-stranded DNA (L151, 229 bp) was incubated with 50 µM AZB037 in 
50 mM Tris buffer at pH 7 for 2 h in the dark (lane a) or with irradiation using a sun 
lamp (65 W, 25 cm in distance) (lane b). Incubation mixtures, which contained 1 µg 
of calf thymus DNA, were subjected to phenol/chloroform extraction, ethanol 
precipitation, and 10% piperidine at 95 ºC for 15 min prior to electrophoresis. Lanes 
G, GA, and CT are Maxam-Gilbert sequencing lanes. 
 
a  G   GA CT   b
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AZB037 cleavage duplex DNA in the pH dependent manner. 
The pH dependence of DNA cleavage by AZB037 was investigated by 
carrying out incubations of 5’-radiolabeled DNA with 50 µM AZB037 in phosphate 
buffer (pH 6) and Tris buffer (pH 7, 8, and 9), followed by piperidine/heat treatment 
and electrophoresis. As shown in Figure 2-7, the DNA cleavage was most 
pronounced at pH 9, and at both pH 8 and 9, cleavage at all sites was observed, with 
enhanced cleavage at all G residues. At lower pH, weaker, G-selective cleavage was 
observed. These results are in qualitative accordance with the supercoiled DNA 
cleavage studies, in which AZB037 was 3.8 times more effective at pH 8 compared to 
pH 7 (vide supra). The isomerization of N-propargylic imines to the corresponding 
allenes requires basic conditions.14, 15   The pH dependence of the DNA cleavage by 
AZB037 may similarly reflect a requirement for isomerization of the propargylic 
substituent prior to the cleavage event. The nature of the pH-dependent DNA 
cleavage exhibited by AZB037 is distinct from that observed for the benzothiazolium 
salt AZB004 and the benzimidazolium skipped aza-enediyne AZB017. The 
guanosine-selective DNA cleavage by AZB004 is pH-independent between pH 6 and 
9,28 and the benzimidazole AZB017 causes cytosine-selective cleavage at pH 6 and 7 



















Figure 2-7 DNA cleavage by AZB037 is pH-dependent. Double-stranded, 5'-labeled 
DNA (L151, 229 bp) was incubated with 50 µM AZB037 in pH 6 and 10 mM sodium 
phosphate buffer or pH 7, 8, or 9 and 10 mM Tris buffer at 37 ºC for 2 h. DNA 
reaction samples were extracted with phenol/chloroform, subjected to ethanol 
precipitation, and treated with 10% piperidine (95 ºC, 15 min) prior to 
electrophoresis. Lanes 1, 3, 5, and 7 are DNA-incubated in the absence of AZB037 at 
pH 6, 7, 8, and 9, respectively. Lanes 2, 4, 6, and 8 are DNA-incubated with AZB037 
at pH 6, 7, 8, and 9, respectively. Lanes G, GA, and CT are Maxam-Gilbert 
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G-selective cleavage is due to singlet-oxygen-independent guanine oxidation.  
Several possible origins of the G-selective DNA cleavage by AZB037 
observed after piperidine/heat treatment were explored. As has been observed with 2-
alkynyl benzothiazolium salts,28 selective alkylation of guanine residues in DNA can 
lead to stable adducts that undergo cleavage upon treatment with hot piperidine, in 
analogy to the Maxam-Gilbert G-selective cleavage reaction with dimethyl sulfate. In 
the case of the 2-alkynyl benzothiazolium triflate AZB004, these adducts can be 
observed as low-mobility electrophoretic bands.36 A 5’-32P-labeled 14 base-pair 
duplex was incubated with 500 µM AZB004 or AZB037 at 37 ºC, for 2 h, and the 
DNA products were immediately subjected to gel electrophoresis (Figure 2-8). While 
the incubations with AZB004 afford a band migrating more slowly than the 
unmodified, labeled DNA (lane 1 in Figure 2-8), no such band is observed in the case 
of AZB037. These results indicate that AZB037 does not form an adduct with the 
DNA or, if an adduct is formed, it cannot be resolved by gel electrophoresis under 
these conditions. This later possibility is unlikely, given the ready detection by gel 
electrophoresis of adducts formed between short duplex oligonucleotides and the 
related compounds AZB004 (Figure 2-8) and AZB017.27, 36 













Figure 2-8  Pyridinium skipped aza-enediyne AZB037 does not form a stable adduct 
with DNA. A 5’-32P-labeled 14-mer duplex was incubated alone (lane Ctr) or with 
500 µM AZB004 in 10 mM sodium phosphate buffer at pH 6 (lane 1) or 500 µM 
AZB037 in 10 mM sodium phosphate buffer at pH 6 (lane 2), pH 7 (lane 3) or pH 8 
(lane 4) and 37 ºC for 2 h, and the products were analyzed by electrophoresis. No 
low-mobility adduct is observed in the case of AZB037. 
 
Guanine is the most easily oxidized DNA base, and a number of oxidants, 
such as singlet oxygen, lead to G-selective cleavage of DNA.37, 38 In addition to the 
lack of evidence for a photochemical mechanism of DNA cleavage (vide supra), the 
possible involvement of singlet oxygen in the G-selective DNA cleavage by AZB037 
is excluded by the observation of equal DNA cleavage efficiency in D2O and H2O.39, 
40 (Figure 2-9)  
 
Ctr 1      2       3      4
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Figure 2-9 Solvent isotope effects on the DNA cleavage due to AZB037 and singlet 
oxygen. Double-stranded, 5’-labeled DNA (R378, 229 bp) was incubated with 50 µM 
AZB037 in 10 mM sodium phosphate buffer pH 7 at 37 ºC for 2 h in H2O (lane 2) or 
D2O (lane 3) or irradiated (65 W sun lamp, 15 cm in distance) in the presence of in 5 
µM rose Bengal for 70 min in H2O (lane 5) or D2O (lane 6). Lane 1 and 4 are control 
in H2O in the absence of AZB037 or rose Bengal. All sample were subjected to 
phenol/chloroform extraction, ethanol precipitation, and treatment with 10% 
piperidine (95 ºC, 15 min) prior to electrophoresis. 










However, there is evidence that the G-selective cleavage by AZB037 proceeds 
through guanine oxidation. Incubation of calf thymus DNA with AZB037 followed 
by enzymatic hydrolysis and analysis by HPLC with electrochemical detection reveal 
the formation of 8-oxo-dG (5.7 ± 0.4/105 mol of dG). The ratio of 8-oxo-dG/dG in 
DNA incubated in the presence of AZB037 is over 100 times greater than the ratio of 
DNA incubated in the absence of AZB037 (0.046 ± 0.006/105 mol of dG).  
Frank DNA strand scission is due to deoxyribosyl hydrogen-atom abstraction.  
The sequence-independent, frank-strand scission of DNA by AZB037 is 
similar to that observed by the hydroxyl radical.41  A difference between the DNA 
cleavage because of AZB037 and that because of hydroxyl radicals is the sensitivity 
of the later to specific cosolvents. The rate of reaction between the hydroxyl radical 
and DMSO42  is over 300 times faster than that for acetonitrile.43  The addition of 5% 
of DMSO as a cosolvent in hydroxyl radical DNA cleavage reactions causes near 
complete inhibition of the DNA cleavage, when compared to the cleavage in the 
presence of 5% acetonitrile (Figure 2-10 B). In contrast to this very pronounced 
inhibitory effect of DMSO on the DNA cleavage because of hydroxyl radicals, there 
is only a very subtle effect of DMSO cosolvent on the DNA cleavage because of 
AZB037 (Figure 2-10 A). 
The ability of the minor-groove binding DNA ligand distamycin A to inhibit 
the DNA cleavage by AZB037 was also investigated. The 229 bp, 5’-labeled DNA 
oligonucleotide was incubated with AZB037 (500 µM) in phosphate buffer at pH 8 
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for 2 h at 37 ºC in the absence or presence of distamycin A (1-500 µM), and the DNA 
cleavage products were resolved by PAGE after piperidine/heat treatment. Under 
these conditions, the DNA cleavage by AZB037 is predominantly sequence-
independent in the absence of distamycin A (lane 1 in Figure 2-11). In the presence of 
distamycin A, the DNA cleavage because of AZB037 is selectively inhibited at sites 
on the 229-bp-labeled DNA oligonucleotide containing four or more consecutive AT 
base pairs (lanes 2-4 in Figure 2-11). The observation of a distamycin A "footprint" 
indicates that attack by AZB037 occurs from the minor groove face44 of the DNA 






























Figure 2-10  DNA cleavage because of AZB037 is relatively insensitive to DMSO. 
(A) 5’-Labeled double-stranded DNA (L151, 229 bp) was incubated with 500 µM 
AZB037 in 50 mM Tris buffer at pH 8 and 37 ºC for 12 h in the presence of either 
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(B) 5’-Labeled double-stranded DNA (L151, 229 bp) was subjected to a hydroxyl 
radical generated by the Fenton reaction [0.05% H2O2, 1.5 mM L-ascorbic acid, 15 
µM Fe(NH4)2(SO4)2, and 0.3 mM EDTA] in 50 mM sodium phosphate at pH 8 and 
room temperature for 2 min in the presence of either 5% DMSO (lanes 5 and 6) or 
































Figure 2-11  Distamycin inhibits the cleavage of DNA by AZB037 by blocking 
access to the minor groove. Double-stranded, 5’-labeled DNA (L151, 229 bp) was 
incubated in the presence of various concentrations of distamycin A (0, 1, 10, and 100 
µM, lanes 1-4) in 50 mM phosphate buffer at pH 8 and 37 ºC for 15 min, followed by 
the addition of AZB037. After an additional 2 h, the DNA was purified by 
phenol/chloroform extraction and ethanol precipitation, followed by treatment with 
10% piperidine (95 ºC, 15 min) and electrophoresis. The sequence to the right of the 
figure corresponds to regions of protection from AZB037-mediated DNA cleavage in 
the presence of distamycin A. 





To more closely examine the nature of the DNA products formed in the 
presence of AZB037, a 5’-labeled, 14 base-pair duplex oligonucleotide was incubated 
with 500 µM AZB037 for 14 h at 37 ºC and the DNA products were analyzed by 
high-resolution PAGE, both before and after piperidine/heat treatment. As a control, 
the DNA products formed by treating the labeled DNA with hydroxyl radicals were 
also analyzed. Hydroxyl radicals42 and other radical-based DNA cleavage agents1, 45, 
46 that abstract the 4’-hydrogen atoms from the minor groove of DNA lead to the 
formation of 3’-phosphoglycolate-terminated DNA fragments. As shown in Figure 2-
12, the expected 3’-phosphate-terminated and 3’-phosphoglycolate-terminated DNA 
products of hydroxyl radical DNA cleavage are resolved as a doublet of bands at each 
cleavage site, with the less abundant 3’-phosphoglycolate-terminated products 
migrating slightly faster than the more abundant 3’-phosphate-terminated products, 
which are identical to the products of Maxam-Gilbert sequencing reactions. A 
comparison of the products of hydroxyl radical cleavage to those produced by 
AZB037 prior to piperidine/heat treatment (lane 1 in Figure 2-12) demonstrates that 
AZB037 also affords 3’-phosphoglycolate-terminated DNA cleavage products, 
although, in the case of AZB037, the ratio of the 3’-phosphoglycolate-terminated to 
3’-phosphate-terminated products is lower than in the case of the hydroxyl radical. 
After piperidine/heat treatment of the DNA treated with AZB037, additional cleavage 
affording 3’-phosphate-terminated products is observed at all cleavage sites but 
especially at G residues (lane 2 in Figure 2-12). While the presence of 3’-
phosphoglycolate-terminated DNA cleavage products is commensurate with 
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deoxyribose 4’-hydrogen-atom abstraction,46 it is possible that other sites of 
deoxyribose hydrogen-atom abstraction are involved in the DNA cleavage by 
AZB037. Attack at other hydrogen atom sites in the minor groove of DNA, including 
the deoxyribose 5’ position, leads to 3’-phosphate-terminated products.46, 47 The 
deoxyribose 4’ and 5’ hydrogens line the edge of the DNA minor groove, where 
negative-charge density is highest.48 It is possible that cationic AZB037 or the 
corresponding aza-enyne allene forms weak, sequence-independent electrostatic 
associations with DNA that may help position it for hydrogen-atom abstraction at 


























Figure 2-12  Pyridinium triflate AZB037 cleavage of DNA produces 3’-
phosphoglycolate-terminated products (arrow pointed). A 5’-labeled 14-mer duplex 
oligonucleotide was incubated with AZB037 (500 µM) in 50 mM Tris buffer at pH 7 
for 14 h at 37 ºC, and the DNA cleavage products were compared to those generated 
by the hydroxyl radical [0.05% H2O2, 1.5 mM ascorbate, 15 µM Fe(NH4)2(SO4)2, and 
0.3 mM EDTA for 2 min at room temperature]. Lane 1, AZB037. Lane 2, AZB037 
followed by piperidine/heat treatment. Lane •OH, hydroxyl radical. Lanes G, GA, and 
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The above results show that the pyridinium skipped aza-enediyne AZB037 
cleaves DNA through two pathways. The observation of sequence-independent, 
frank-strand scission, distamycin footprints, and 3’-phosphoglycolate products all 
indicate a radical-based DNA cleavage mechanism involving deoxyribose hydrogen-
atom abstraction. The lack of inhibition by DMSO and the ratio of 3’-
phosphoglycolate-terminated/3’-phosphate-terminated products observed with 
AZB037 indicate that diffusible hydroxyl radicals are not involved in the DNA 
hydrogen-atom abstraction. Although the identity of the radicals (or diradicals) 
responsible for the DNA hydrogen-atom abstraction in the presence of AZB037 is not 
known, certain observations point to a role of aza-Myers or aza-Schmittel cyclization 
in this process. Efficient DNA cleavage requires both the presence of the skipped aza-
enediyne moiety and basic pH, which may induce the isomerization of the skipped 
aza-enediyne to the aza-enyne allene required for diradical-generating cyclization. 
Attempts to identify the trapping products of this cyclization have not been successful 
because of the complexity of reaction mixtures when AZB037 is incubated under 
DNA cleavage reaction conditions (The difficulty in isolating hydrogen atom trapping 
products of C2-C6 cyclization of 1-hepta-1,2-dienyl-2-(2-phenyl)ethynyl-benzene has 
been noted).11  
The second pathway of DNA cleavage by AZB037 leads to G-selective 
cleavage products after piperidine/heat treatment. The inability to detect DNA 
adducts with AZB037 and the observation of 8-oxo-dG products indicate that this G-
selective cleavage proceeds through DNA oxidation. This DNA oxidation does not 
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require light and is not mediated by singlet oxygen. On the basis of the DMSO 
inhibition results, it is also unlikely that this oxidation is mediated by hydroxyl 
radicals. One possible, unifying mechanism to account for both the sequence-
independent, frank DNA strand scission and the G-selective DNA cleavage by 
AZB037 involves guanine H8 hydrogen-atom abstraction or oxidation by a species 
derived from AZB037 after aza-Myers or aza-Schmittel cyclization.37 However, the 
details of the mechanism for DNA oxidation by AZB037 are not clear, and alternative 
processes that do not involve cyclization cannot be excluded at this time.  
Conclusions 
In conclusion, I have reported the synthesis of a series of N-propargyl-2-
alkynylpyridinium triflates as pyridinium-based skipped aza-enediynes that may 
undergo base-promoted isomerization and cyclization to diradicals capable of 
cleaving DNA. The efficient DNA cleavage by these pyridinium salts requires the 
presence of the skipped aza-enediyne functionality and basic pH but does not require 
light. Detailed analysis of the DNA cleavage by one member (AZB037) of this class 
has shown that two pathways for DNA cleavage exist. One pathway leads to 
sequence-independent, frank DNA strand scission through deoxyribose 4’-hydrogen-
atom abstraction. The second pathway leads to G-selective DNA cleavage after 
piperidine/heat treatment. This second pathway involves DNA oxidation and the 
formation of 8-oxo-dG.  
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Radical-based DNA cleavage agents based on enediyne or enyne allene 
diradical-generating cyclizations are known; nonetheless, this is the first example in 
which a heteroatom variant diradical-generating cyclization has been employed in the 
design of a DNA cleavage agent that demonstrates radical-based DNA cleavage 
products. The ease of preparation of these pyridinium skipped aza-enediynes makes 
them attractive for further elaboration and optimization through, for example, the 
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Chapter 3                                                                                 
Experimental Procedure: DNA Cleavage Chemistry of Pyridine-Based 
Heterocyclic Skipped Aza-Enediynes 
Synthesis of pyridine-based heterocyclic skipped aza-enediynes 
General Procedures. Unless otherwise noted, all materials were obtained 
from commercial suppliers and used without further purification. Ether and 
tetrahydrofuran were distilled from sodium/benzophenone immediately prior to use. 
Dichloromethane, dichloroethane and pyridine were distilled from calcium hydride 
immediately prior to use. Triethylamine and N,N-diisopropylethylamine were distilled 
from calcium hydride and stored over potassium hydroxide pellet. Copper (I) iodide 
was purified by stirring the CuI in a saturated KI solution, diluting with H2O and 
filtering and drying the resultant solid, which was stored under argon. All reactions 
were performed under argon in oven-dried glassware. 
Unless otherwise noted, NMR spectra were determined in CDCl3 on a 
spectrometer operating at 300 MHz (1H), 75 MHz (13C) and 282 MHz (19F). Unless 
otherwise noted, mass spectra were obtained by chemical ionization using methane as 




General Procedures: Sonogashira Couplings with 2-Bromopyridine.1 A 250 mL 
three-necked flask equipped with a condenser was purged with argon and quickly 
fitted with a U-shaped adapter connected to a 5 mL round-bottomed flask charged 
with Pd(PPh3)2Cl2 (0.57 g, 0.81 mmol). CuI (0.095 g, 0.50 mmol), triethylamine (60 
mL), trimethylsilyl acetylene (3.06 g, 30.5 mmol), and 2-bromopyridine (3.97 g, 25.1 
mmol) were placed into the reaction flask. The reaction was initiated by the addition 
of the palladium catalyst, and the reaction mixture was heated under reflux for 18 h. 
The reaction mixture was filtered through activated alumina, which was subsequently 
washed with EtOAc. The combined filtrate was washed with saturated NaHCO3, 
water, and brine. The solvent was dried (Na2SO4) and evaporated, and the 2-alkynyl 





2-Trimethylsilanylethynylpyridine (16b). Kugelrohr distillation afforded 
2.62 g (58% yield). 1H NMR δ: 0.27 (s, 9 H), 7.20 (ddd, 1 H, J = 7.8, 3.6, 1.2 Hz), 
7.43 (ddd, 1 H, J = 7.8, 1.8, 1.2 Hz), 7.62 (ddd, 1 H, J = 7.8, 7.8, 1.8 Hz), 8.54 (ddd, 1 
H, J = 3.6, 1.8, 1.8 Hz). 13C NMR δ: 0.7, 94.3, 103.3, 122.6, 126.8, 135.7, 142.6, 






2-[(Triisopropylsilanyl)ethynyl]pyridine (16c). Kugelrohr distillation 
afforded 2.58 g (34% yield). 1H NMR δ: 1.09-1.16 (m, 21 H), 7.21(ddd, 1 H, J = 7.5, 
4.8, 1.2 Hz), 7.46 (ddd, 1 H, J = 7.8, 1.2, 0.9 Hz), 7.62 (ddd, 1 H, J = 7.5, 7.5, 1.8 
Hz), 8.58 (ddd, 1 H, J = 4.8, 1.8, 0.9 Hz). 13C NMR δ: 11.3, 18.5, 91.8, 105.6, 122.8, 
127.6, 136.0, 143.1, 149.6. MS m/z: 260 (MH+). HRMS m/z: calcd for C16H25NSi, 




2-(Phenylethynyl)pyridine (16d). Purification by flash chromatography 
(siliga gel, 10% EtOAc in hexane) afforded 0.54 g (30%) of 16d. 1H NMR δ: 7.21 
(ddd, 1 H, J = 6.5, 4.8, 1.2 Hz), 7.24-7.35 (m, 3 H), 7.50 (ddd, 1 H, J = 6.7, 1.1, 1.1 
Hz), 7.56-7.59 (m, 2 H), 7.64 (ddd, 1 H, J = 7.7, 7.7, 1.8 Hz), 8.59 (ddd, 1 H, J = 4.8, 
1.8, 1.1 Hz). 13C NMR δ: 88.6, 89.2, 122.2, 122.7, 127.1, 128.3, 128.9, 132.0, 136.1, 






2-(4-Trifluoromethylphenylethynyl)pyridine (16e). Purification by flash 
chromatography (silica gel, 60% EtOAc in hexane) afforded 1.37 g (19%) of 16e. 1H 
NMR (500 MHz) δ: 7.25 (ddd, 1 H, J = 5.8, 4.8,1.0 Hz), 7.52-7.54 (m, 1 H), 7.59-
7.61 (m, 2 H), 7.67-7.70 (m, 3 H), 8.62 (ddd, 1 H, J = 4.8, 1.8, 1 Hz). 13C NMR (125 
MHz) δ: 87.4, 90.6, 123.8 (q, CF3, JCF = 272 Hz), 123.2, 125.3 (q, JCF = 4 Hz), 126.1, 
127.3, 130.6 (q, JCF = 32 Hz), 132.2, 136.2, 142.8, 150.2. MS m/z: 248 (MH+). 




2-(4-Methoxyphenylethynyl)pyridine (16f). Kugelrohr distillation afforded 
0.37 g (25% yield). 1H NMR δ: 3.78 (s, 3 H), 6.85 (dd, 2 H, J = 6.9, 2.1 Hz), 7.17 
(ddd, 1 H, J = 7.5, 4.8, 1.2 Hz), 7.43-7.52 (m, 3 H), 7.61 (ddd, 1 H, J = 7.5, 7.5, 1.8 
Hz), 8.55 (ddd, 1 H, J = 4.8, 1.7, 0.9 Hz). 13C NMR δ: 55.2, 87.5, 89.4, 114.0, 114.2, 
122.3, 126.8, 133.5, 136.0, 143.7, 149.9, 160.1. MS m/z: 210 (MH+). HRMS m/z: 






2-(3,4,5-Trimethoxylphenylethynyl)pyridine (16g). Purification by flash 
chromatography (silica gel, 10% EtOAc in hexane) afforded 0.53 g (63% yield) of 
16g. 1H NMR δ: 3.85 (s, 9 H), 6.83 (s, 2 H), 7.21 (ddd, 1 H, J = 7.8, 4.8, 1.2 Hz), 7.49 
(d, 1 H, J = 7.8 Hz), 7.67 (ddd, 1 H, J = 7.8, 7.8, 1.8 Hz), 8.59 (d, 1 H, J = 4.8 Hz). 
13C NMR δ: 56.1, 60.9, 87.7, 89.4,109.2, 117.1, 122.7, 126.9, 139.2, 139.3, 143.3, 
150.0, 153.0. MS m/z: 270 (MH+). HRMS m/z: calcd for C16H15NO3, 270.1130; 















4-Methyl-2-phenylethynylpyridine (16h). A mixture of 4-methyl-2-
(trifluoromethanesulfonyl)oxypyridine (1.20 g, 4.9 mmol), prepared according to the 
method of Savage and co-workers,2  tetrahydrofuran (15 mL), N,N-
diisopropylethylamine (2.6 mL), and phenylacetylene (0.76 g, 7.5 mmol) was 
combined with tri(dibenzylideneacetone)dipalladium(0) (0.23 g, 0.25 mmol) and tri-
o-tolulylphosphine (0.03 g, 0.99 mmol) using a modification of the general procedure 
above. Evaporation of the solvent followed by flash column chromatography (silica 
gel, 20% EtOAc in hexane) afforded 0.47 g (50% yield) of 16h as a dark brown oil. 
1H NMR δ: 2.29 (s, 3 H, CH3), 7.00 (ddd, 1 H, J = 5.1, 1.5, 0.6), 7.29-7.32 (m, 4 H), 
7.54-7.57 (m, 2 H), 8.42 (d, 1 H, J = 5.1). 13C NMR δ: 20.7, 88.6, 88.7, 122.3, 123.7, 
127.9, 128.2, 128.8, 131.9, 143.1, 147.2, 149.6. MS m/z: 194 (MH+). HRMS m/z: 










2-(2-Phenethyl)pyridine (14). Into a pressure tested, glass reaction vessel 
was placed 2-(2-phenylethynyl)pyridine 16d (0.2 g, 1.12 mmol), ethanol (75 mL), 
and 10% palladium on an activated carbon catalyst (0.02 mg). Hydrogenation was 
performed in a Parr apparatus under 40 psi hydrogen for 3 h. The reaction mixture 
was filtered through Celite, which was then washed with methanol. The combined 
filtrate was concentrated to afford 0.195 g of 14 (96% yield) as a brown oil. 1H NMR 
δ: 3.07-3.15 (m, 4 H), 7.07-7.13 (m, 2 H), 7.18-7.33 (m, 5 H), 7.54 (ddd, J = 7.8, 7.8, 
1.8, 1 H), 8.58-8.60 (m, 1 H). 13C NMR δ: 35.8, 40.0, 121.0, 122.8, 125.8, 128.1, 
128.3, 136.1, 141.3, 149.0, 160.9. MS m/z: 184 (MH+). HRMS m/z: calcd for 












General Procedure: Alkylation of Pyridines with Propargyl Triflate or 
Methyl Triflate. Prop-2-ynyl-2-trifluoromethansulfonate (0.48 g, 2.6 mmol) 
prepared according to method of Vedejs and co-workers3 was added to a 25 mL pear-
shaped flask containing ether (9 mL) chilled at -42 ºC. In a separate 25 mL pear-
shaped flask, the 2-substituted pyridine, dissolved in ether (9 mL) and cooled to -42 
ºC, was added dropwise via cannula to the prop-2-trifluoromethansulfonate solution 
or to a solution of methyl triflate in ether. After the reaction mixture was stirred for 2 
h, it was filtered with a fritted glass funnel and washed with cold ether to obtain a 







2-Ethynyl-1-prop-2-ynylpyridinium Triflate (17a). Obtained as a pink solid 
(0.6 g, 42% yield). mp: 120-122 ºC. 1H NMR (acetone-d6, 500 MHz) δ: 3.62 (t, 1 H, J 
= 2.6 Hz), 5.42 (s, 1 H), 5.86 (d,1 H, J = 2.5 Hz), 8.38 (dd, 1 H, J = 6.6, 7.8 Hz), 8.50 
(d, 1 H, J = 7.8), 8.85 (dd, 1 H, J = 7.8, 7.8 Hz), 9.47 (d, J = 6.6, 1 H). 13C NMR 
(acetone-d6, 125 MHz) δ: 50.7, 74.1, 74.5, 81.6, 99.0, 122.3 (q, CF3, J = 321 Hz), 
129.4, 134.1, 137.3, 147.2, 147.7. MS (FAB) m/z: 290 (MH+), 142. HRMS (FAB) 
m/z: calcd for C11H9F3NO3S, 290.0099; found, 290.0106. Anal. Calcd for 
C11H8F3NO3S+/3H2O: C, 44.45; H, 2.94; N, 4.71; S, 11.01. Found: C, 44.55; H, 2.71; 









1-Prop-2-ynyl-2-trimethylsilanylethynylpyridinium Triflate (17b). 
Recrystallized from chloroform/hexane to afford 0.40 g (64% yield) of 17b as white 
plates. mp: 65 ºC (dec). 1H NMR (500 MHz) δ: 0.31 (s, 9 H), 2.78 (t, 1 H, J = 2.5 
Hz), 5.58 (d, 2 H, J = 2.5 Hz), 8.02 (d, 1 H, J = 7.9 Hz), 8.08 (dd, 1 H, J = 7.9, 6.9 
Hz), 8.53 (dd, 1 H, J = 7.9, 7.9 Hz), 9.20 (d, 1 H, J = 7.9 Hz). 13C NMR δ: -1.1, 49.8, 
73.3, 79.5, 92.7, 119.2, 120.6 (q, CF3, J = 320 Hz), 127.8, 132.1, 136.6, 146.2, 146.7. 
MS (FAB) m/z: 364 (MH+), 214, 176. HRMS(FAB) m/z: calcd for C13H16NSi, 
214.105203; found, 214.103528. Anal. Calcd for C14H16F3NO3SSi+/3H2O: C, 45.52; 
















1-Prop-2-ynyl-2-[(triisopropylsilanyl)ethynyl]pyridinium Triflate (17c). 
Recrystallization from chloroform/hexane yielded 0.17 g (34% yield) of 17b as white 
flakes. mp: 123-124 ºC. 1H NMR δ: 1.12-1.15 (m, 18 H), 1.18-1.29 (m, 3 H), 2.73 (t, 
1 H, J = 2.7 Hz), 5.62 (d, 2 H, J = 1.5 Hz), 8.03 (ddd, 1 H, J = 7.8, 1.2), 8.09 (ddd, 1 
H, J = 7.8, 6.6, 1.2), 8.52 (dd, 1 H, J = 7.8, 7.8), 9.25 (d, 1 H, J = 6.6). 13C NMR δ: 
11.1, 18.4, 49.9, 73.5, 79.4, 94.6, 117.4, 127.9, 132.4, 136.7, 146.0, 147.2. MS m/z: 
448 (MH+), 298, 260. HRMS m/z: calcd for C20H29F3NO3SSi, 448.1590; found, 
448.1611. Anal. Calcd for C20H28F3NO3SSi: C, 53.67; H, 6.31; N, 3.13; S, 7.16. 
















2-Phenylethynyl-1-prop-2-ynylpyridinium Triflate (17d). Obtained as a 
gray solid (0.152 g, 73%). mp: 106-107 ºC. 1H NMR [dimethyl sulfoxide (DMSO)-
d6]1 δ: 4.05 (t, 1 H, J = 2.4), 5.74 (d, 2 H, J = 2.4), 7.56-7.85 (m, 3 H), 7.84 (d, 2 H, J 
= 6.6), 8.17 (ddd, 1 H, J = 7.8, 6.3, 1.5), 8.45 (dd, 1 H, J = 7.8, 1.5), 8.68 (ddd, 1 H, J 
= 7.8, 7.8, 1.5), 9.26 (d, 1 H, J = 6.3). 13C NMR (DMSO-d6, 125 MHz) δ: 49.4, 75.1, 
80.1, 81.4, 106.55, 118.9, 127.4, 129.2, 132.0, 132.1, 132.6, 136.4, 146.2, 146.1. MS 
m/z: 368 (MH+), 218. HRMS m/z: calcd for C17H12F3NO3S, 368.0568; found, 
368.0573. Anal. Calcd for C17H12F3NO3S: C, 55.58; H, 3.29; N, 3.81; S, 8.73. Found: 



















(17e). Recrystallization from chloroform/ether afforded 0.54 g of 17e as a white 
powder (49% yield). mp: 151-153 ºC (dec). 1H NMR (DMSO-d6, 500 MHz) δ: 4.08 
(t, 1 H, J = 2.5), 5.80 (d, 2 H, J = 2.5), 7.99 (d, 2 H, J = 8.0 Hz), 8.08 (d, 2 H, J = 8.0 
Hz), 8.25 (ddd, 1 H, J = 7.7, 6.0, 1.5 Hz), 8.53 (dd, 1 H, J = 7.7, 1.5 Hz), 8.74 (ddd, 1 
H, J = 7.7, 7.7,1.0 Hz), 9.32 (dd, 1 H, J = 6.0, 0.5). 13C NMR (DMSO-d6, 125 MHz)  
δ: 49.5, 75.0., 81.5, 81.6, 103.9, 123.0 (q, CF3, JCF = 321 Hz), 124.7 (q, JCF = 271 
Hz), 123.2, 126.0 (q, JCF = 4 Hz), 127.2, 131.0 (q, JCF = 32 Hz), 132.5, 133.4, 135.8, 
146.3, 146.4. MS (FAB) m/z: 286 (C17H11F3N+). HRMS (FAB) m/z: calcd for 
C17H11F3N, 286.0844; found, 286.0845. Anal. Calcd for C18H11F6NO3S+/3H2O: C, 
















2-(4-Methoxyphenylethynyl)-1-prop-2-ynylpyridinium Triflate (17f). 
Recrystallization from methylene chloride/hexane afforded 17f as green crystals (0.19 
g, 68% yield). mp: 142-145 ºC (dec). 1H NMR (CD3OD, 500 MHz) δ: 3.51 (t, 1 H, J 
= 2.5), 3.89 (s, 3 H), 5.69 (d, 2 H, J = 2.5), 7.07-7.09 (m, 2 H), 7.74-7.77 (m, 2 H), 
8.03 (ddd, 1 H, J = 8, 6, 1), 8.28 (dd, 1 H, J = 7.0, 1.0 Hz), 8.57 (ddd, 1 H, J = 8.0, 
8.0, 1.0 Hz), 9.16 (dd, 1 H, J = 6.0, 1.0 Hz). 13C NMR (CD3OD, 125 MHz) δ: 50.5, 
75.0, 80.47, 81.3, 111.4, 112.0, 115.6, 117.4, 132.9, 135.1, 136.0, 139.6, 146.4, 146.9, 
164.4. MS m/z: 398 (MH+), 210. HRMS m/z: calcd for C18H15F3NO4S, 398.0674; 
found, 398.0678. Anal. Calcd for C18H14F3NO4S: C, 54.41; H, 3.55; N, 3.52. Found: 





















(17g). Recrystallization from chloroform afforded 0.23 g (54% yield) of bright yellow 
needles. mp: 162-163 ºC (dec). 1H NMR (CD3OD, 500 MHz) δ: δ: 3.58 (t, 1 H, J = 
2.7 Hz), 3.84 (s, 3 H), 3.89 (s, 6 H), 5.74 (d, 2 H, J = 2.7 Hz), 7.14 (s, 2 H), 8.08 (ddd, 
1 H, J = 8.0, 6.3, 1.5 Hz), 8.34 (dd, 1 H, J = 8.0, 1.5 Hz), 8.61 (ddd, 1 H, J = 8.0, 8.0, 
1.0 Hz), 9.20 (dd, 1 H, J = 6.3, 1.0 Hz). 13C NMR (CD3OD, 125 MHz) δ: 50.7, 57.0, 
61.3, 75.0, 80.0, 81.5, 110.5, 111.5, 115.2, 127.8, 133.2, 139.3, 143.4, 146.5, 147.0, 
155.0. MS m/z: 308 (C19H18NO3+). HRMS m/z: calcd for C19H18NO3, 308.1287; 
found, 308.1291. Anal. Calcd for C20H18F3NO6S: C, 52.51; H, 3.97; N, 3.06; S, 7.01. 













4-Methyl-2-phenylethynyl-1-prop-2-ynylpyridinium Triflate (17h). 
Recrystallization from chloroform/ether afforded 0.20 g of 17h as an off-white 
powder (67% yield). mp: 165-167 ºC. 1H NMR (500 MHz) δ: 2.67 (s, 3 H), 3.49 (t, 1 
H, J = 2.5), 5.64 (d, 2 H, J = 2.5), 7.54 (dddd, 2 H, J = 7.5, 7.5, 1.5, 1.5), 7.50 (dddd, 
1 H, J = 7.5, 7.5, 1.5, 1.5), 7.78-7.80 (m, 2 H), 7.91 (dd, 1 H, J = 6.5, 1.5), 8.21 (d, 1 
H, J = 1.5), 8.99 (d, 1 H, J = 6.5). 13C NMR (125 MHz) δ: 20.7, 48.7, 73.9, 79.2, 
79.8, 107.2, 119.4, 128.0, 129.0, 131.8, 132.5, 132.6, 136.9, 144.4, 160.8. MS m/z: 
382 (MH+), 232. HRMS m/z: calcd for C18H15F3NO3S, 382.0725; found, 382.0717. 
Anal. Calcd for C18H14F3NO3S: C, 56.69; H, 3.70; N, 3.67. Found: C, 56.18; H, 3.32; 














2-Ethynyl-1-methylpyridinium Triflate (18a). Obtained as a pink solid (0.5 
g, 90% yield). mp: 140 ºC (dec). 1H NMR (acetone-d6, 500 MHz) δ: 4.62 (s, 3 H), 
5.31 (s, 1 H), 8.22 (dd, 1 H, J = 7.0, 6.0 Hz), 8.38 (d, 1 H, J = 7.0 Hz), 8.71 (ddd, 1 H, 
J = 7.0, 7.0, 1.3 Hz), 9.21 (d, 1 H, J = 6.0 Hz). 13C NMR (acetone-d6, 125 MHz) δ: 
48.4, 74.5, 97.7, 122.3 (q, CF3, J = 321 Hz), 128.6, 133.3, 138.0, 146.3, 148.7. MS 








1-Methyl-2-phenylethynylpyridinium Triflate (18d). Recrystallization from 
dichloromethane/ether afforded 0.05 g (24% yield) of 18d as an light greenish-white 
solid. 1H NMR (DMSO-d6) δ: 4.45 (s, 1 H), 5.73 (s, 3 H), 7.56-7.59 (m, 3 H), 7.82 (d, 
2 H, J = 7.0 Hz), 8.10 (dd, 1 H, J = 6.0, 6.0 Hz), 8.33 (d, 1 H, J = 7.0 Hz), 8.57 (dd, 1 
H, J = 6.0, 6.0 Hz), 9.10 (d, 1 H, J = 5.0 Hz). 13C NMR (DMSO-d6, 125 MHz) δ: 
47.3, 80.3, 105.2, 119.0, 126.7, 129.2, 131.4, 131.7, 132.5, 137.0, 144.8, 147.3. MS 









1-Methyl-2-(4-trifluoromethylphenylethynyl)pyridinium Triflate (18e). 
Obtained as an off-white solid (0.3 g, 98% yield). mp: 143-144 ºC (dec). 1H NMR 
(DMSO-d6) δ: 4.47 (s, 3 H), 7.95 (d, 1 H, J = 8.2 Hz), 8.05 (d, 1 H, J = 8.2 Hz), 8.14 
(ddd, 1 H, J = 7.6, 6.1, 1.5 Hz), 8.43 (dd, 1 H, J = 6.9, 1.2 Hz), 8.61 (dd, 1 H, J = 6.9 
Hz), 9.14 (d, 1 H, J = 6.1 Hz). 13C NMR (DMSO-d6) δ: 47.4, 81.8, 102.6, 124.5 (q, 
JCF = 270 Hz), 120.0 (q, CF3, JCF = 320 Hz), 123.3, 125.5 (q, JCF = 4 Hz), 127.3, 
130.8 (q, JCF = 32 Hz), 131.8, 133.3, 136.5, 144.9, 147.5. MS (CI) m/z: 262 








2-(4-Methoxyphenylethynyl)-1-methylpyridinium Triflate (18f). Obtained 
as a white solid (0.3 g, 98% yield). mp: 172 ºC (dec). 1H NMR (400 MHz) δ: 3.88 (s, 
3 H), 4.48 (s, 3 H), 7.06 (ddd, 2 H, J = 6.8, 2.4, 2.4 Hz), 7.72 (ddd, 2 H, J = 6.8, 2.4, 
2.4 Hz), 7.94 (ddd, 1 H, J = 7.6, 7.6, 1.2 Hz), 8.22 (dd, 1 H, J = 8.4, 1.2 Hz), 8.49 (dd, 
1 H, J = 7.6, 1.2 Hz), 8.91 (d, 1 H, J = 6.0 Hz). 13C NMR δ: 48.0, 56.2, 80.5, 109.8, 
112.1, 115.9, 123.9, 127.0, 132.4, 135.8, 145.7, 147.8, 164.1. MS m/z: 224 





1-Prop-2-ynylpyridinium Triflate (19). Obtained as a white powder (1.2 g, 
88% yield). mp: 53-54 ºC (dec). 1H NMR (DMSO-d6) δ: 4.04 (t, 1 H, J = 2.6 Hz), 
5.62 (d, 2 H, J = 2.6 Hz), 8.20 (dd, 1 H, J = 7.5, 6.4 Hz), 8.66 (dddd, 1 H, J = 7.5, 7.5, 
1.3, 1.3 Hz), 9.11 (dd, 1 H, J = 6.4, 1.3 Hz). 13C NMR (125 MHz) δ: 49.9, 75.5, 81.4, 
120.0 (q, CF3, JCF = 320 Hz), 128.3, 144.4, 146.6. MS m/z: 118 (C8H8N+). HRMS 








2-Phenethyl-1-prop-2-ynylpyridinium Triflate (20). Obtained as a beige 
solid (0.09 g, 5% yield). mp: 106-107 ºC. 1H NMR δ: 3.22 (t, 2 H, J = 7.8 Hz), 3.53 
(t, 1 H, J = 2.6 Hz), 3.56 (t, 2 H, J = 7.8 Hz), 5.52 (d, 2 H, J = 2.6 Hz), 7.23-7.34 (m, 
5 H), 7.96-8.01 (m, 2 H), 8.47-8.53 (m, 1 H), 9.09 (d, 1 H, J = 6.0 Hz). 13C NMR δ: 
34.6, 35.1, 48.6, 75.3, 81.5, 127.4, 128.0, 129.6, 129.9, 130.7, 140.1, 146.5, 147.5, 
159.6. MS m/z: 222 (C16H16N+), 184. HRMS m/z: calcd for C16H16N, 222.1283; 
found, 222.1284. Anal. Calcd for C17H16F3NO3S: C, 54.98; H, 4.34; N, 3.77; S, 8.63. 







1-Prop-2-ynyl-2-trifluoromethylpyridinium Triflate (21). Obtained as a 
white powder (0.6 g, 37% yield). mp: 87-88 ºC (dec). 1H NMR δ: 3.68 (t, 1 H, J = 2.7 
Hz), 5.75 (d, 2 H, J = 2.7 Hz), 8.53 (dd, 1 H, J = 7.0, 7.0 Hz), 8.71 (dd, 1 H, J = 6.6, 
1.5 Hz), 8.94 (dd, 1 H, J = 7.0, 7.0 Hz), 9.66 (dd, 1 H, J = 6.0, 0.9 Hz). 13C NMR 
(CDCl3, 125 MHz) δ: 50.8, 73.9, 83.0, 120.9 (q, CF3, JCF = 320 Hz), 122.0 (q, CF3, 
JCF = 273 Hz), 129.3 (d, JCF = 5 Hz), 133.4, 141.2 (d, JCF = 36 Hz), 150.4, 150.6. MS 
m/z: 336 (MH+), 186 (C9H7F3N+). HRMS m/z: calcd for C10H7F6NO3S, 336.0129; 
found, 336.0137.  
Supercoiled DNA Cleavage Assay 
The DNA cleavage efficiency of these pyridinium salts was determined by 
incubation with aqueous solutions of supercoiled ФX174 plasmid DNA. The 
supercoiled DNA was diluted to 50 µM base pairs in 50 mM N,N,N-
tris(hydroxymethyl)aminomethane (Tris) buffer at pH 7 or 8. The reaction mixtures 
containing the compound and 13% (v/v) DMSO were incubated for 24 h at 37 ºC 
(unless otherwise noted). DNA products were separated by agarose gel 
electrophoresis [1× Tris-borate-N,N,N',N'-ethylenediaminetetraacetic acid (EDTA) 
(TBE) at 90 V for 1 h], stained with ethidium bromide (0.25 µg/mL), and the images 
were analyzed using a fluorimager with ImageQuant software. After we corrected for 
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the differential staining ability of the different forms of DNA,4 the percent cleavage 
was determined using equation [1]. 
 
  I] [form  II] [form  III]) (2[form 
   II] [form  III]) (2[form        cleavagePercent 
++
100×+
=                   [1] 
 
Normalized DNA cleavage at each drug concentration was calculated using equation 
[2]. The values of normalized percent cleavage of DNA presented in Table 2-2 
represent the mean ± standard deviation from at least three determinations. 
 
(control) cleavagepercent   -  100
(control) cleavagepercent   -  (drug) cleavagepercent     cleavagepercent  Normalized =  
[2] 
DNA Oligonucleotide Cleavage Assay.  
Two 5’ singly end-labeled DNA oligonucleotides were used for DNA 
cleavage assays. A 14 base-pair oligonucleotide was prepared by 5’ labeling of 
d(GATAATGGATAAGC) with [γ-32P]ATP (Amersham) using T4 polynucleotide 
kinase. The labeled DNA was purified by elution through a Bio-Rad Biospin column 
and annealed with an excess of unlabeled d(GCTTATCCATTATC). The resulting 
duplex was purified by preparative polyacrylamide gel electrophoresis (PAGE). A 
228 base-pair DNA fragment was prepared as previous described.5  Briefly, 40 pmol 
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of the L151 [d(CGGCATCAGAGCAGATTGTA)] or R378 
[d(AACGTCGTGACTGGGAAAAC)] primer was 5’-labeled with [γ-32P]ATP using 
T4 polynucleotide kinase and was purified by elution through a Biospin column. The 
purified radiolabeled primer was then used directly in a polymerase chain reaction 
(PCR) reaction by adding 40 pmol of the reverse unlabeled primer R378 (or L151), 
10 ng of pUC19 DNA template, 5 µL of 10× buffer (100 mM Tris-HCl, 15 mM 
MgCl2, and 500 mM KCl at pH 8.3), 0.2 mM dNTPs, and 2.5 units of Taq DNA 
polymerase (Roche) and adjusting with H2O to 50 µL. PCR was then performed 
(initial denaturation at 95 º C for 5 min; the cycling conditions were as follows: 95 º C 
for 15 s, 55 º C for 30 s, and 72 º C for 1 min, for 25 cycles, and then final extension 
was done at 72 º C for another 5 min). The PCR product was purified with a 
Microcon PCR spin column (Millipore), which separated the PCR product from its 
primers, the dNTPs, and the polymerase.  
Unless otherwise noted, DNA cleavage reactions were carried out in 20 µL 
reaction mixtures consisting of 25,000 cpm of 5’-radiolabeled DNA fragments, drug, 
5% DMSO, and 10 mM Tris-HCl buffer (pH 7) with or without 1 µg of calf thymus 
DNA. The samples were incubated at 37 º C for 12 h. The reaction mixtures were 
diluted with 100 µL of precipitation buffer (10 µg of glycogen and 0.45 M sodium 
acetate at pH 5.2), extracted with phenol/chloroform, and precipitated with ethanol. 
The pellets were washed twice with 70% ethanol. One set of samples was subjected 
to heat treatment with 10% piperidine at 95 º C for 15 min. The samples were then 
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dissolved in formamide loading dye and analyzed by 8% denaturing PAGE. The 
images were visualized by PhosphoImager (Molecular Dynamics model 445 SI).  
8-Oxo-Deoxyguanosine Analysis.  
A 120 µL reaction mixture consisting of calf thymus DNA (approximately 3.6 
mM base pairs) in 5% DMSO in 50 mM Tris buffer (pH 7) with or without 17f (5 
mM) was incubated at 37 º C for 2 h in the dark. The reaction mixture was extracted 
with phenol/chloroform, and the DNA was precipitated with ethanol. The pellets were 
washed with 70% ethanol (3×) and lyophilized. The DNA was enzymatically digested 
with nuclease P1 (2 mM NaOAc at pH 4.5 and 0.1 mM ZnCl2) and alkaline 
phosphatase (80 mM Tris buffer at pH 9.0). The digested mixture was directly 
analyzed by high-performance liquid chromatography (HPLC) [Beckman Ultrasphere 
ODS column (4.6 × 2500 mm) with isocratic elution (4 mM citric acid, 8 mM 
ammonium acetate, and 20 mg/L EDTA at pH 4.0 with 5% MeOH] using a UV 
dector (254 and 280 nm) and a four-channel electrochemical detector (0, +150, +290, 
and +380 mV). The mole ratio of 8-oxo-dG, whose concentration was determined 
coulometrically versus a standard curve of authentic material, to deoxyguanosine 
(dG), whose concentration was determined from the absorbance at 260 nm versus a 
standard curve of authentic material, was calculated. Oxidative damage was 
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Chapter 4                                                                               
G-Quadruplex DNA as a Potential Target for Drug Design                       
and G-Quadruplex -Interactive Agents   
Guanine-rich sequences throughout the genome may form unusual, stable 
structures called G-quadruplex. The most obvious of these guanine-rich sequences is 
at the telomere. Telomeres maintain the integrity of the chromosome end and 
represent a means of controlling the cellular lifespan.1 Besides telomeric DNA, other 
guanine-rich regions include a number of gene promoters2, 3, 4, 5 which are also 
capable of forming G-quadruplex structures. It is believed that there is a correlation 
between G-quadruplex structure and gene function and genetic stability.6, 7  The 
discovery of an increasing number of proteins that interact with G-quadruplex 
structures and the possibility of a biological role for G-quadruplex DNA offers a 
novel avenue for targeted drug discovery. In addition to targeting these DNA 
structures with G-quadruplex interactive agents, other avenues include designing 
molecules that interact with G-quadruplex binding/interacting proteins.   
In this chapter, the general concepts related to G-quadruplex DNA leading to 
potential targets for drug design will be introduced. The discussion will begin with 
the topology of G-quadruplex structures and variation in stoichiometry, along with 
examples that are based on information from NMR and X-ray crystallographic studies 
for each class of G-quadruplex structure.  In the following section, the high likelihood 
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of the existence of G-quadruplex sequences in the living cell will be discussed. 
Closing the section will be a brief discussion of stability of G-quadruplex formation 
from a kinetic viewpoint. The next section will present more information on 
telomeres and telomerase which be considered as an early target in anticancer drug 
development from the G-quadruplex DNA perspective. Resolving duplex structures is 
required for metabolism of DNA, e.g., replication, repair and recombination, and it 
can be expected that this resolution is also required for G-quadruplex DNA. Thus, G-
quadruplex unwinding helicases will be introduced, including helicases in the RecQ 
family.8  Also discussed will be SV40 large T antigen (T-ag), which possesses no 
known G-quadruplex binding domain, yet has been reported have the ability to 
resolve G-quadruplex structures.9  All the background information presented will lead 
up to a discussion on drug design and development focused on three different themes, 
(i) anti-cancer drug development efforts focused on telomerase (ii) G-Quadruplex-
interactive agents that target telomeres which could also affect the G-quadruplex 
interacting proteins and (iii) G-quadruplex-interactive agents targeted towards 
regulatory regions, e.g., promoter regions, many of which contain G-rich sequences. 
The rest of the chapter will be devoted to the discussion of selectivity and affinity of 
G-quadruplex-interactive agents with a listing of examples from a variety of classes 





G-quadruplex structures, which can form from G-rich DNA, consist of 
stacked guanine tetrads (G-tetrads). The G-tetrad comprises a planar arrangement of 
four guanines associated by cyclic Hoogsteen hydrogen bonds, involving N1, N2, N7, 
and O6 of each guanine base (Figure 4-1). Monovalent cations, e.g., Na+ and K+, 
stabilize G-quadruplex structures by binding with the guanine O6 carbonyl oxygen in 







Figure 4-1  G-tetrad 
 
Variations in G-quadruplex molecularity and topology give rise to a wide 
variety of structures. Extensive reviews about G-quadruplex structure and topology 
are available. (Kerwin, S.M., 2000;12  Simonsson, T. 2001.13) G-quadruplex DNA can 
form from four strands of G-rich DNA in a parallel arrangement, in which each four-









































stranded structure is called G4 DNAa (Figure 4-2). There are several examples of G4 
structures, such as, the crystal structure of a G4 formed from d(TG4T) in the presence 
of Na+ ions,14 and the structure from an NMR study of a G4 formed by d(T2G4T) in 
K+ containing solution.15  
G-quadruplex DNA may also form from two DNA strands each of which 
contains two or more G repeats to form G’2 DNA (Figure 4-2) also referred to as 
dimeric hairpin quadruplex DNA.  An example of G’2 is the crystal structure of 
d(TAGGGTTAGGGT) sequence in the presence of  K+. All four strands have parallel 
orientation with TTA-propellerb  loops.16 NMR studies showed that 
d(TAGGGTTAGGGT) sequence in K+ ion- containing buffer forms both a parallel 
G’2 structure with two propeller loops and an anti-parallel G’2 structure with two 
lateralc loops.17 Other examples of G’2 structures are formed by an oligonucleotide 
containing two repeats of Tetrahymena telomeric sequence, d(TG4T2G4T) in Na+-ion 
containing solution. NMR studies demonstrate that under these condition this 
sequence forms two G’2, each containing both parallel and anti-parallel strand 
orientations with two lateral loops, and these interconvert in the solution; the one with 
two lateral loops that are at the same side of G-tetrads is called head to head, the other 
with two lateral loops are opposite side of G-tetrads called head to tail.18 
Alternatively, single-stranded DNA containing multiple runs of G is able to 
form G4’ DNA (Figure 4-2), also known as unimolecular or intramolecular G-
                                                 
a I will use “G4” term only to refer to an intermolecular four stranded G-quadruplex.  
b Propeller loop is also referred as external loop, double-chain-reversal loop or dog-eared. 
c Lateral loop is also referred as edgewise loop. 
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quadruplex. Wang and Patel showed an example of a G4’ structure with parallel and 
anti-parallel strands connected by two lateral loops and one diagonal loop in the 
NMR studies of an oligonucleotide consisting of the human telomeric sequence 
d[AG3(T2AG3)3]  in Na+-ion containing solution.19  An alternative example of G4’ 
has been reported by Neidle et al,16 from X–ray crystallographic analyses of the same 
sequence in K+ ion environment in which all strands are parallel connected by 
propeller loops. However, subsequently, Patel’s group and Yang’s group 
independently reported NMR studies of the formation of G4’ from 
d[TTG3(T2AG3)3A]20 d[TAG3(T2AG3)3TT]21 and d[AAG3(T2AG3)3AA]22 sequences 
in K+ solution. These structures shared a mixed parallel and anti-parallel strand 
arrangement with combinations of two lateral and one propeller loops. The two 








Figure 4-2  G-quadruplex structures. Different topological forms of G4, G’2 and G4’   
 
While previous studies of G-quadruplex DNA employed non-physiological 
concentrations of cations like Na+, K+ or NH4+, recent studies demonstrate that in the 
cellular milieu G-quadruplex can form at lower cation concentration. Even in the 
absence of these cations, molecular crowding, for example, that induced by high 
concentration of PEG, can also promote G-quadruplex formation.23 In the living cell 










nucleic acids and polysaccharides24 the crowding could affect the rate, equilibria, and 
even mechanism of the cellular reactions.25, 26 There are a couple of studies presenting 
the effect of molecular crowding on G-quadruplex formation and transition.27, 28, 29 
The most recent study showed that under cation–deficient conditions, molecular 
crowding due to PEG200 can induce intramolecular G-quadruplex formation of 
d(T2AG3)4 and d[G3(T2AG3)3] sequences. Furthermore, d[G3(T2AG3)3] in PEG gave 
rise to CD spectra similar to those in the presence of K+, which were interpreted as 
arising from parallel and anti-parallel-stranded G-quadruplex structures.23  
A wide variety of G-rich sequences from the human genome has been shown 
to form G-quadruplex structures in vitro, or is predicted to form these structures. In 
addition to the G-quadruplex structures formed from oligonucleotides encompassing 
human telomeric repeats,30 (vide infra) additional G-quadruplex structures have been 
shown to form in vitro from oligonucleotides containing G-rich elements in rDNA 
and mammalian immunoglobulin heavy chain switch regions,8 c-Myc,5, 31, 32  
polypurine tract of hypoxia inducible factor 1alpha promoter,33 muscle–specific 
genes,34 the promoter region of c-kit oncogene,3 the fragile X syndrome d(CGG)n 
nucleotide repeats,35 the cystatin B promoter36and the insulin gene.37 G-quadruplex 
DNA is believed to be involved in regulation of gene expression.2, 3, 4, 5 Additionally, 
there is a prediction of putative quadruplex sequences throughout the human genome; 
as many as 376,000 potential quadruplexes could exist38 and it has been suggested 
that there is a correlation between G-quadruplex formation and gene function. 
Moreover, it was reported that the promoter regions are significantly enriched in G-
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quadruplex motif39 and was proposed that G-quadruplex might be involved in gene 
regulation, functioning as transcriptional repressors. Also, it was noted that proto-
oncogenes have a very high potential for G-quadruplex formation (this may be the 
means by which nature contributes to genomic destabilization) and tumor suppressor 
genes have very low potential for G-quadruplex formation (by which nature may 
minimize genomic instability).6  
Along with these predictions about the prevalence of G-quadruplex structures 
throughout the genome, the identification of many G-quadruplex interacting proteins 
supports a biological role for G-quadruplex DNA in living cells. Some of the proteins 
that have been reported to bind to or cleave G-quadruplex DNA include hPot1,40, 41, 42 
hnRNP A1,42 hnRNP D,43, 44, 45 GQN1,46 BLM,47 and WRN35, 48 in humans, TGP in 
Tetrahymena thermophila,49, 50, 51 TEBPs in Stylonychia lemnae,52 and 
KEM1/SEP1,53, 54 Sgs155 in Saccharomyces cerevisiae. Some of these proteins are 
involved in the resolution of otherwise kinetically stable G-quadruplex structures, at 
the human telomere, hPot1 binds to single-stranded telomeric repeat, which suggests 
that hPot1 caps the telomere, protecting it from degradation.56, 57  Also, the binding of 
hPOT1 disrupts G-quadruplex which allows the 3’end of the telomere to function as a 
primer for telomerase. 
Some of the strongest evidence for the existence of G-quadruplex structure in 
vivo is from Maizels’ group.58  Using electron microscopy, it was demonstrated that 
G-quadruplex structures can form in vitro and in vivo during the transcription of G-
rich regions. While a RNA/DNA hybrid forms on the C-rich template strand during 
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transcription, there is a loop-formation on the G-rich coding strand, called “G-loops”, 
containing G-quadruplex structures. This G-loop formation was demonstrated within 
an E. coli strain NM256 containing a G-rich insert, and lacking both RNase H, an 
enzyme digesting RNA strand of RNA/DNA hybrid, and RecQ helicase. Moreover, 
the presence of G-quadruplex structures in G-loops was shown by cleavage by GQN1 
nuclease as well as binding to a recombinant nucleoline that specifically and tightly 
binds to G-quadruplex DNA.59 
 
 
   A                                                                  B 
Figure 4-3 (A) Diagram of G-loops, displays the DNA/RNA hybrid on the template 
strand and G-quadruplex on the G-rich strand.  (B)  Electron micrograph of G-loop in 
plasmid transcribed in E. coli.58 
Not only can DNA fold into G-quadruplex structures, RNA also has ability to 
form G-quadruplex structure, indeed, these RNA G-quadruplexes may be more 
prevalent than DNA G-quadruplexes.60 Several groups have shown that G-quadruplex 
RNA is more stable than the corresponding DNA.61, 62  Besides, RNA is single-
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stranded which means that the G-quadruplex formation does not have to compete 
with complementary strand hybridization. The recent work by Balasubramanian’s lab 
demonstrated that G-quadruplex forming sequences at 5’ untranslated regions on 
mRNA of NRAS proto-oncogene transcript can repress the mRNA translation. 
Furthermore, they performed bioinformatics analysis and revealed that 2,922 out of 
38,915 5’ untranslated regions in proto-oncogene transcripts contain one or more G-
quadruplex forming sequences. The frequency of G-quadruplex motif in 5’ 
untranslated regions is 4.8 times higher than that of G-quadruplex motif in the 
genome.63 
In analogy to the formation of G-loops during transcription, it is predicted that 
whenever double-stranded DNA is converted into single-stranded DNA during 
dynamic processes, like, replication and recombination, the transient denatured-G-
rich sequence could readily form G-quadruplex structures. The rate of G-quadruplex 
formation in vitro is more likely to be slow in the case of intermolecular G-
quadruplex and is more likely to be very fast in the case of intramolecular G-
quadruplex. There are several reports that demonstrate the slow rate of dissociation 
and association of intermolecular G-quadruplex structure62, 64 for examples, G4 
formed from d(T2G4T2) possesses a dissociation rate of 1.3 x  10-7 s-1  at 37 ºC.16  
Additionally, slow dissociation rates have been demonstrated by NMR studies; the 
imino protons of guanine can be seen in NMR, showing that they exchange at a very 
slow rate with solvent protons compared to the NMR time scales.5, 60 Once G-
quadruplex is formed, it is very stable, as indicated by Tm; thus it would not be 
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expected to dissociate spontaneously in vivo, and it may necessitate some 
mechanisms, such as, special helicases playing a role to unwind this particular 
structure. (A more detailed discussion will be presented below)    
Telomeres and Telomerase 
Telomeres are protein-DNA complexes at the ends of linear eukaryotic 
chromosomes that protect the chromosome end from degradation or end to end fusion 
maintaining the integrity of the chromosome end by not being recognized as DNA 
double strand breaks.65, 66  
Telomeric DNA sequence consists of G-rich tandem repeats, in the case of 
human telomeres contain up to several thousand of repetitive DNA sequence of 5’-
TTAGGG-3’/ 5’CCCTAA-3’. The extreme 3’ end of the telomeric DNA is single-
stranded G-rich overhang, approximately 100-200 nucleotides long.67, 68 With 
telomere-associated proteins, such as, TRF1, TRF2 and hPOT1,69 the 3’overhang can 
invade upstream double-stranded telomeric DNA, forming a T-loop.70  
The strongest evidence for the formation of telomeric G-quadruplex structures 
in cells come form structure of ciliates. Schaffitzel, Pluckthun and colleagues 
generated two high-affinity single-chain antibody fragments, Sty3 and Sty 49 which 
interact with parallel G-quadruplex structure and with either parallel or antiparallel G-
quadruplex structure, respectively. Using these probes, they showed that the 
antiparallel G-quadruplex structures form at telomeres in macronucleus but not the 
micronucleus or the replication band of Stylonychia  lemnae.52, 71 
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In dividing cells telomeres progressively shorten upon each cell division due 
to removal of the final primer in the lagging-strand synthesis, so called the “end 
replication problem”.72, 73, 74 Due to this telomere shortening, the telomeres eventually 
shorten to a critical length, leading to senescence in which cells permanently arrest 
proliferation.75, 76 However, in embryonic cells, male germ line cells and their 
descendants’ epithelial tissue, there is expression of ribonucleoprotein enzyme 
complex, telomerase. Telomerase contains hTERT, a reverse transcriptase protein and 
hTR, a template RNA.77, 78  This reverse transcriptase maintains telomere length in 
these cells.79, 80  Interestingly approximately 85-90% of human tumor cells express 
telomerease activity81 which provides these cells infinite replicative capability. A 
small percent of cancer cells may rely on an “Alternative lengthening of telomere” 
(ATL) mechanism, most likely involving homologous recombination, for telomere 
maintenance.81, 82, 83  
G-Quadruplex unwinding helicases  
The unwinding of duplex DNA is a prerequisite for DNA replication, repair 
and recombination, providing the single-stranded DNA template for DNA polymerase 
to copy. The DNA helicases enzymatically unwind duplex DNA to facilitate strand 
separation reaction. Helicases disrupt the base pair hydrogen bonds which is 
accomplished in a reaction coupled with hydrolysis of a nucleotide 5’-triphosphate 
(NTP).84, 85, 86, 87 
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A number of genetic disorders characterized by genomic instability and a 
predisposition to cancer have been identified, including autosomal recessive disorders 
in which the underlying defect affects members of one family of DNA unwinding 
enzymes, the RecQ family of helicases.88, 89, 90 The RecQ family of helicases is highly 
conserved across species, including bacteria, fungi, plants, animals and humans. All 
RecQ helicases unwind duplex DNA substrates in the 3’ 5’ direction and require 
ATP. In cells that are defective in RecQ helicases, replication is abnormal and the 
responses to DNA-damaging agents are compromised.88, 91  
There are at least 16 members of the RecQ family, e.g., RecQ (Escherichia 
coli),92 Sgs1P (Saccharomyces cerevisiae), Rgh1 (Schizsaccharomyces pombe), BLM 
(Homo sapiens, mutated in Bloom’s syndrome),93 WRN (Homo sapiens, mutated in 
Werner’s syndrome), RECQL4 (Homo sapiens, mutated in Rothmund-Thomson 
syndrome),94 and RECQ5 (Homo sapiens). As previously mentioned, mutations in 
yeast Sgs1P, human BLM and WRN genes result in genetic instability, premature 
aging and a shortened life-span. Bloom’s syndrome, Werner’s syndrome and 
Rothmund-Thomson syndrome are associated with frequent development of 
malignancies.  
E. coli RecQ can unwind a broad range of duplex DNA substrates including 
duplexes with blunt ends, 3’or 5’ overhangs and forked DNA. In addition, RecQ can 
also unwind G4 DNA.8, 95, 96  Sgs1p, WRN and BLM unwind duplex DNA in the 
3’ 5’ direction, and all require a substrate with a 3’ single-stranded tail. Moreover, 
these eukaryotic RecQ helicases also have been shown to unwind G-quadruplex 
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structures. BLM can unwind G4 DNA 10-20 fold more efficiently than double 
stranded DNA substrates.47 WRN efficiently unwinds G’2 DNA with about 3.5 
greater efficiency than it unwinds duplex DNA.35  Sgs1p unwinds G-G paired 
substrates at least 10 fold more efficiently than it unwinds duplex substrates.55 The 
latest human protein that was reported to unwind-quadruplex DNA is a DEXH 
helicase named G4 resolvase-1(G4R1), a gene product of DHX36.97 DEXH helicase 
possesses ability to unwind G4 DNA in an ATP dependent manner and also prefers 
G4 DNA as a substrate over 3’-overhang duplex, 5’-overhang duplex or replication 
folk-like duplex structures. 
SV40 Large T antigen is a multifunctional protein with ATPase, helicase and 
DNA-binding activities.98 It is required for replication of the SV40 chromosome and 
for regulation of both viral and cellular genes.99, 100 SV 40 DNA has the possibility to 
form G quadruplex structures;101 therefore, SV40 large T antigen, which possesses 
helicase activity, may be needed to unfold quadruplex structures in order to 
efficiently process replication of viral genome. As a matter of fact, it was shown that 
SV40 large T antigen can unwind four stranded DNA structure.9 Unlike other 
helicases unwinding G-quadruplex structure (e.g. E. coli RecQ,8 Sgs1p,55 BLM,47 and 
WRN35) possessing G-quadruplex binding domain, RQC domain, which is found only 
RecQ family,102  SV40 large T antigen has no reported G-quadruplex  recognition 
domain.  
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Anti-cancer drug development efforts focused on telomerase. 
The ribonucleoprotein enzyme complex telomerase is typically absent in most 
normal cells, yet is expressed in more than 85% of cancer cells, where it plays a 
critical role in maintenance of telomere function. Targeting telomerase is one strategy 
for anticancer therapy.103, 104, 105  There are several approaches to target telomerase. In 
one approach, the hTR template RNA component of the telomerase ribonucleoprotein 
enzyme is targeted using oligonucleotide-based inhibitors in a manner similar to 
antisense targets of mRNA. Oligonucleotides complimentary to the hTR template that 
are designed for increased stability could interrupt telomerase activity, resulting in 
telomere shortening and leading to cell cycle arrest or apoptosis.106, 107, 108, 109, 110  The 
challenges of this particular approach include the potential instability of 
oligonucleotides, difficult target delivery, and poor cellular uptake of 
oligonucleotides.  However, a synthetic lipid-conjugated, 13-mer oligonucleotide 
N3’-P5’-thio-phosphoramidate, GRN163,  which is believed to be a telomerase 
template antagonist developed by Geron Corporation, is proposed to bind to hTR in 
the active site of telomerase and act as a competitive (with respect to primers) 
inhibitor of telomerase enzymatic activity. Currently, GRN163 is in Phase I/II clinical 
trials to treat patients with chronic lymphocytic leukemia. Another approach involves 
targeting the telomerase catalytic protein subunit hTERT with nucleotide analogs. For 
example, 3-azido-2’,3’-dideoxythymidine (AZT), currently being used as a viral 
reverse transcriptase inhibitor in anti-HIV, was the first nucleotide analog that was 
tested against telomerase. Additional nucleotide analogs, AZT-5’-triphosphate, AZT-
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TP, 2’,3’-dideoxyguanosine, ddG,111 6-thio-7-deaza-2’-deoxygaunosine-5’-
triphosphate (TDG-TP)112 have been tested. Another approach to targeting telomerase 
is exemplified by the non-nucleosidic compound BIBR1532, which is a mixed-typed 
noncompetitive inhibitor of telomerase. BIBR1532 is thought to have a mechanism 
similar to that of non-nucleosidic HIV-I reverse transcriptase inhibitors.113, 114, 115 
Nevertheless, telomere shortening caused by these nucleoside and non-nucleoside 
hTERT inhibitors was often found to be insufficient and not practical to kill the cells. 
In addition there was an extensive lag period from initial dosing to telomere 
shortening leading to senescence.116, 117  However, the combination therapy of 
telomerase inhibitors with other anti-cancer chemotherapeutics or irradiation, as well 







Figure 4-4 Structure of BIBR1532 
G-Quadruplex-interactive agents targeting telomeres  
As mentioned previously, the inhibition of hTERT exhibits an extensive lag 
period from initial dosing to telomere shortening effect leading to senescence.116, 117   
In addition, about 15-10 % of cancer cells do not express telomerase. One strategy to 
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target these cancer cells is to target their telomeres using G-quadruplex DNA 
interactive compounds. Targeting telomeres can be of benefit not only in telomerase-
independent cells but also in telomerase-dependent cells, affecting telomerase activity 
by sequestering the single-stranded telomeric primer. Cech’s group had shown that 
the telomeric G-quadruplex structure facilitated and stabilized by K+ ions was able to 
inhibit telomerase activity.118 Several effects could arise directly from the 
stabilization of telomeric G-quadruplex structures. G-quadruplex-interactive ligands 
may induce a telomere dysfunction which results in a more rapid response on cellular 
growth and the induction of apoptosis compared to hTERT inhibition. These effects 
can be characterized by, for instance, the appearance of anaphase bridges and end-to-
end fusion of chromosomes.119  For examples, the interference of the telomere – 
capping caused by the dissociation of TRF2 from telomeres leads to rapid loss of the 
telomeric 3’-overhang and the induction apoptosis. The dissociation of TRF2 from 
telomeres might also disturb T-loops and induce anaphase bridge formation.120  
Furthermore, several essential protein functions could be impacted by G-quadruplex 
interactive ligands, such as, inhibition G-quadruplex unwinding by helicases (or even 
telomerases). 
A wide variety of G-quadruplex-interactive agents have been investigated for 
telomere-interaction and below are discussed those compounds that have progressed 
the farthest in biological characterization.  
The very first molecule that was shown to interact with G-quadruplex DNA 
structure and inhibit telomerase enzyme is a 2,6-diamidoanthraquinone derivative,121, 
 141
122  called BSU-1051, which was proof of this particular concept and laid the 
groundwork for the field of G-quadruplex-interactive compounds. The initial seed 
sown by BSU-1051 has resulted in a tremendous explosion of knowledge in the field 
of G-quadruplex-interactive agents during the subsequent ten years. BSU-1051 binds 
to G4 DNA formed from [d(T2AG3T)]4 by interaction at the 5’-AG step. Telomerase 
inhibition by this compound was studied utilizing telomerase primer extension assay 
without using PCR-based amplification of the primer extension products. With an 18-
nucleotide primer [d(T2AG3)3], the formation of 34-mers and higher products is 
significantly inhibited by BSU-1051 via targeting of G-quadruplex structure formed 
by these products.121   
After the introduction of BSU-1051, additional anthraquinones and numerous 
other ligands have been investigated as telomeric G-quadruplex-interactive 
compounds. Stephen Neidle’s research group has extensively studied more 
anthraquinone analogs and a series of di- and tri-substituted acridine derivatives. 
BRACO-19, one of the most interesting compounds of tri-substituted acridine series, 
induces chromosome end-to-end fusion consistent with telomere uncapping. 
BRACO-19 inhibits growth of DU145 prostate cancer cells faster than expected from 
solely inhibiting catalytic telomerase activity and the growth inhibition is 
accompanied with an increase in expression of p16INK4a and p21 proteins.122  
Moreover, BRACO-19 decreases nuclear hTERT protein expression in vitro and in 
vivo.123  
 142
Hurley’s research group has studied TMPyP4 and other porphyrin derivatives 
that bind to G-quadruplex DNA. Exposure of cancer cells to TMPyP4 results in the 
generation of anaphase bridges and  the induction of cellular growth arrest, 
senescence, apoptosis, and telomere length shortening.124  Fluoroquinophenoxazines, 
other series form Hurley’s lab, interact with G-quadruplex structure and inhibit the 
replication of G-quadruplex DNA in a Taq-polymerase stop assay.119   
RHPS4, a pentacyclic quinoacridinium salt presented by Kelland’s group that 
stacks at the end of G4 DNA, can induce the shortening of the telomeres and decrease 
the proliferation of the breast cancer cells simultaneously with reduction of 
telomerase activity and a lower expression of the hTERT gene. Moreover, RHPS4 
can induce growth arrest of cancer cells that possess telomere maintenance by a non-
telomerase mechanism (ALT). 125 
Telomestatin, a natural product from  Streptomyces anulatus 3533-SV4, 
selectively binds to G-quadruplex structure; it not only binds tightly to G4’ DNA but 
also facilitates its formation.126 Telomestatin potently inhibits telomerase activity. 
Long-term treatment of cells with telomestatin results in impaired telomeric overhang 






















































Figure 4-5  Examples of G-quadruplex-interactive ligands 
The challenges of this approach are in modulating the specificity of these 
compounds to G-quadruplex structures versus double stranded DNA and other 
structural motifs which may be transiently present in certain cellular processes. 
Another issue is selectivity for cancer cell telomeres versus those of normal cells as 
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well as avoiding the possibility of toxicity due to interaction with G-quadruplex 
structures in other regions of the genome besides the telomere. 
There is an awareness of the presence G-rich regions that could form G- 
quadruplex structures not only at the telomere but also throughout the genome, 
especially in the promoter regions or proto-oncogenes. Once G-quadruplex is formed, 
it is predicted that it would not dissociate spontaneously in vivo, and it is also 
expected that some mechanisms may be needed to resolve this special structure, such 
as, unwinding by helicases. Therefore, inhibition of helicase G-quadruplex unwinding 
activity in either the telomeres or other G-quadruplex forming regions is an 
alternative approach for anti-cancer therapy. G-quadruplex interactive agents that 
stabilize such structures may serve as specific G-quadruplex helicase inhibitors for 
this purpose.  
In addition, inhibition of helicase unwinding activity arising from G-
quadruplex structure stabilization and the ability to specifically inhibit the unwinding 
process for G-quadruplex structure could be a means to help understand the biological 
role of G-quadruplex structures. Furthermore, even if such G-quadruplex-interactive 
agents fail to inhibit a given helicase, the potential selectivity of these compounds for 
other G-quadruplex interactive proteins would help us understand the structure basic 
of these protein-G-quadruplex interaction. Selective inhibition of G-quadruplex 
helicase or other G-quadruplex-interactive proteins with selective G-quadruplex DNA 
ligands could provide important insights into the cellular roles of these proteins. 
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G-Quadruplex - interactive agents targeting promoters and RNA 
As mentioned previously, G-quadruplex formation could occur in G-rich 
regions, such as promoter region of c-myc, other than telomeres.  The c-myc gene 
encodes a transcription factor that regulates other genes associated with cell growth, 
proliferation, loss of differentiation and apoptosis.128  NHE III1, a 27-base pair 
sequence upstream of P1 promoter of c-myc, which plays a major role in the 
regulation of c-myc transcription, contains a G-rich strand on the non-coding strand. 
TMPyP4 as a G-quadruplex interactive ligand is shown to stabilize G-quadruplex 
structure and can downregulate c-myc expression via both mRNA and protein 
expression and also repress the expression of hTERT.4, 129  Recently, quindoline 
derivatives, such as, derivative c and i, have been shown to interact with G-
quadruplex DNA and inhibit the amplification of c-myc promoter region. Also, both 













Figure 4-6  Quindoline derivatives 
Along similar lines, the ribosomal DNA contains G rich sequences on the 
non-template strand. The transcription of ribosomal DNA occurs at a very high rate 
with a high density of polymerase I along the template DNA which means that there 
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is a need for high accessibility of the single strand template.131, 132  During the 
transcription, after denaturing of the templates, the non-template strands could form 
G-quadruplex structures, and it has been suggested that nucleolin protein interacts 
with G-quadruplex structures on the non-template strand to make the coding strands 
more available for multiple rounds of transcription.59 Moreover, the rate of ribosomal 
RNA biosynthesis is deregulated and increased in the cancer cells. The antitumor 
agent CX-3543, a quinobezoxazine analog from Cylene Pharmaceuticals, was 
designed to target G-quadruplex structures. CX-3543 shows binding selectivity to G-
quadruplex structures over duplex DNA, and is the first such compound in phase 1 
clinical trial (with advanced solid tumors or lymphomas) as a ribosomal RNA 
biogenesis inhibitor (RBI). CX-3543 is thought to disrupt the interaction between the 
nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA template 














Figure 4-7   
                                                 




Another example of G-quadruplex-interactive molecule that also affects non-
telomeric G-quadruplex structures is a disubstituted triazine derivative, 12459. 
Besides binding to telomeric G-quadruplex and inhibits telomerase,133 12459 can 
induce telomere shortening and apoptosis in cancer cells by downregulating 
telomerase activity. This effect involves alternative spicing pattern of the hTERT 
gene. The 5’end of hTERT intron 6 contains GGG repeats and is able to form G-
quadruplex structure; it is possibly that 12459 interacts with hTERT pre-mRNA by 














In conclusion, in the context of anti-cancer drug development, G-quadruplex-
interactive compounds are an interesting approach. G-quadruplex-interactive 
molecules could serve as inhibitors for telomerase-mediated extension of telomeric 
DNA or  helicase-unwinding of G-quadruplex DNA by stabilizing quadruplex 
structures that must be resolved in order to elongate the telomere or to replicate DNA. 
Binding of G-quadruplex-interactive ligands is also shown to inhibit the transcription 
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by interaction with G-quadruplex structures at promoter regions or other regulatory 
regions of certain genes or to alter splice-site selection by interaction with pre-mRNA 
G-quadruplex structures. The primary effect that has been observed from G-
quadruplex-interactive compounds is telomere dysfunction by interfering with the 
telomere-capping. Moreover, this G-quadruplex-binder/stabilizer approach would be 
beneficial for targeting certain cells which do not utilize telomerase mechanism but 
rely on an alternative mechanism for the lengthening of telomeres (ALT).  
Selectivity of G-quadruplex-interactive agents 
In this section, G-quadruplex-interactive agents and a discussion of issues 
related to the target specificity and affinity of G-quadruplex ligands will be presented. 
There are a number of G-quadruplex interactive ligands, of which some are natural 
occurring and many are man made by design. Several of them have been studied 
extensively and systematically. Quite a few techniques have been utilized to study the 
interactions between the ligands and G-quadruplex DNA, in trying to assess the 
binding and/or stabilization of G-quadruplex structure and to comprehend the affinity 
and selectivity of the ligands.  The most common approaches to characterize these 
ligands involve biophysical techniques, e.g., UV-Visible, fluorescence, CD, and 
NMR spectroscopy ; and non-cell based biological assays, e.g., TRAP assay and 
primer extension assay. In this section, telomerase inhibition studies are also 
mentioned. It is noteworthy that we should be concerned about the method used when 
we analyze the IC50 value from telomerase assays. The widely used method for 
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telomerase activity assay is a TRAP (telomeric repeat amplification protocol) 
assay.135 Using TRAP assays, after extension of telomerase substrate, the extension 
products are amplified by Taq polymerase-PCR, in which the ligands may also inhibit 
the amplification of G-rich oligonucleotide by Taq polymerase. Thus, we commonly 
see more potent IC50s from TRAP assay when compared to direct telomerase assays 
such as that developed by Sun and coworkers.136 
In the following sections several examples of compounds from literature that 
interact with G-quadruplex are presented, of which some were used in this research 
work. 
Perylene diimides 
The N, N’-bis[2-(4-piperidine)-ethyl]-3,4,9,10-perylenetetracarboxylic 
diimide (PIPER),137 containing two positive charges, had been reported as a specific 
G-quadruplex-interacting compound. The NMR and modeling experiments revealed 
that at a 1:1 PIPER to G4 DNA [d(TTAGGGTTA)]4   ratio PIPER externally stacks 
on the 3’-terminal of G-tetrad. PIPER was shown to be a good telomerase inhibitor in 
direct telomerase primer extension assay without PCR-based amplification. However, 
it takes several rounds of telomeric repeat elongation by telomerase before the 
inhibitory effect from PIPER can be seen; the inhibition probably arises from the G-
quadruplex stabilization of PIPER.137 Moreover, PIPER was the first compound 
demonstrated to be a G-quadruplex-interactive molecule that can also facilitate the 
formation of G-quadruplex structures. PIPER facilitates the formation of dimeric and 
tetrameric G-quadruplex DNA structures from single-stranded DNA containing two 
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tandem repeats of d(TTAGGG).138  In addition, PIPER inhibits Sgs1 G-quadruplex-
helicase (both G4 and G’2 DNA) activity by stabilizing the G-quadruplex structures, 
whereas no effect on duplex DNA unwinding activity was seen.139 Based on PIPER, a 
G-quadruplex-specific cleavage agent, perylene-EDTA•Fe (II), was designed. In the 
presence of DTT and without exclusion of oxygen, perylene-EDTA•Fe (II) 
selectively cleaves G’4 DNA formed by either tandem d(TTGGGG)4 or 
d(TTAGGG)4 containing DNA.140 The Kerwin research group has also designed other 
perylene diimide analogs. These works revealed that ligand aggregation is correlated 
with G-qaudruplex DNA binding selectivity. Tel01, having morpholino moieties at 
both ends of perylene diimide, binds selectively to G-quadruplex DNA. This 
selectivity derives from the pH-dependent aggregation of the ligand. At pH 7, Tel01 
is aggregated, as observed by resonance light scattering (RLS), and selectively binds 
G-quadruplex DNA; whereas PIPER, which is not aggregated at this pH, binds to 
both G-quadruplex DNA and duplex DNA. At pH 8.5, PIPER and Tel01 are both 
aggregated and selectively bind G-quadruplex DNA.141, 142 The anionic Tel12 which 
does not undergo aggregation (or if aggregation occurs, the aggregates are not RLS 
active) selectively and weakly bind to G-quadruplex structures.143 In addition, 
Kerwin’s group illustrated the relative G-quadruplex selectivity over double-stranded 
DNA for the series of perylene diimides at pH 7 
(Tel10>Tel04>Tel01>Tel08>PIPER>Tel03). 
Continuing studies of perylene diimide derivatives, several analogs of PIPER 
were synthesized and the effect of the different side chains on G-quadruplex 
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formation and telomerase inhibition were studied. It has been suggested that 
electrostatic interactions between perylene diimide side chains and grooves of G-
quadruplex structures is important. Savino’s group synthesized more derivatives of 
perylene diimides and studied their ability in inducing G-quadruplex structure and 
telomerase inhibition. It has been shown that electrostatically deficient PIPER2, 
lacking a positive charge under the incubation conditions (pH 6.5), could not induce 
the formation of G-quadruplex structure from a d(TTAGGG)2 containing single-
stranded DNA. Under the same conditions, DAPER, PIPER3 (Tel08), PIPER5 
(Tel01), PIPER6 and PIPER7 containing positive charges induce the G’2 structure 
formation; PIPER4 (Tel10) is less efficient in doing so, while PIPER prefers to 
induce the formation of G4 structure rather than G’2. Besides, only PIPER can induce 
the formation G4 DNA structure; DAPER and PIPER3 can induce only G’2 structure. 
When these compounds were incubated with a DNA sequence that can preferentially 
form a G4’ structure, PIPER, PIPER3 (Tel08), PIPER5 (Tel01), PIPER6 and PIPER7 
induce the G-quadruplex structure, but PIPER4 does so only at higher concentration. 
At higher pH (pH 7.5), the G-quadruplex inducing efficiency is not changed much, 
but PIPER4 (Tel10) and PIPER5 (Tel01) turn out to be less efficient compounds. This 
effect likely arises from the aggregation of ligands leading to their precipitation out of 
the solution.  
PIPER3, PIPER6, PIPER7 and DAPER are better telomerase inhibitors than 
PIPER in a TRAP assay using d(TTAGGG)2 containing telomerase substrate (pH 7.5 
for PIPER3, PIPER6 and  PIPER7; and pH 8.3 for DAPER and PIPER3). PIPER4 
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and PIPER5 cannot inhibit the telomerase in TRAP assay at pH 7.5. Besides the 
importance of positive charge on the side chains,  Savino’s group also suggested that 
compounds with longer positively charged side chains are better in inducing G’2 
formation.144, 145  
Tuntiwechapikul also looked at the effect of pH on G-quadruplex binding in 
different charge states of perylene derivatives. P-His selectively binds to G-
quadruplex in the zwitterionic state (pH 6).146 
Another variation on the perylene diimide structures are the coronene 
compounds, e.g., CORON and other derivatives. These compounds contain four 
hydrophilic side chains, two at the end, similar to previous perylene compounds and 
two extra ones on the rings after cyclization at the bay regions. Molecular modeling 
data of CORON and G4’ show that the aromatic core of CORON is superimposed 
with the terminal of G-tetrad of G4’and the four side chains of CORON lie towards 
the grooves of G-quadruplex structure. CORON, CORON2, CORON3 and CORON4 
exhibited an ability to induce G’2 and G4’ formation with preference for G4’ 
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The porphyrin molecules, for example, CuTMPyP4, bind to double stranded 
DNA by hemi-intercalation in which the CuTMPyP4–DNA complex is stabilized by 
electrostatic interactions between the positively charged nitrogen atoms of 
CuTMPyP4 and negatively charged phosphate groups of DNA backbone.148 The 
metal free cationic porphyrin 5,10,15,20-tetra-(N-methyl-4-pyridyl) porphine, 
TMPyP4, can bind to different types of nucleic acid stuctures, e.g., duplex DNA,149, 
150 triplex DNA,151 RNA,152  and G-quadruplex DNA.153, 154, 155, 156, 157 It has been 
reported that the modes of binding of TMPyP4 to double-stranded DNA depend on 
the DNA sequence, with intercalation between 5’-GC-3’149 and binding to minor 
groove of AT-rich sequences.158 The nature of the G-quadruplex binding of TMPyP4 
has been controversial; several models have been suggested. Hurley’s group proposed 
that TMPyP4 binds to the G4’ DNA structure formed from 
d(CATGGTGGTTTGGG(TTAGGG)3TTACCAC) by stacking externally to the 
guanine tetrad153 and Li’s group believes that TMPyP4 binds in a  4:1 ratio with G4’ 
folded from d[AG3(T2AG3)3] or G’2 formed from [d(G4T4G4)]2.155 by mixed mode of 
end stacking within loops and intercalating between G-tetrads. Yamamoto’s group 
showed that TMPyP4 binds to parallel G4 formed from [d(TTAGGG)]4 by stacking at 
5’ terminal  guanine tetrad,156 Li’s group suggests that TMPyP4 binds to parallel G4 
formed from [d(TG4T)]4 by end stacking of  guanine tetrad with 2:1 ratio of TMPyP4 
to G4.155  The most recent binding model is found in the crystal structure of a G’2-
TMPyP4 complex reported by Neidle’s group. TMPyP4 is shown to not bind to the 
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G-tetrad, instead it binds with G’2 (the propeller loops) formed from d(TAG3T2AG3) 
sequence by stacking on the TTA nucleotides.159 
Moreover, it has been found that TMPyP4 inhibits telomerase by interacting 
with G-quadruplex DNA (G4’).160 TMPyP4 has been shown to be an inhibitor of E. 
coli RecQ activity towards unwinding G4 with low specificity,8 in which IC50 value 
of inhibition of G4 unwinding and IC50 value of inhibition of double stranded 
unwinding are only 5 folds apart.  TMPyP4 inhibits Sgs1 helicase activity to unwind 
both G4 and G’2 DNA.161  In case of BLM and WRN helicase activity, TMPyP4 can 
also inhibit unwinding of G4. One cause of this effect arises from TMPyP4 
interfering with the binding of helicase protein to G4 DNA.162  Nevertheless, 
TMPyP4 can inhibit helicase activity of BLM to unwind G4, holiday junction 
substrates (structure that is mimic of homologous recombination intermediate) and 










































TMPyP4                                                     NMM
Pentacationic manganese(III) porphyrin 1  




N-methyl mesoporphyrin IX, NMM, which is anionic at physiological pH, selectively 
binds to G’2 DNA and G4 DNA over duplex DNA.164, 165   NMM  also is an inhibitor 
of RecQ helicase, inhibiting unwinding of G4 over duplex DNA.8 Against Sgs1 and  
BLM, NMM inhibits unwinding of G4 over duplex DNA and holiday junction 
substrates.163  Moreover, inhibition of G4-unwinding activity of BLM by NMM does 
not involve prevention of the binding of the helicase to G4 or by inhibiting ATPase 
activity required for helicase unwinding.163 One of the newest porphyrin derivatives 
to be explored, pentacationic manganese (III) porphyrin 1, contains an aromatic core 
which may interact with G-tetrads and four long, flexible cationic arms which might 
interact with loops or grooves of G-quadruplex structures. This compound binds to 
G4’ formed by d[AG3(T2AG3)3] 4 orders of magnitude better than double stranded 
DNA. This derivative also inhibits telomerase activity in TRAP assay (IC50 = 0.58 
µM)166 
Distamycin A  
Distamycin A, a duplex-DNA minor groove binding agent, has also been 
reported to bind G4 DNA, although the mode of G-quadruplex DNA binding remains 
controversial.167, 168  An initial NMR study showed that distamycin A binds to G4 
DNA (formed from [d(TG4T)]4) by groove binding.167, 169 Later on it was shown by 
another NMR binding study with G4 (formed from [d(TG3TTA)]4) that distamycin A 
interacts with G4 by binding on the terminal G-tetrad and contacting the flanking 
bases.168 Distamycin A inhibits double-stranded DNA unwinding activity of WRN 
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and BLM helicases,170 but it does not inhibit the G4 unwinding activity of BLM.168  
Distamycin A is also an inhibitor of SV 40 large T antigen duplex helicase activity 


















Distamycin A  
Figure 4-13 
Carbocyanines 
Spectroscopic studies showed that DODC (3,3’-diethyloxadicarbocyanine) 
interacts with G’2-DNA structures by groove binding interactions, but it has been  
suggested that it binds differently to G4 stuctures.172, 173 Absorption spectroscopic 
titration showed that  DODC binds to G’2 formed from [d(G4T4G4)]2  5 times stronger 
than to double-stranded DNA.172 Moreover, equilibrium competition dialysis 
demonstrated that DODC prefers to bind G’2 over G’4 and G’4 over G4; 
nevertheless, DODC showed a preference for triplex DNA (poly dA:[poly T]2) 
binding over the G-quadruplex DNA.174  Another interesting carbocyanine dye, DTC 
(N,N’-diethylthiacarbocyanine) was shown to bind G’4 and G4 by absorption 
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spectroscopy. Additionally, DTC can inhibit telomerase in direct assay and also 











DODC DTC  
Figure 4-14 
Anthraquinone analogs 
Anthraquinone derivatives are well-known duplex DNA biding agents. 
Derivatives having side arms that are proximal, e.g., 1,4-diamidoanthraquinone and 
1,8-diamidoanthraquinone, intercalate into double stranded DNA with the side arms 
located in the same groove. Derivatives that have 1,5- or 2,6-disubstituents, e.g., 1,5-
diamidoantraquinone and 2,6-diamidoantraquinone, threading-intercalate into double 
stranded DNA such that the side chains occupy both the major and minor groove.51, 
176, 177 Molecular modeling and DNase I footprinting suggested that 2,6-
diamidoanthraquinones prefer to bind triplex DNA over double stranded DNA. BSU-
1051, a 2,6-diamidoanthraquinone derivative, was demonstrated by NMR to bind in 
an intercalation binding mode at the 5’-AG step to G4 formed from [d(T2AG3T)]4. 
Moreover, in telomerase primer extension assay which used an 18-nucleotide primer 
[d(T2AG3)3], BSU-1051 was shown to inhibit telomerase at 34-mers and higher 
products by targeting G-quadruplex structures.121 Other examples of difuctionalized 
amidoanthraquinone as telomerase inhibitor were shown by Neidle’s group who 
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prepared and examined the in vitro cytotoxicity, telomerase inhibition using TRAP 
assay, and Taq polymerase inhibition (Taq polymerase assay serves as a screening 
test for duplex DNA binding) of a series of 1,4-, 1,6-, 1,5-, 1,8-, and 2,7- 
difunctionalized amidoanthraquinone. It was suggested that the positions of 
disubstituents are not important, but the natures of disubstituents always required a 
terminal cationic groups. However, it should be noted that, in these series of 
difuctionalized amidoanthraquinones, there is no significant correlation between 
telomerase activity and cytotoxicity among the compounds (detailed in Perry, P.J, 
1998178, 179). 
Anthraquinone-related natural products, anthracycline anticancer antibiotic, 
e.g., daunorubicin, doxorubicin, nogalamycin, which can intercalate double stranded 
DNA, have been shown to inhibit the duplex unwinding by SV 40 large T antigen 
helicase  in the model that used 17-mer annealed with complementary M13mp19(+) 






























Acridine derivatives  
Based on the concept of stabilizing G-quadruplex structures, Neidle’s research 
group has systemically studied structure activity relationships of the acridine 
derivatives targeting telomerase activity. The planar chromophore and basic 
heterocyclic nitrogen atom of acridine structure which is comparable to the 
anthraquinone scaffold is appealing as G-quadruplex interacting compound.  The first 
acridine analogs synthesized and examined as telomerase inhibitors were a series of 
3,6-disubstituted acridines.  Using TRAP assay, the IC50s are in micromolar range (1-
8 µM) and all compounds studied showed no effect on Taq polymerase activity up to 
at least 50 µM concentrations. However, 3,6-disubstituted acridines with bulky 
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aminoalkyl substituents and the one with  morpholino substituents are inactive as 
telomerase inhibitors in TRAP assay.182 Moreover, docking with NMR structure of 
G4’ DNA folded from d[AG3(TTAG3)3]  and molecular modeling  suggested that 
disubstituted acridine with pyrrolidino groups stacks on the 5’-terminal of G-tetrad, 
between quartet and TTA loop.183, 184, 185 It is worth noting that from SPR binding 
studies, this 3,6 disubstituted acridine derivative 4 with pyrrolidino groups has been 
































 Later, trisubstitued acridines were designed, adding a substituent at the 9-
position predicted to increase the interaction with G-quadruplex structure. Computer 
modeling suggested that while two amidoalkylamino substituents at the 2- and 6-
positions lie in two opposite grooves of G4’, the 9-position substituent is directed 
towards the other groove of G4’. SPR binding studies showed that the trisubstitued 
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acridine derivatives, with 9-anilino substituents, derivative 1 and BRACO-19, bind to 
G4’ more strongly than 2,6-disubstituted acridines (30-40 times) and display a 10-
fold higher affinity than duplex DNA. BRACO-19 shows an ability to stabilize G4’ 
structure by altering the melting temperature (∆Tm = 27.5 ºC at 1 µM of ligand).  Both 
derivatives are approximately 50-80 times more potent in a TRAP assay (IC50 of 
BRACO-19 = 0.12 µM)184 than disubstituted acridines.185, 186 The optimal length at 
the 3- and 6- positions is two carbon chains between amide groups and terminal 
nitrogens in order to maximize G-quadruplex binding properties and selectivity as 
well as telomerase inhibitory activity. Increasing these side chains lengths leads to 
decrease telomerase inhibitory activity.186  Optimization at the 9-position with one 
additional carbon linker leads to the newest trisubstituted acridine derivative 2 with 
slightly improved ability to stabilize G4’ structure by ∆Tm of 29.5 ºC at 1 µM of 


































There are other variations of acridine which are interesting. A series of 2,6-, 
2,7- and 3,6-disubstituted acridone derivatives were presented as significant 
telomerase inhibitors in TRAP assay. Bis-2,6-disubstituted acridone derivatives were 
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more potent than bis-2,7- or bis-3,6-disubstituted derivatives. However, none of 

















Pentacyclic quinoacridinium salts, RHPS3 and RHPS4, exhibit telomerase 
inhibitory activity in TRAP assay with IC50 values of 0.25 and 0.33 µM, respectively. 
Both derivatives show some selectivity to G-quadruplex formed from d(T2G20T2), 
G4’ folded from (d[AG3(T2AG3)3]  and Triplex DNA (poly(T)•[poly(dA)•poly(T)]) in 
competition dialysis experiments.189  NMR study of RHPS4 and G4 folded from 
d(TTAGGGT) sequence in the presence of K+  suggested that RHPS4 stacks at the 
















Pentacyclic crescent-shaped dibenzophenanthroline derivatives have been 
developed as G-quadruplex binding stabilizing agents as telomerase inhibitors. 
MMQ3 stabilizes G4’ (∆Tm = 19.7 ºC at 1 µM of ligand) and inhibits telomerase 
activity in TRAP assay (IC50=28 nM), but also displays inhibitory effects on Taq 
polymerase (IC50=0.8 µM). BOQ1, a macrocyclic compound with two 
dibenzophenanthroline units, can stabilize G4’ structure (∆Tm = 28 ºC at 1 µM of 
ligand), inhibits telomerase activity in TRAP assay (IC50=0.13 µM), but also inhibits 
Taq polymerase (IC50=0.3 µM). BOQ1 also induces the formation of intermolecular 
G-quadruplex structure. In competition dialysis experiments, BOQ1 prefers to bind to 
G-quadruplex structures from d(T2G20T2) sequence, G4’ folded from d[A(G3T2A)3G3]  






















Both di- and trisubstituted acridines were shown to inhibit BLM and WRN 
helicase unwinding of G4 structure. Trisubstituted acridine derivative 1 and BRACO-
19 are approximately 15-25 times and 10 times more potent at inhibition of BLM and 
WRN, respectively, than pyrrolidino-disubstituted acridines. The G4-unwinding 
inhibitory effects by BRACO-19 were associated with a decrease of helicase binding 
to G4 DNA. It should be noted that BRACO-19 also inhibits helicase activity of BLM 
and WRN to unwind synthetic holiday junction with a potency comparable to the 
unwinding of G4 DNA.162  
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Ethidium bromide and derivatives.  
Well known duplex DNA intercalator, ethidium bromide,194 also binds with 
triplex195, 196 and G-quadruplex structures.197, 198  Ethidium bromide binds to G4 
formed from [d(T4G4)]4197 and the G4’ formed from the human telomeric sequence 
[d(AG3(T2AG3)3)];199 There is disagreement over the exact G-quadruplex binding 
mode, intercalation or external stacking of ethidium bromide.167, 197  Ethidium 
bromide is not a good inhibitor in the TRAP assay, and not surprisingly, 
preferentially inhibits Taq polymerase activity. However, certain ethidium bromide 
derivatives, e.g., ethidium bromide derivative 1, inhibit telomerase in TRAP assay 
with little effect on Taq polymerase. Competition equilibrium dialysis shows 
ethidium bromide derivative 1 to be somewhat selective for binding to G4’ folded 
from d(AG3(T2AG3)3) and G-quadruplex structure formed from d(T2G20T2) over 
duplex DNA [both calf thymus DNA and poly d(GC)].199, 200 As an intercalator for 
duplex DNA, ethidium bromide also inhibits the duplex unwinding activity of T ag,180 
but only modestly inhibits duplex unwinding activity of  WRN (IC50 ~ 10µM) and 














The natural product telomestatin, isolated from Streptomyces anulatus 3533-
SV4, was shown to be a potent telomerase inhibitor in TRAP assay (IC50 = 0.005 µM) 
with no effect on DNA polymerase activity and weak inhibitory effect on a reverse 
transcriptase (e.g., IC50 of HIV- reverse transcriptase = 19.4 µM).201  Without the 
presence of  any Na+ or K+ in solution, telomestatin facilitates the G4’ formation from 
repeated telomeric sequence, d[(T2AG3)4] , but  it shows much less efficiency in 
facilitating and/or stabilizing G-quadruplex structure from the sequence containing 
six consecutive guanine, d[C2ACT5A4GA4G6ACTG2].126 Telomestatin is shown to be 
G4’-tight binder and is not easily dissociated from G4’-telomestatin complexes.202  
Intriguingly, telomestatin induces conformational change of the G-quadruplex 
structure shown by CD studies. The d[(T2AG3)4] sequence displays CD spectra 
differently in Na+, K+, mixed salts of Na+- K+ and no salt conditions; however, 
telomestatin converts those G-quadruplex conformations to the one that  similar to the 
one that also given by Na+ containing environment which believed to be the structure 
called basket-type anti-parallel, comprised of a combination of loops, lateral-
diagonal-lateral loops.203  The selectivity of telomestatin to G-quadruplex structure 
was demonstrated. In FRET-Tm experiment, telomestatin stabilizes G4’ structure and 
displays some selectivity over double-stranded DNA. In polymerase stop assay using 
the DNA-template containing d[(T2AG3)4] sequence, telomestatin significantly 
increased a pausing site at the  G4’-forming site  in dose-dependent manner, whereas 
with the modified DNA-template containing d[T2AGAG]4 sequence which cannot 
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form G-quadruplex structure, the increase of pausing is not observed. This result also 
supports the presumption that telomestatin inhibits the polymerase activity by 
interacting with the G-quadruplex in the template and its selectivity to the G-



















Hurley’s group proposed two possible binding modes of telomestatin based on in 
silico simulation; telomestatin may bind to G4’ (d[AG3(T2AG3)3]) in a 2:1 complex 
(telomestatin to G4’) by either external stacking (each telomestatin stacks between 
loop and G-tetrad) or intercalating between G-tetrads (one is between top tetrad and 
middle tetrad, the other is between middle tetrad and bottom tetrad).204  Moreover, the 
short-term cellular exposure of telomestatin arrests the cellular growth and 
significantly decreases telomeric G-overhang127 and the double stranded telomeric 
repeats;205 the long-term cellular exposure of telomestatin at non-cytotoxic 
concentration also causes cellular senescence and telomere erosion.124 Interestingly, 
 174
the telomestatin treated cells display a decrease of POT1 and TRF2, proteins 
involving in telomere capping and t-loop maintenance.205 In brief, telomestatin, a 
relatively novel G-quadruplex binding molecule to date, potently inhibits telomerase 
activity, selectively binds to G-quadruplex structure, impairs telomeric overhang 
structure and causes cellular senescence.  
Other G-quadruplex interactive agents 
The number and diversity of G-quadruplex interactive ligands have 
significantly increased and continue to expand rapidly. The interactions of the ligands 
with the G-quadruplex can occur by several means; stacking on the surface of G-
tetrad or intercalating between G-tetrads participating in π- π interactions, binding 
with grooves between the phosphodiester linkages, interacting with loop, such as , 
d(TTA) in repeats of  d(T2AG3) containing sequence or could be by a combination of 
these modes of interaction.  There are still many molecules that have been studied for 
instance:  Fluoroquinophenoxazines, e.g. QQ58, has been demonstrated to interact 
with both G4 and G4’ quadruplex structures. NMR studies reveal that QQ58 stacks at 
3’-end G-tetrad of G4 (d[TAG3T2A]4), similar to the G4 binding of PIPER. From 
photo-mediated DNA cleavage pattern and NMR, it was suggested that QQ58 off 
center-externally binds at the very first G-tetrad of G4’folded from d[AG3(T2AG3]3). 
Furthermore, the G-quadruplex interaction of fluoroquinophenoxazine leads to 
inhibition of telomerase and increase in pause site in the polymerase stop assay. 
Hoechst 33258, a bis-benzimidazole compound, binds to minor groove of the duplex 
DNA especially at A-T rich sequences.206, 207  It also it has been shown to bind to 
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intramolecular G-quadruplex formed by promoter region of human c-myc, d(GG 
GGAGGG TGG GGA GGG TGG GGA AGG TGG GG)  with moderate affinity and 
it is proposed that it may interact with AAGGT loop of G quadruplex structure.208 
This compound is required in concentrations up to 10 µM to reach 50% inhibition of 
duplex unwinding activity of WRN and BLM helicases.170  
Coralyne and berberine are able to induce the formation of G’2 structure from 
d(G3(AT2G3)3T2) sequence. It was shown that both compounds can stabilize G4’. 
Using FRET techniques,  their binding affects an increase in the G4’melting 
temperature, whereas there is no significant effect on melting temperatures of double 
stranded genomic DNA, and both compounds are able to inhibit telomerase in TRAP 
assay. In both cases, the effects of coralyne binding to G-quadruplex are more 
pronounced than berberine.209 Quindoline derivatives have been designed and studied 
as G-quadruplex binding ligands.210, 211 Quindoline derivatives 1, can induce and/or 
stabilize the G-qaudruplex formation from d[G3(T2AG3)]3 sequence in the presence of 
K+ salt, which gives rise to a slow moving band. Also, quindoline derivatives 1 
display some G-quadruplex selectivity over duplex DNA in competition dialysis 
experiment and also inhibit telomerase in TRAP assay.130  From spectroscopic 
studies, Quercetin show to bind to G4 structure.212 Octacationic zinc phthalocyanine 
(ZnPc) show to stabilize G4’ by increasing the Tm and inhibit telomerase in TRAP 
assay (IC50 = 0.23 µM). From CD spectroscopic analysis, it suggested that ZnPc 
could alter the conformation of G4’ from antiparallel to parallel form.213 In vitro 
experiments have shown that pyridine-dicarboxyamide compound, 360A selectively 
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binds to G-quadruplex DNA folded from AG3(T2AG3)3  sequence and also, in the cell 
culture experiments, it was found that the tritiated 360A binds to the  terminal region 
of the chromosome of both human normal cells and tumor cells.214 The compound 
360A inhibits cellular proliferation and induces apoptosis of both telomerase-positive 
cell lines and ALT cell lines.215 Se2SAP, a selenium-substituted expanded porphyrin, 
was designed, based on the TMPyP4 and telomestatin molecules, and synthesized by 
Hurley’s lab. Se2SAP binds to G4’ DNA and selectively binds the c-MYC G-
quadruplex. This ligand is able to convert parallel G4’ consisting of all propeller 
loops formed from c-MYC sequence to a mixed parallel and antiparallel G4’ 
consisting of one lateral loop and two propeller loops.  Se2SAP binds to G4’ causing 
a Taq polymerase to pause at the at the G-quadruplex forming site.203, 216 Another 
compound that binds to G-quadruplex structure and is used in a number of 
quadurplex binding studies is TOTA, a trioxatriangulenium ion. TOTA is 
demonstrated by NMR binding studies to exhibit similar effects to those observed in 
end-stacking of perylene diimides upon binding to G4 DNA. Although TOTA does 
not show any selectivity for binding to double-stranded DNA or G-quadruplex DNA, 
photochemical cleavages of these two DNA  structures containing  d(T2AG3)4 or 



























































































Figure 4-23  More examples of G-quadruplex interactive agents 
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G-quadruplex-interactive agents one of the essential tools in disclosing the 
role and function of G-quadruplex motifs that could be present in the human telomere 
and along the human genome. Searching for selective ligands for G-quadruplex DNA 
and understanding their binding behaviors and cellular effects mediated by their 
interaction with G-quadruplex DNA are still necessary. Even more challenging is the 
creation of molecules that are specific for a variety of G-quadruplex conformers, 
especially to the one of interest. We still do not understand the exact conformations 
and folding pattern of G-quadruplex at the telomere or at other sites located along the 
genome (if there are any). It is worth believing that different G-rich DNA sequences 
in the cell adopt different conformations because in vitro experiments demonstrate 
that structural diversity.  
For example, for the purpose of G-quadruplex DNA targeted drug design, the 
multiple in vitro-determined structures for human telomeric G-quadruplexes leads to 
uncertainty concerning which exact conformation of G-quadruplex structure we really 
want to target. In addition, the multiplicity of potential, non-telomeric G-quadruplex 
structures could lead to interactions with G-quadruplex structures that we may not 
want to target through, for example, helicase protein inhibition at these sites. On the 
other hand, these non telomeric G-quadruplex structures may serve as targets in their 
own right, for example, G-rich regions at the promoter sites which are potentially 
important in regulation of growth and proliferation are also of interest.     
In the following chapter, G-quadruplex unwinding activity of SV 40 large T 
antigen is confirmed and utilized as an indicator to assess the ability of compounds 
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studied to interact with and/or stabilize G-quadruplex DNA.  Potent and selective 
inhibitors of the G-quadruplex DNA helicase activity of T-ag were found. G-
quadruplex DNA binding studies of these T-ag G-quadruplex helicase inhibitors was 
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Chapter 5                                                                                
Simian Virus 40 Large T-antigen G-Quadruplex DNA Helicase 
Inhibition by G-Quadruplex DNA-Interactive Agents 
The ability of G-rich telomeric DNA sequences to adopt G-quadruplex 
structures, particularly in the presence of small molecule ligands, may form the basis 
for an anticancer therapy strategy by virtue of the ability of these G-quadruplex-
interactive ligands to inhibit telomerase and alter telomere dynamics in cancer cells.1, 
2, 3, 4  Other G-rich regions of the genome,5, 6  including a number of gene promoters,7, 
8, 9, 10 are also capable of forming G-quadruplex structures, which may serve as targets 
for transcriptional control through small molecule ligands.  There are predictions of in 
excess of 370,000 putative quadruplex-forming sequences throughout the human 
genome.11, 12  It has been suggested that there is a correlation between G-quadruplex 
formation and genetic stability13 and gene function.14, 15  Perhaps the strongest 
evidence for the formation of G-quadruplex DNA in cells comes from visualization 
by electron microscopy of G-loops, G-quadruplex DNA-containing structures formed 
on the non-template strand during transcription of G-rich DNA in E. coli.16 
Evidence for a biological role of G-quadruplex DNA includes a growing list 
of proteins that display specific interactions with these higher-order DNA 
structures.17  Helicases in the RecQ family, including E. coli RecQ,18 Sgs1p,19 
BLM,20 and WRN21 have been shown to possess G-quadruplex unwinding ability.  
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These RecQ family helicases share a C-terminal G-quadruplex binding domain, 
RQC.22  While it has been hypothesized that the G-quadruplex unwinding activity of 
these RecQ helicases is required to resolve structures that form throughout the 
genome during DNA replication and recombination,20 the exact biological role for the 
G-quadruplex DNA unwinding activity of these RecQ helicases is not known.    
 To date, few non-RecQ-family helicases have been shown to unwind G-
quadruplex DNA structures.23  SV40 large T-antigen (T-ag) is a multifunctional 
protein required for viral replication and transformation whose functions include 
double-stranded DNA helicase activity.24 The replication of the SV40 genome has 
many biochemical similarities to that of eukaryotic chromosomes, and is often 
employed as a model system for studying cellular DNA replication.25, 26, 27 In addition 
to its duplex DNA helicase activity, T-ag has also been reported to unwind G-
quadruplex structures.28 The role for this G-quadruplex helicase activity in SV40 
replication has not been determined, but an unusual four-stranded G-quadruplex has 
been observed by NMR for an oligonucleotide encompassing GGGCGG repeat 
sequence in the SV40 genome.29  Interestingly, certain antiproliferative G-rich 
oligonucleotides (GROs), which can form dimeric or monomeric G-quadruplex 
structures30 have been shown to inhibit T-ag duplex helicase activity.31 Given the 
kinetic stability of G-quadruplex DNA32 and the well-established ability of G-
quadruplex structures to serve as efficient blocks to DNA polymerization,33 the ability 
of hexameric helicases such as T-ag to unwind these structures may be a general 
requirement for efficient DNA replication. 
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There is a growing interest in G-quadruplex DNA-interactive agents as 
potential telomere and telomerase-targeting agents1, 2 or transcriptional regulators.34 
One promising class of quadruplex selective-ligands are perylene diimides (Figure 5-
1).35, 36, 37, 38, 39, 40, 41 Recent NMR studies of N,N’-bis[2-(1-piperidino)-ethyl]-3,4,9,10-
perylenetetracarboxylic acid diimide (PIPER)35 and N,N’-bis(4-morpholinylpropyl)-
3,4,9,10-perylenetetracarboxylic acid diimide (Tel01)42 (Figure 5-1) indicate that 
these molecules bind to G-quadruplex DNA by stacking on the faces of the terminal 
G-tetrads, thereby stabilizing the G-quadruplex structure.  Interestingly, the 
selectivity of these ligands for G-quadruplex DNA versus duplex DNA can be quite 
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The potential of G-quadruplex DNA-interactive agents to interfere with G-
quadruplex DNA helicases such as those of the RecQ family has been recognized as a 
potential therapeutic approach.44 Inhibition of G-quadruplex helicases involved in 
telomere maintenance by telomerase or telomerase-independent (ALT) pathways may 
provide a means of limiting the replicative capacity of cancer cells.   Alternatively, 
inhibiting the helicase unwinding G-quadruplex structures formed in oncogene 
promoters may result in transcriptional down-regulation of these genes. While a 
number of G-quadruplex-interactive ligands have been reported to inhibit the G-
quadruplex unwinding activity of RecQ helicases, issues of selectivity remain.  The 
cationic porphyrin TMPyP4 (Figure5-2) inhibits the G-quadruplex helicase activity of 
E. coli RecQ,18  yeast Sgs145 and human BLM45, 46 and WRN46 helicases, although the 
inhibition is generally not selective for G-quadruplex versus duplex DNA.  In 
contrast, the anionic porphyrin NMM (Figure 5-2) is a specific inhibitor of the G-
quadruplex helicase activity of RecQ,18 BLM,45, 47 and Sgs1.45  PIPER (Figure 5-1) is 
also a potent and selective inhibitor of Sgs1.48  However, the molecular features of G-
quadruplex-interactive agents that give rise to potent and selective RecQ G-
quadruplex helicase inhibition are not well established.  Distamycin (Figure 5-2), 
which binds to G-quadruplex DNA, does not inhibit the G-quadruplex helicase 
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Unlike these studies of the RecQ helicases, there have been no studies of the 
effects of G-quadruplex DNA-interactive agents on T-ag G-quadruplex helicase 
activity. Proposed therapeutic approaches involving G-quadruplex interactive agents 
require selective targeting, not only of G-quadruplex structures but also of specific G-
quadruplex-associated proteins.  As different families of G-quadruplex helicases may 
interact differently with their substrates, certain types of G-quadruplex ligands may 
be better inhibitors of specific helicase families.   Studies of the effect of a variety of 
G-quadruplex-interactive agents on different G-quadruplex helicases will lead to a 
better understanding of the structural basis for selective targeting of different families 
of G-quadruplex DNA helicases.  Inhibitors of specific classes of G-quadruplex 
helicases may be useful as tools to elucidate the role of G-quadruplex unwinding in 
specific biological processes or as therapeutic agents targeting these processes.   
Here, in the Kerwin lab, I confirm and expand upon the previous report of T-
ag G-quadruplex helicase activity.  I demonstrate that this G-quadruplex helicase 
activity is efficient compared to the duplex helicase activity of T-ag.  Analysis of the 
SV40 genome demonstrates the presence of sequences that may form intramolecular 
G-quadruplexes, which are the presumed natural substrates for the G-quadruplex 
helicase activity of T-ag.  A number of G-quadruplex interactive agents as well as 
new perylene diimide derivatives have been investigated as inhibitors of both the G-
quadruplex and duplex DNA helicase activities of T-ag.  I find that a unique subset of 
these G-quadruplex interactive agents inhibit the G-quadruplex DNA unwinding 
activity of T-ag, relative to those reported to inhibit G-quadruplex DNA unwinding 
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by RecQ-family helicases.  I also find that certain perylene diimides are both potent 
and selective inhibitors of the G-quadruplex DNA helicase activity of T-ag.  Binding 
studies of these T-ag G-quadruplex helicase inhibitors have been carried out.  These 
studies indicate that in addition to binding affinity, other aspects of G-quadruplex-
interactive agents may be important for effective inhibition of T-ag G-quadruplex 
helicase. 
Preparation of DNA substrates 
A 5’-radiolabeled DNA oligonucleotide (DNA1, Figure 5-3) containing two 
TTGGGG repeats was annealed in a K+-ion-containing buffer to form predominantly 
the dimeric G-quadruplex structure (G’2), which was purified by preparative 
polyacrylamide gel electrophoresis.  In addition to its altered gel mobility, this 
structure was characterized by DMS protection which demonstrated reduced 
accessibility of the G’s in the TTGGG repeats relative to unfolded DNA1 (Figure 5-
4).  While the structure of the G’2-DNA1 shown in Figure 5-3 is of a head-to-tail type 
with lateral loops on opposite ends of the G-tetrad stack, our characterization was not 
able to distinguish this form from alternative possible structures including head-to-
head or basket-type dimers.  Annealing the same DNA1 oligonucleotide in Na+-ion-
containing buffer afforded the tetrameric G-quadruplex (G4, Figure 5-3), which was 
also purified by preparative electrophoresis and characterized by DMS protection of 
the Gs forming the G-tetrads (Figure 5-4).  A duplex helicase substrate containing a 
3’-single-stranded tail (ds-DNA2/3) was prepared by annealing 5’-radiolabeled 
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oligonucleotide DNA2 with a complementary strand containing an oligonucleotide-
























































Figure 5-4   DMS footprinting analysis of the G’2 DNA and G4 substrates in the 
presence of 10 mM KCl. The various incubation times with DMS as indicated (5, 10, 
20, 30 min). The guanines in the tetrads which participate in G-quadruplex formation 
are protected from methylation. The experiments simultaneously performed with the 
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T-ag unwinds a G-quadruplex substrate better than a duplex DNA 
substrate 
Based upon the work of Manor and co-workers,28 I, in the Kerwin Lab, 
explored the alkali metal ion effects on SV40 T-ag helicase activity employing G’2, 
G4, and duplex DNA substrates.  Helicase reactions were carried out in the presence 
of either 400 ng or 800 ng of commercially available recombinant T-ag.  In the 
presence of Mg2+ and ATP (4 mM), T-ag efficiently unwinds the G’2-DNA substrate 
in an alkali metal ion-independent fashion (Figure 5-5).  In contrast, G4-DNA is 
unwound preferentially in Na+-containing buffer. Presumably, the increased stability 
of G4-DNA in K+-containing buffer inhibits the unwinding of this substrate.   Both in 
the case of G’2 and G4-DNA, the T-ag unwinding of G-quadruplex substrates 
requires ATP. 
While the duplex DNA unwinding activity of T-ag is well established, in our 
hands commercially available T-ag converts the duplex ds-DNA2/3 substrate to a 
high-mobility product in an ATP-independent fashion.  This product, corresponding 
to the band labeled “X” in Figure 5-5, runs faster than single-stranded DNA2 under 
both native (Figure 5-6) and denaturing PAGE (Figure 5-6).   In the presence of ATP, 
the duplex ds-DNA2/3 substrate is converted to this high-mobility product and single-
stranded DNA2, and the formation of both products is not sensitive to the nature of 
the alkali metal ion present.  Comparison of the duplex versus G’2-DNA unwinding 
efficiency of commercial T-ag indicates that G’2-DNA is unwound at least as 
efficiently as the duplex substrate; however, the presence of an apparent nuclease 
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Figure 5-5 Comparison of alkali metal ion effects on SV40 T-ag helicase activity 
with G’2, G4, and ds DNA substrates.  Helicase reactions were carried out in the 
presence of 10 mM KCl (K+) or NaCl (Na+) on 5’-labeled G’2-DNA1 (A), 5’-labeled 
G4-DNA1 (B), or 5’-labeled ds-DNA2/3 (C).  Lanes NE are control G’2, G4, or ds 
DNA.  Lanes NA are substrate DNA in the presence of 800 ng T-Ag without ATP.  
Lanes 1 are substrate in the presence of 400 ng T-ag, and 4 mM ATP.  Lanes 2 are 
substrate in the presence of 800 ng T-ag and 4 mM ATP.  Helicase unwinding 
reactions were carried out at 37 °C for 90 min, and the products analyzed by non-
dentaturing gel electrophoresis.  The mobility of G2’, G4. ds, DNA1. DNA2 are 
indicated.  A high mobility product “X” was observed for certain batches of 
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Figure 5-6 Unwinding of ds-DNA2/3 (0.38 pmol) or ss-DNA2 (0.38 pmol) by SV40 
large T antigen (850 ng T-ag). Helicase reactions were carried out in the presence of 4 
mM ATP and 10 mM KCl on 5’-labeled ds-DNA2/3 (1), or 5’-labeled ss-DNA2 (2). 
Lane ds and lane ss are ds-DNA2/3 and ss-DNA2, respectively. Lanes NE are 
substrate DNA in the absence of T-Ag.  Helicase activity was determined after 15 h 
incubation at 37°C. Panel A, the samples were subjected to non-denaturing PAGE; 
panel B the samples were subjected to denaturing PAGE. 
A. 
B.  
ds ss NE             1
ds ss NE             1 NE             2




A better comparison of the duplex versus G’2-DNA unwinding activity of T-
ag was obtained using immunochromatography-purified recombinant T-ag expressed 
in insect cells.‡, 49 This source of T-ag did not display the apparent nuclease activity 
associated with the commercially available material.   In the presence of increasing 
concentrations of this T-ag, the duplex ds-DNA2/3 substrate is unwound to single-
stranded DNA2 in an ATP-dependent fashion without the production of higher-
mobility products (Figure 5-7A).  However, the concentration of T-ag required for 
unwinding of the duplex DNA substrate is 6- to 8-fold higher than that required for 
unwinding the G’2-DNA substrate (Figure 5-7B).  This preference for unwinding G-
quadruplex DNA is not shared by other helicases. The concentration of T-ag required 
to completely unwind the G’2-DNA substrate under these conditions (0.35 nM T-Ag 
hexamer) is 100-times lower than the approximate substrate concentration in these 
assays (38 nM), further illustrating the efficiency of the G-quadruplex helicase 








                                                 
‡ Immunochromatography-purified recombinant T-ag expressed in Sf9 insect cells 








Figure 5-7 Comparison of duplex and G-quadruplex DNA helicase activity of T-ag.  
Incubation of 0.38 pmoles of 5’-labeled ds-DNA2/3 (A) or G’2-DNA1 (B) was 
carried out with the indicated concentration of recombinant, immunopurified T-ag 
and 4 mM ATP for 90 min at 37 °C in 10 mM Tris-HCl, 10 mM KCl, 10 mM MgCl2, 
0.5 mM DTT, 50 µg/µL BSA, 0.1 mM EDTA, and 10 % glycerol at pH 7.  The 
reaction products were analyzed by non-denaturing gel electrophoresis.  Lanes NE are 
DNA substrate in the absence of T-ag and lanes NA are the substrate in the presence 
of T-ag but without added ATP. 
These studies confirm and expand upon the earlier report by Manor and co-
workers of the G-quadruplex helicase activity of T-ag.28 It is shown that T-ag 
unwinds G’2-DNA with a relatively high efficiency and preference when compared 
to a duplex DNA.  The RecQ-family helicases, which also unwind G-quadruplex 
DNA, possess a RQC G-quadruplex DNA binding motif.  SV40 T-ag does not 
possess a RQC domain or any other previously-reported G-quadruplex DNA-
interactive protein motif.  Thus, the mode of interaction of T-ag with G-quadruplex 
NE     NA               1.4     1.0     0.7    0.35   0.17      NE     NA              1.4     1.0      0.7    0.35 0.17 nM T-ag






DNA may be distinct from that for RecQ-family helicases and other G-quadruplex-
associated proteins.   
Potential intramolecular G-quadruplex DNA structures in SV40 DNA.   
 The demonstration of a robust G-quadruplex unwinding activity of SV40 T-ag 
led to an investigation of the potential G-quadruplex structures in the SV40 genome.  
Although a four-stranded G-quadruplex structure had been identified by NMR 
analysis of an oligonucleotide incorporating an SV40 5’-GGGCGG-3’ repeat,29 no 
prior work has explored the potential for intramolecular G-quadruplex structures in 
SV40 DNA.  A number of algorithms have been proposed to identify putative 
intramolecular G-quadruplex forming regions in DNA and RNA.11, 12, 50  The QGRS 
Mapper algorithm is available on-line and is representative of other approaches in that 
it searches user-defined windows of sequence for four runs of two or more 
consecutive G’s separated by loops of intervening bases that can vary from zero up to 
a user-defined maximal loop length.51  
In work carried out by Dr. Sean M. Kerwin, employing QGRS Mapper, a 
number of putative intramolecular G-quadruplex DNA-forming regions were 
identified in the SV40 genome.  The location of these regions on the SV40 genome is 
shown in Figure 5-8 and the sequences are provided in the appendix C.  These 
potential G-quadruplex-forming regions are not uniformly distributed throughout the 
SV40 genome, but rather occur primarily near the origin of replication and adjacent to 
the poly-adenylation signals for the early and late transcripts.  There is a strong strand 
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bias for the location of the remaining potential G-quadruplex forming regions, which 
are distributed on the coding strand, most notably on the early transcripts.  
Dr. Kerwin found that the results of the search for potential G-quadruplex-
forming regions were relatively insensitive to the search parameters of sequence 
window and loop size; however, the results were very dependent on the minimum 
number of G-tetrads allowed.  The results discussed above derived from searches in 
which the minimum number of G-tetrads was two; changing this parameter to three 
results in the identification of a single potential G-quadruplex structure in SV40.  This 
presumably more robust G-quadruplex occurs within the promoter region at position 
41-102 and consists of multiple runs of three consecutive G’s, such that multiple 
potential G-quadruplex structures may form.  Interestingly, this region also 
encompasses six GGGCGG repeats, which are highlighted below.  An 
oligonucleotide encompassing this repeat, dTGGGCGGT, forms a unique four-
stranded G-quadruplex containing a C-tetrad sandwiched between adjacent G-tetrad 
stacks.29 Assuming a similar arrangement can be formed in intramolecular 
quadruplexes, this QGRS from SV40 could adopt multiple such quadruplexes with 
loop sizes ranging from three to five nucleotides.  
 
GGGGCGGAGA ATGGGCGGAA CTGGGCGGAG TTAGGGGCGG  
 





The potential G-quadruplex-forming region above occurs close to the origin of 
replication.  To the extent that this or the other potential G-quadruplex-forming 
regions in SV40 fold into intramolecular DNA G-quadruplex structures, they could 
hinder the replication of the viral DNA in the absence of a means to unfold these 
structures.   The robust G-quadruplex unwinding ability of SV40 T-ag could provide 






























Figure 5-8 Map of SV40 genome showing the location of potential G-quadruplex-
forming G-rich sequences (QGRS). The QGRS were identified using as search 
parameters: maximum length 30, minimum G-group size 2, loop size from 0 to 22.  
The QGRS at position 79 (underlined) contains multiple runs of three or more G’s..§ 
 
 
                                                 














G-quadruplex DNA-interactive agents inhibit T-ag G-quadruplex helicase 
activity.   
In order to explore the nature of the interaction of T-ag with G-quadruplex 
substrates, a series of previously-reported G-quadruplex-interactive agents were 
assayed for their ability to inhibit the G-quadruplex unwinding ability of T-ag.  The 
anionic N-methyl mesoporphyrin (NMM) inhibits the G-quadruplex unwinding 
ability of T-ag by more than 60% at 100 µM concentration (Figure 5-9A and Table 5-
1).  This inhibition of the G-quadruplex unwinding activity of T-ag by NMM is 
similar to but less effective than the inhibitory effect of NMM on the quadruplex 
unwinding activity of RecQ, Sgs1, BLM and WRN.18, 45  In contrast, the cationic 
porphyrin TMPyP4, which has been shown to be a sub-micromolar inhibitor of 
quadruplex unwinding activity of the RecQ-family helicases BLM,45, 46 WRN,46  
Sgs1,45, 52  and RecQ,18 does not inhibit the quadruplex unwinding activity of T-ag, 
even at concentrations as high as 100 µM (Table 5-1).  Distamycin A, which has been 
reported not to inhibit the quadruplex unwinding activity of BLM, is a modest 
inhibitor of the quadruplex unwinding activity of T-ag (Table 5-1).  The carbocyanine 
DODC was originally reported as a G’2-specific ligand with a novel binding mode 
involving interactions with the groove and loops of these quadruplexes.53, 54  DODC 
modestly inhibits the G’2-unwinding activity of T-ag (Figure 5-9A and Table 5-1).  
Coralyne, a recently-reported selective G-quadruplex ligand and telomerase 
inhibitor,55 also inhibits the quadruplex unwinding activity of T-ag. 
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A number of other G-quadruplex ligands are not effective inhibitors of the quadruplex 
unwinding activity of T-ag.  Hoechst 3325856 and DTC43, 57  have been proposed to 
bind to G-quadruplex structures through groove or loop interactions.   While Hoechst 
33258 can inhibit the duplex helicase activity of WRN and BLM,58 neither this 
compound nor DTC is an effective inhibitor of the quadruplex unwinding activity of 
T-ag (less than 15% inhibition at 10 µM).  Berberine, structurally related to coralyne, 
displays diminished G-quadruplex DNA binding ability and telomerase inhibition55  
and is not an effective inhibitor of the quadruplex unwinding activity of T-ag (Figure 
5-9B).  Duplex DNA intercalators that have also been reported to bind to G-
quadruplex DNA, such as TOTA59 and ethidium bromide60, 61 are also not effective 
inhibitors of T-ag G-quadruplex DNA helicase activity.  However, ethidium bromide 















Figure 5-9  Inhibition of the G-quadruplex DNA helicase activity of T-ag by selected 
G-quadruplex-interactive agents.  Each ligand was incubated with 5’-labeled G’2-
DNA1 in helicase buffer for 60 min prior to the addition of 0.2 µg of recombinant, 
immunopurified T-ag and 4 mM ATP.  After 90 min at 37 °C, the reactions were 
stopped and the products analyzed by non-denaturing gel electrophoresis. Lanes are 
labeled with the final concentration of ligand.  The control lane NE is DNA in the 
absence of both ligand and T-ag and lane 0 is DNA in the presence of T-ag and ATP 
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Table 5-1  SV40 T-Ag G’2 DNA Helicase Inhibition by G-Quadruplex DNA-
Interactive Agents. 
 
Compound Inhibition of T-Ag G’2-DNA1 Unwindinga 
NMM 63 % 
TMPyP4 0 % 
Distamicin A 16 % 
DODC 24 % 
Coralyne 29 % 
a.  At 100  µM 
 
From this study of G-quadruplex-interactive agents two points can be made.  
First, the ability of these compounds to inhibit the G-quadruplex DNA helicase 
activity of T-ag does not correlate with the reported binding mode of these ligands for 
G-quadruplex structures.  Both compounds that have been reported to end-stack on 
G-quadruplex DNA (NMM, coralyne) and those that have been reported to interact 
with loops or grooves of these structures (distamycin A, DODC) are inhibitors of the 
G-quadruplex helicase activity of T-ag.  At the same time, there are also examples of 
both end-stackers (TMPyP4, TOTA, ethidium bromide) and groove/loop binders 
(DTC, Hoechst 33258) that do not inhibit the quadruplex unwinding activity of T-ag.  
This lack of correlation between the reported G-quadruplex DNA binding mode for 
these ligands and their ability to inhibit the G-quadruplex unwinding ability of T-ag 
may be due to the uncertainties associated with the precise G-quadruplex binding 
mode(s) for these ligands.  For example, distamycin has been reported to bind to G-
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quadruplex DNA through interactions with the G-quadruplex grooves63 and by end-
stacking on G-tetrad faces.45  For this and the other ligands examined here, the precise 
nature of the interaction with G-quadruplex DNA may be a function of the specific G-
quadruplex structure. 
A second observation from the above studies is that the G-quadruplex-
interactive agents that inhibit T-ag are different from those that inhibit the RecQ-
family G-quadruplex helicases and vice-versa.  The range of G-quadruplex ligands 
examined in this study is more extensive than previous studies with RecQ helicases.   
However, comparing those ligands that have also been studied for RecQ-family G-
quadruplex DNA helicase inhibition reveals examples of RecQ-family G-quadruplex 
helicase inhibitors that are not T-ag G-quadruplex DNA helicase inhibitors (TMPyP4) 
or are much less effective inhibitors of T-ag (NMM), as well as a T-ag G-quadruplex 
DNA helicase inhibitor that does not inhibit RecQ helicases (distamycin A).  One 
complicating factor in making these comparisons are the different types and 
sequences of G-quadruplex DNA that have been employed in previous helicase 
inhibition studies.  However, given the lack of selectivity of the above agents for 
particular G-quadruplex sequences, the comparisons are still informative.  These 
differences provide evidence that the mode of interaction of RecQ helicases through 
their RQC domains with G-quadruplex DNA is distinct from the interaction of T-ag 
with G-quadruplex DNA substrates. 
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Perylene diimides are potent and selective inhibitors of T-ag G-
quadruplex helicase activity.   
In addition to the G-quadruplex DNA ligands examined above, the T-ag G-
quadruplex DNA helicase inhibition due to a series of perylene diimides was also 
investigated.   In T-ag G-quadruplex DNA helicase assays, the Tel11 is a very 
effective inhibitor, completely preventing the unwinding of G’2-DNA at 10 µM 
concentration (Figure 5-10).   Other perylene diimides, including PIPER and Tel01 
are also very potent inhibitors of the G-quadruplex helicase activity of T-ag, with sub-
micromolar IC50 values, similar to Tel11 (Table 5-2).  These three perylene diimides 
are the most potent inhibitors of the G-quadruplex helicase activity of T-ag of all of 
the G-quadruplex DNA ligands examined here.  One of these perylene diimides, 
PIPER, was also previously shown to be a potent inhibitor of the G-quadruplex DNA 
unwinding activity of Sgs1p.48  
While both Tel01 and PIPER have been shown to undergo pH-dependent 
aggregation in aqueous solutions, Tel11, which bears constitutively positively 
charged side chains, has a reduced propensity for self-association.  Tel12, with 
anionic phosphonate side chains, also has a reduced propensity for self-association 
compared to Tel01 and PIPER, but is only a weak inhibitor of the G-quadruplex DNA 
helicase activity of T-ag (Table 5-2).  Tel18 and Tel34, cationic perylene diimides 
with modified chromophores, are more active than Tel12, but much less effective 
inhibitors compared to Tel11, despite the presence of identical side chains in these 














Figure 5-10 Inhibition of the G-quadruplex DNA helicase activity of T-ag by Tel11.  
Tel11 was incubated with 5’-labeled G’2-DNA1 in helicase buffer for 60 min prior to 
the addition of 0.2 µg of recombinant, immunopurified T-ag and 4 mM ATP.  After 
90 min at 37 °C, the reactions were stopped and the products analyzed by non-
denaturing gel electrophoresis.  Lanes are labeled with the final concentration of 
Tel11.  The control lane NE is DNA in the absence of both Tel11 and T-ag; lane NA 
is DNA in the presence of T-ag without ATP and Tel11 and lane 0 is DNA in the 


















Tel01 0.22 ± 0.06 
PIPER 0.16 ± 0.02 
Tel11 0.13 ± 0.06 
Tel12 50 ± 9 
Tel18 35 ± 2 
Tel34 5 ± 4 
 
 
The ability of certain perylene diimides to inhibit the G-quadruplex helicase 
activity of T-ag is striking when compared to other G-quadruplex-interactive agents.  
Those perylene diimides bearing basic or constitutively cationic side chains are 
particularly effective inhibitors, indicating that electrostatic interaction with the G-
quadruplex DNA may play an important role in preventing access by T-ag.  Both 
Tel01 and PIPER have been shown to facilitate the formation of G-quadruplex DNA 
from single-stranded DNA, and a possible role for this in the apparent inhibition of 
the T-ag G-quadruplex DNA helicase observed here was examined.  Incubation of 
partially annealed G’2-DNA1 with PIPER or Tel01 under the helicase assay 
conditions did not result in the formation of additional G-quadruplex DNA. This 
indicates that these perylene diimides do not act by facilitating the reannealing of G-
quadruplex DNA from single-stranded DNA formed by T-ag helicase activity in these 
assays, but rather inhibit the formation of these single-stranded DNA products. 
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The ability of these perylene diimides to inhibit the duplex DNA helicase 
activity of T-ag was also investigated.  Some perylene diimides, such as Tel01 and 
PIPER, showed no inhibition of the duplex DNA unwinding activity of T-ag at 
concentrations as high as 100 µM (Figure 5-11 and Table 5-3), in contrast to their 
sub-micromolar inhibitory effects on the G-quadruplex DNA unwinding activity of T-
ag.  This lack of inhibition of the duplex helicase activity of T-ag by Tel01 and 
PIPER demonstrates that their potent G-quadruplex helicase inhibition is not simply 
due to ligand aggregation. Shoichet and co-workers have shown that ligand 
aggregation can lead to non-specific inhibition of a wide range of enzymes.64   If 
these perylene diimides were inhibiting T-ag through aggregation-mediated 
sequestration of the enzyme, they would be equally effective in preventing the 
unwinding of both substrates.  In fact, Tel01 undergoes aggregation under the 
helicase assay conditions as evidenced by a lack of Tel01 fluorescence, distinctive 
red-shift and hypochromicity in the Tel01 absorbance spectrum, and a distinctive 
resonance light-scattering signal (Figure 5-12).  Previous studies have demonstrated 
that aggregation of perylene diimides is correlated with increased binding selectivity 
for G-quadruplex DNA.41, 42  The selective inhibition of the G-quadruplex helicase 
activity of T-ag by aggregating perylene diimides such as Tel01 may reflect this 
binding selectivity for G-quadruplex DNA.  However, in this case, the aggregates do 
not interact directly with the helicase, as evidenced by the lack of inhibition of the 
duplex unwinding activity. 
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Tel11, which is also a potent inhibitor of the G-quadruplex unwinding activity 
of T-ag is only a moderate inhibitor of the duplex helicase activity (Table 5-3).  
Although not as selective for inhibiting the G-quadruplex helicase activity of T-ag, 
Tel11 is selective; there is an approximately 400-fold difference in the concentrations 
required for G-quadruplex versus duplex helicase inhibition.  However, not all 
perylene diimides display a high degree of selectivity in inhibiting the G-quadruplex 
helicase activity of T-ag.  The chromophore-modified perylene diimides Tel18 and 
Tel34 are moderate inhibitors of the duplex helicase activity of T-ag (Figure 5-11 and 
Table 5-3) and show little selectivity for G-quadruplex or duplex helicase inhibition.   
Interestingly, the anionic perylene diimides Tel12, the most potent perylene diimide 
inhibitor of T-ag duplex DNA helicase activity (Table 5-3) is the least effective G-
quadruplex helicase inhibitor and is therefore modestly selective for inhibiting the 




















Figure 5-11  Inhibition of the duplex DNA helicase acitivty of T-ag by selected G-
quadurplex-interactive perylene diimides.  Each ligand was incubated with 5’-labeled 
ds-DNA2/3 in helicase buffer for 60 min prior to the addition of 0.4 µg of 
recombinant, immunopurified T-ag and 4 mM ATP.  After 90 min at 37 °C, the 
reactions were stopped and the products analyzed by non-denaturing gel 
electrophoresis.  Lanes are labeled with the final concentration of ligand.  The control 
lane NE is DNA in the absence of both ligand and T-ag and lane 0 is DNA in the 
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Table 5-3  SV40 T-Ag Duplex DNA Helicase Inhibition by perylene diimides. 
Perylene 
Diimides Inhibition of T-Ag duplex unwinding
a 
Tel01 0 % 
PIPER 0 % 
Tel11 43 %b 
Tel12 71 %c 
Tel18 55 % 
Tel34 100 % 
a.Percent inhibition at 100 µM perylene diimide.   b. at 50 µM.  c. at 25 µM 















































Figure 5-12 Resonance light scattering ( ) and fluorescence spectra ( ) of 1 µM 
Tel01 in helicase buffer [pH 7]. 
 
NMM also displays preference for inhibiting the G-quadruplex DNA helicase 
activity of T-ag.  NMM does not inhibit the duplex unwinding activity of T-ag at 100 
µM, the highest concentration tested (Figure 5-13 and Table 4).  In contrast, 
TMPyP4, which does not inhibit the G-quadruplex unwinding activity of T-ag, 
inhibits the duplex helicase activity with an IC50 of approximately 10 µM (Table 4).  
Many of the other G-quadruplex DNA interactive agents that are also known to bind 

































Figure 5-13 Inhibition of the duplex DNA helicase activity of T-ag by selected G-
quadruplex-interactive agents.  Each ligand was incubated with 5’-labeled ds-
DNA2/3 in helicase buffer for 60 min prior to the addition of 0.4 µg of recombinant, 
immunopurified T-ag and 4 mM ATP.  After 90 min at 37 °C, the reactions were 
stopped and the products analyzed by non-denaturing gel electrophoresis.  Lanes are 
labeled with the final concentration of ligand.  The control lane NE is DNA in the 
absence of both ligand and T-ag and lane 0 is DNA in the presence of T-ag and ATP 
with no added ligand. 
Table 5-4 SV40 T-ag duplex DNA helicase inhibition by G-quadruplex interactive 
agents. 
Compound Inhibition of T-Ag duplex unwindinga 
NMM 0 % 
TMPyP4 55 %b 
Distamycin A 100 % 
DODC 100 % 
Coralyne 57 % 
a. Percent inhibition at 100 µM.   b. at 10 µM.  
NE       0       10    100    0.1    10    0.01    1    100     1    100 0.01     1     100    µM   
ds-DNA2/3
ss-DNA2
NMM     TMPyP4   Distamycin A     DODC        Coralyne
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SPR analysis of the G-quadruplex binding of T-ag inhibitory and non-
inhibitory ligands reveals differences in binding affinity and kinetics. 
The selectivity for inhibiting T-ag G-quadruplex DNA helicase activity versus 
duplex DNA helicase activity demonstrated by Tel01, PIPER, Tel11 and NMM 
provides strong evidence that these inhibitors act by binding to the G-quadruplex 
DNA substrate, preventing its unwinding by T-ag, as opposed to binding to T-ag.  In 
order to gain more insight into the G-quadruplex DNA binding characteristics that 
may be involved in effective T-ag G-quadruplex helicase inhibition, the binding of 
two representative ligands to an intramolecular G-quadruplex DNA was examined 
using surface plasmon resonance, in collaboration with Dr. Wendi M. David at Texas 
State University, San Macros and a fellow graduate student in the Kerwin lab, Mireya 
Rodriguez. 
We performed SPR-binding studies utilizing intramolecular human telomeric 
sequence 5’-biotinylated-(TTAGGG)4TT which can form G4’ structure. SPR analysis 
of TMPyP4, which is inactive as an inhibitor of T-ag G-quadruplex unwinding 
activity, and Tel11, which is the most potent inhibitor of T-ag G-quadruplex 
unwinding activity among G-quadruplex binding agents tested, demonstrated that 
these two ligands possess different binding behaviors (Figure 5-14). TMPyP4 showed 
a fast on and off rate to G-quadruplex DNA with a kon = 8.05 × 105 M-1 and koff = 
0.133 s-1 when using the 1:1 Langmuir binding model in the BIAevaluation software. 
The analysis of steady state equilibrium binding constant of TMPyP4 to quadruplex 
DNA showed KD = 0.16 µM. On the other hand, Tel11 demonstrated a slow on rate at 
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low concentrations and a fast on rate at higher concentrations. However, at all 
concentrations of Tell1, we observed a slow off rate which is much slower than that 
observed for TMPyP4. These two different binding characteristics suggest that there 
are two different binding modes of Tel11, one with tight binding and high affinity 
which exhibits slow dissociation, the other being a non-specific binding mode with 
quick dissociation at higher concentration of Tel11. Moreover, using the 
BIAevaluation software, the dissociation rate of Tel11 from the quadruplex DNA 
complex, calculated by analyzing the latter phase of dissociation (74 seconds after 
Tel11 starts to dissociate), is 1.36 × 10-3  s-1. The difference in the kinetics of 
dissociation between TMPyP4 and Tel11 is 100 fold. This implies that slow 
dissociations of Tel11-G-qaudruplex complex is a contributing factor in this T-ag G-
















Figure 5-14  SPR sensorgrams for the interaction of TMPyP4 (Panel A) and Tel11 
(Panel B) with the human telomeric intramolecular G-quadruplex.  The 
concentrations of TMPyP4 are 50, 150, 300, 450, and 1350 nM, respectively, from 
bottom to top.  Concentrations of Tel11 solutions are 5, 10, 50, 100, 150, 200, and 
350 nM, respectively, from bottom to top.  Experiments were conducted at 25 °C in 











DNA binding affinity alone does not lead to T-ag helicase inhibition.   
In collaboration with Mireya Rodriguez, the interaction of representative 
inhibitors with the G’2-DNA1 and ds-DNA2/3 substrates were determined by 
fluorescence titration in the helicase buffer.  In order to provide further insights into 
the duplex- and G-quadruplex DNA binding factors that give rise to potent T-ag 
helicase inhibition by these ligands, examples of selective (NMM, Tel11), non-
selective (Tel12), and inactive (TMPyP4) G-quadruplex helicase inhibitors that 
display changes in fluorescence upon DNA addition under the helicase assay 
conditions were employed for these studies.   
Titrations of a solution of NMM (1 µM) with G’2-DNA1 and ds-DNA2/3 
(Figure 5-15A) in helicase buffer demonstrate the previously reported G-quadruplex 
DNA-specific increase in the fluorescence of this ligand.65  Non-linear least-squares 
fitting of the observed fluorescence increase to a simple equilibrium binding model66  
affords a dissociation constant for NMM binding to this G-quadruplex DNA of 0.09 ± 
0.04 µM and a binding site size of 0.44 ± 0.04 quadruplex (Table 5-5).  The apparent 
stoichiometry of one NMM to two quadruplexes has precedent in the previously 
reported ability of end-stacking ligands such as PIPER to bridge two G-
quadruplexes.35 The lack of fluorescence change upon the addition of ds-DNA2/3 to 
NMM leads to a lower limit for the dissociation constant for the NMM-duplex DNA 
complex of 50 µM.   The binding selectivity of NMM for G’2-DNA1 revealed in 
these titrations is reflected in the selectivity for G-quadruplex DNA helicase 
inhibition by NMM in the T-ag assays (Tables 5-1 and 5- 4).   
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Similar fluorescence titrations carried out with TMPyP4 displayed a more 
complex behavior (Figure 15-15B).  Addition of either G’2-DNA1 or ds-DNA2/3 to 
solutions of TMPyP4 (1 µM) cause an initial decrease of ligand fluorescence that is 
only observed at very low concentrations of added DNA.  In the presence of higher 
concentration of DNA, the ligand fluorescence increases.  Both G’2-DNA1 and ds-
DNA2/3 have single-stranded DNA tails, and the initial fluorescence quenching 
observed for these two DNA structures may be due to single-strand DNA-mediated 
aggregation of this ligand, as has been seen for related cationic porphyrins.67 Because 
the T-ag unwinding of these two DNA substrates are differentially inhibited by 
TMPyP4, this putative single-stranded DNA interaction with TMPyP4 can not be the 
origin of the helicase inhibition.   Fitting the portion of the titration curve associated 
with the G-quadruplex- or duplex-DNA-mediated fluorescence increase65 affords 
apparent dissociation constants of 1.0 and 0.19 µM, respectively (Table 5-5).   This 
binding preference of TMPyP4 for the duplex DNA helicase substrate is in accord 
with the selective inhibition of the duplex helicase activity of T-ag displayed by this 
porphyrin (Table 4).    
The fluorescence due to solutions of Tel11 (1 µM) is quenched upon addition 
of either G’2-DNA1 or ds-DNA2/3 (Figure 5-15C), similar to what has been reported 
earlier for this ligand.36   This quenching occurs at concentrations of DNA well below 
that of the ligand, indicating that multiple ligands bind to each DNA structure, which 
is also similar to what was observed previously.36 Fitting the fluorescence data to a 
simple multi-site binding model66 results in a calculated dissociation constant of 0.27 
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± 0.11 µM with 28 ± 5 binding sites per G’2-DNA1.   The dissociation constant for 
ds-DNA2/3 is only slightly higher, 0.42 ± 0.60 µM, with 25 ± 8 binding sites per 
DNA.   In contrast to the approximately 400-fold selectivity exhibited by Tel11 for 
G-quadruplex versus duplex DNA helicase inhibition, this perylene diimide displays 
less than two-fold binding preference for the G-quadruplex DNA substrate (Table 5-
5).  
The anionic Tel12 also undergoes fluorescence quenching in the presence of 
the G’2-DNA substrate; however, upon addition of ds-DNA2/3 very little change in 
fluorescence is observed (Figure 5-15D).  The increased selectivity for G-quadruplex 
DNA binding by Tel12 as compared to Tel11 has been noted.36  The dissociation 
constant for G’2-DNA1 binding by Tel12 (0.95 ± 0.60 µM) is a least fifty-fold lower 
than that for ds-DNA2/3, for which a lower limit of 50 µM is estimated (Table 5-5).  
Despite this high level of G-quadruplex DNA binding selectivity, Tel12 does not 
selectively inhibit the G-quadruplex DNA unwinding activity of T-ag (Table 5-3).   
While the inhibitory effects of Tel12 on the G-quadruplex helicase activity of T-ag 
can be understood on the basis of its association with the G-quadruplex DNA 
























Figure 5-15 G-quadruplex- and duplex-DNA binding by selected G-quadruplex-
interactive agents determined by fluorescence titrations with ds-DNA2/3 and G’2-
DNA1 in helicase reaction buffer.   The ligands NMM (A), TMPyP4 (B), Tel11 (C), 
and Tel12 (D) (1 µM) and various concentrations of G’2-DNA (filled squares) or ds-
DNA2/3 (open circles) were mixed in buffer containing 10 mM Tris-HCl buffer (pH 
7), 10 mM KCl, 10 mM MgCl2, 0.5 mM 1,4-dithiothreitol, 0.1 mM EDTA, 10% 
glycerol.  The solutions were allowed to equilibrate and their fluorescence was 
measured.  The curves represent the non-linear least squares fits of the data to the 
quadratic binding equation.  
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Table 5-5  G-Quadruplex and Duplex DNA Binding by G-Quadruplex-Interactive 
SV40 T-ag Inhibitors  
Compound 
Kd G’2-DNA1a 
(binding site size)b 
Kd ds-DNA2/3a 
(binding site size) 
NMM 
0.09 ± 0.04 µM 
(n = 0.44 ± 0.04) 
NBc 
TMPyP4 
1.0 ± 0.9   µM 
(n = 0.44 ± 0.25) 
0.19 ± 0.08 µM 
(n = 1.1 ± 0.2) 
Tel11 
0.27  ± 0.11 µM 
(n = 28 ± 5) 
0.43 ± 0.25 µM 
(n = 26 ± 8) 
Tel12 
0.95 ± 0.60 µM 
(n = 2.3 ± 1.1) 
NBc 
a.  Determined by fluorescence titration of G’2-DNA or ds-DNA2/3 into solutions 
of ligands (1 µM) in helicase buffer (10 mM Tris (pH 7), 10 mM KCl, 10 mM MgCl2, 
0.5 mM 1,4-dithiothreitol, 0.5 mM EDTA, 10 % glycerol).  Dissociation constants 
were determined by non-linear least squares fitting of the increase or decrease of 
fluorescence due to ligand binding to DNA as described in the experimental section. 
b.  Expressed as the ratio of ligand to DNA structure. 








These DNA binding data reveal that factors other than binding affinity for the 
substrate DNA play a role in effective T-ag helicase inhibition.   The binding 
affinities for the G-quadruplex DNA helicase substrate of these four ligands differ by 
only a factor of ten, yet the helicase inhibitory potency for these ligands range from 
very potent (sub-micromolar IC50) to inactive.  The interaction of Tel12 with G-
quadruplex DNA, although similar in affinity to that for TMPyP4, is more effective in 
preventing T-ag unwinding than that of TMPyP4.  The large difference in T-ag G-
quadruplex DNA helicase inhibition between the anionic perylene diimide Tel12 and 
the cationic perylene diimide Tel11 is not reflected in a similarly large difference in 
binding affinity for these two ligands to the DNA substrate.  
The precise requirements for effective inhibition of the quadruplex helicase 
activity of T-ag by G-quadruplex-interactive compounds remain unclear.  The 
previously reported observation that certain GROs inhibit the duplex helicase activity 
of T-ag31 may be due to the G-quadruplex structures of these GROs binding tightly to 
T-ag and preventing helicase activity.   In this scenario, G-quadruplex ligands that 
bind to and facilitate this interaction of quadruplex structures and T-ag would be 
more effective inhibitors than ligands whose binding to G-quadruplex structures 
inhibits T-ag binding.   This is similar to the case reported for NMM inhibition of 
BLM, in which NMM binding to quadruplex DNA does not inhibit BLM binding, but 
rather serves to stabilize the interaction and prevent both dissociation and 
translocation.45   However, NMM is only a modest inhibitor of the quadruplex 
unwinding by T-ag, and this could be due to differences in the way that these two 
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different helicases interact with G-quadruplex DNA or to a different means of 
inhibition by G-quadruplex ligands in the case of T-ag.  T-ag lacks the RQC domain 
that is responsible for G-quadruplex DNA binding by RecQ family helicases such as 
BLM, and so it is quite likely that the specific interactions made between T-ag and 
quadruplex DNA are different from those of RecQ helicases.  On the other hand, 
those ligands which inhibit the quadruplex helicase activity of T-ag most strongly, 
Tel01, PIPIER, and Tel11, share an ability to bind to G-quadruplex DNA with high 
stiochiometry, indicating that this is an important feature for T-ag inhibition that is 
different from the model for RecQ helicase inhibition by NMM.    
Conclusions 
Previous reports of G-quadruplex helicase activity have focused on the RecQ 
family of helicases.  While not all DNA helicases have the ability to unwind G-
quadruplex DNA structures, SV40 T-ag does have this ability.  The demonstration 
that the duplex and G-quadruplex unwinding activity of T-ag are comparable, along 
with the identification of sequences that may adopt a G-quadruplex conformation in 
the SV40 genome, indicate that hexameric, replicative helicases may play a role in 
resolving G-quadruplex DNA structures during DNA replication.  The mechanism by 
which hexameric helicases unwind G-quadruplex DNA is not known; however, it is 
distinct from that employed by the RecQ helicases.  The interaction of T-ag with G-
quadruplex DNA substrates is different from that of the RecQ helicases, which 
involve a conserved RQC domain.  T-ag does not contain a RQC domain, or any 
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other protein domain previously identified as a G-quadruplex DNA binding motif.  
These differences between the RecQ helicases and T-ag are reflected in the different 
types of G-quadruplex-interactive ligands that inhibit these two distinct families of G-
quadruplex helicases.  Studies of the T-ag G-quadruplex helicase inhibition by a 
range of G-quadruplex-interactive agents indicates that binding affinity alone does 
not predict effective helicase inhibition.  Specific binding interactions with the 
substrate DNA may be more effective in preventing access to, or processing of the 
DNA substrate as compared to other binding interactions, and these may vary from 
one family of G-quadruplex helicases to another.   Additional factors, such as the 
kinetics of dissociation of the ligand-G-quadruplex complex and the binding 
stoichiometry of these G-quadruplex ligands may also play a role in effective helicase 
inhibition.  The perylene diimides Tel11, identified as the most potent inhibitor of the 
G-quadruplex helicase activity of T-ag, binds to the substrate DNA with high 
stoichiometry, and dissociates slowly from the complex formed with an 
intramolecular G-quadruplex.   Interestingly, despite a relative lack of selectivity in 
binding to the G-quadruplex versus the duplex DNA substrate, Tel11 is highly 
selective for inhibiting the G-quadruplex helicase activity of T-ag; the duplex helicase 
activity is only inhibited at concentrations of Tel11 400-fold higher than those 
required to inhibit the quadruplex helicase activity.   The identification of potent and 
selective inhibitors of the G-quadruplex helicase activity of T-ag provides tools for 
probing the specific role of this activity in SV40 replication.  These studies may lead 
to new insights into the role of G-quadruplex structures in DNA replication and may 
 262
ultimately allow the targeting of these structures in the design of highly selective 
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Chapter 6                                                                               
Experimental Procedures: Targeting SV40 Large T-Antigen G-
Quadruplex DNA Helicase Activities by G-Quadruplex Interactive 
Agents 
DNA preparation 
The following deoxyoligonucleotides were used in the studies: DNA1, TTG 
GGG TTG GGG CTA CGC GAT CAG; DNA2, GAG CAG CAA TAC ACG A; 
DNA3, TCG TGT ATT GCT GCT CTC TCT CTC TC. DNA1 and DNA2 were 5’-
labeled with [γ-32P] ATP using T4 polynucleotide kinase and purified by elution 
through a Bio-Rad Biospin column. The formation of DNA1-G’2 was performed as 
described.1
Briefly, the radiolabeled DNA1 was dissolved in TE buffer (0.5 µM), heated for 5 
min at 95 °C and rapidly cooled in ice.  Then KCl was added to a final concentration 
of 0.3 M and the solution was heated at 45 °C in a water bath and annealed for 40-45 
h.  DNA1-G4 was formed similarly by replacing the KCl with NaCl (0.5 M).  Duplex 
DNA was formed by annealing 5’-radiolabeled DNA2 and non-labeled DNA3 at 1:3 
ratio in TE buffer.  The mixture was heated at 95 °C for 5 min and slowly cooled to 
room temperature for approximately 16 h. All annealed DNA samples were purified 
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by 12 % non-denaturing polyacrylamide electrophoresis and eluted in buffer prior to 
use. 
Helicase assay 
Helicase assays were carried out in 10 µL of a solution containing 10 mM 
Tris-HCl buffer (pH 7), 10 mM KCl, 10 mM MgCl2, 0.5 mM 1,4-dithiothreitol, 50 
µg/µl BSA, 2 mM ATP, 0.1 mM EDTA, 10% glycerol, 32P-labeled DNA substrate 
(0.38 pmol) and SV40 large T antigen [0.2–0.85 µg protein]. The reactions were 
performed at 37 °C for 90 min. The reactions were terminated by adding a stop 
solution which contained 15% glycerol, 3% SDS, 20 mM EDTA, 8 mM tris-HCl pH 
8, 0.8 mM bromophenol blue and 1 mM xylene cyanol and, in the case of duplex 
unwinding assays, 1.14 pmol of unlabeled DNA2.  The reaction products were 
separated by electrophoresis in 12% non-denaturing polyacrylamide gels. 
Fluorescence Spectroscopy 
Spectra were recorded on a Hitachi model F-2000 Spectrofluorometer in 
silanized quartz cuvettes or on a Beckman Coulter model DTX 800 plate reader using 
black polystyrene 384-well microplates (Nunc).  The compounds (1 µM) and various 
concentrations of G’2-DNA or ds-DNA2/3 were mixed in buffer containing 10 mM 
Tris-HCl buffer (pH 7), 10 mM KCl, 10 mM MgCl2, 0.5 mM 1,4-dithiothreitol, 0.1 
mM EDTA, 10% glycerol.  The solutions were allowed to equilibrate and their 
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fluorescence was measured.  Dissociation constants were determined by non-linear 
least squares fitting of the increase or decrease of fluorescence due to ligand binding 
using the procedure described by Aldrich-Wright.2 Briefly, the equilibrium 
dissociation constant (Kd) is expressed as: 
Kd = [LT – LB][ST-LB]/[ LB]  [1] 
Where LB is the concentration of bound ligand complex sites and LT and ST are the 
total concentrations of ligand and DNA binding sites respectively.  
The amount of complex formed is proportional to the change in fluorescence 
according to the following equation: 
LB = (∆F/∆Fmax)LT   [2] 
Where ∆F is the increase or decrease in fluorescence upon addition of each DNA 
concentration, and ∆Fmax is the maximum change in fluorescence at saturating 
conditions.  
Combining equation [1] and equation [2] affords the quadratic equation [3]: 
 
LT(∆F/∆Fmax)2 –(LT + ST +Kd) (∆F/∆Fmax) + ST = 0    [3] 
 
Solving for the root of quadratic equation [3] leads to: 
∆F/∆Fmax = ((LT + ST +Kd)-(((( LT + ST +Kd)2)-(4* LT* ST*)) ))/(2* LT)     
[4] 
The change in fluorescence, ∆F/∆Fmax, determined experimentally was plotted 
against the total number of binding sites, ST, which is equal to the total concentration 
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of DNA multiplied by the number of binding sites per structure. The number of 
binding sites per DNA structure (n) was be determined by substituting ST= DNAT*n  
in equations [3] and [4]. 
  
Surface Plasmon Resonance 
The SPR experiments were performed using a Biacore X optical biosensor 
system with streptavidin-coated sensor chips (GE Healthcare).   Sensor chips were 
derivatized on one flow channel with low levels (~200 RU) of 5’-biotinylated DNA 
(5’ BioTEG-(TTAGGG)4TT, Integrated DNA Technologies) in filtered and degassed 
HBS-EP buffer (0.01 M Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v P20 
surfactant) after several preconditioning injections of 1 M NaCl/ 50 mM NaOH.  To 
facilitate and maintain the formation of the intramolecular G-quadruplex DNA, HBS-
EP buffer containing 200 mM KCl was subsequently used both as a running buffer 
and storage buffer for derivatized sensor chips.  Formation of the G-quadruplex was 
verified by the inability of the derivatized chips to bind E. coli single-strand binding 
protein (Sigma-Aldrich) under the conditions used for binding experiments.   
TMPyP4 and Tel11 were dissolved in running buffer (HBS-EP buffer containing 200 
mM KCl) and injected manually (50 µL) at different concentrations using a flow rate 
of 10 µL/min to allow long contact times.   Binding profiles at this flow rate were 
determined to be the same as observed at higher flow rates (20 µL/min) indicating the 
absence of significant mass transport effects. Injections were followed by a 
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dissociation period of 7 minutes (running buffer, 10 µL/min) and subsequent 
alternating injections of running buffer, 5% DMSO, and 1% P20 to wash the flow 
cells.  The experiments were performed in multi-channel mode using a control flow 
cell that was not derivatized with DNA.  All binding responses were determined 
relative to the control flow cell.  Fitting of steady-state equilibrium binding constants 
and kinetic association and dissociation curves was performed using BIAevaluation 
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Summary and Future Directions 
In this dissertation, two diverse works were presented. The first portion 
presents the DNA cleavage studies of a series of pyridinium-based heterocyclic 
skipped aza-enediynes. The second is related to G-quadruplex DNA binding ligands 
whose affect on G-quadruplex T-ag unwinding activity was analyzed. Below are 
highlights that were gathered from these works, as well as some interesting future 
directions that would help us develop better agents.   
Cleavage chemistry of pyridinium-based heterocyclic skipped aza-enediynes 
The synthesis and DNA cleavage properties including mechanistic studies of a 
series of pyridinium skipped aza-enediynes (2-alkynyl-N-propargyl pyridinium salts) 
were reported. These studies demonstrated the success in designing DNA cleavage 
agents utilizing the heterocyclic framework for skipped aza-enediynes. Efficient DNA 
cleavage requires the presence of the skipped aza-enediyne functionality, and optimal 
DNA cleavage occurs at basic pH. The analog containing a p-methoxyphenyl 
substituent (AZB037) is most potent in supercoiled DNA-nicking activity among the 
series studied.  Studies with radiolabeled DNA duplexes reveal that AZB037 
generates non-selective frank DNA strand breaks. Reaction with 5’-end labeled short 
DNA duplexes demonstrated the formation of 3’-phosphoglycolate termini products, 
indicating that deoxyribosyl 4’-hydrogen atom abstraction is involved in the DNA 
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cleavage. Moreover, this compound shows G-selective DNA cleavage after 
piperidine/heat treatment involving DNA oxidation and the formation of 8-oxo-
deoxyguanine. This is the first report of enediyne-like radical-based DNA cleavage 
by an agent designed to undergo an alternative diradical-generating cyclization.    
Due to the simplicity of preparation of these pyridinium skipped aza-
enediynes, they are attractive for further optimization; such as, incorporation of these 
DNA cleavage moieties into DNA-recognition elements. For example, NSC-101327 
is a d(A•T) specific minor groove DNA binding agent. It has been suggested that its 
central part is involved in specific hydrogen bonding to dA•dT pairs, and the 2-
pyridinium units are believed to be responsible for interaction with the negatively 





 Figure E-1  NSC-101327 
 
The marriage of a pyridinium skipped-aza-enediyne AZB037 and simplified 
NSC-101327 structure is predicted to be a new molecule that could be expected to 
bind to d(A•T), minor groove DNA,  directing the AZB037 portion to the site of 














Targeting SV40 T-ag G-quadruplex DNA helicase activity by G-quadruplex 
interactive Agents. 
DNA helicases enzymatically unwind DNA to facilitate strand separation 
required for transcription, DNA repair and replication. In addition to their well-
characterized duplex unwinding activity, certain RecQ helicase have been shown to 
unwind G-quadruplex DNA structures. A prototypical replicative helicase, SV40 T-
ag, was confirmed to have the ability to unwind G-quadruplex DNA structures with a 
comparable activity to unwind duplex DNA. SV40 genome was analyzed for the 
potential intramolecular G-quadruplex formation and shown to have a number of 
putative sites capable of forming intramolecular G-quadruplex DNA, especially at the 
promoter regions, close to the origin of replication.  
A number of G-quadruplex interactive agents as well as perylene diimide 
derivatives were investigated as inhibitors of both the G-quadruplex and duplex DNA 
helicase activities of T-ag. Studies of T-ag G-quadruplex helicase inhibition 
suggested that specific binding interaction of ligands to the DNA substrates, kinetics 
of dissociation and ligand–G-quadruplex complex and binding stoichiometry of the 
ligands may play a role in the effectiveness of helicase inhibition. Moreover, perylene 
diimide Tel11 was shown to be a potent and highly selective G-quadruplex T-ag 
helicase inhibitor.  This finding could provide a tool for probing the specific role of 
this activity in SV40 replication.  Besides, the interaction of T-ag with G-quadruplex 
DNA is expected to be different from RecQ helicases, involving a conserved RQC 
domain. T-ag does not contain a RQC domain or any other known G-quadruplex 
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binding motif. Further supporting this theory, the different classes of G-quadruplex-
interactive ligands inhibit these two G-quadruplex helicase activities differently. 
Nevertheless, the inhibition studies of G-quadruplex-helicase activity of T-ag 
were conducted using G’2, dimeric G-quadruplex structure. The unimolecular G4’ 
would be expected to be more pertinent to the existence of G-quadruplex DNA in 
SV40 genome. With the assay conditions used, there is a technical limitation that 
precludes the use of G4’ as a helicase substrate because single-stranded 
oligonucleotides containing G4’-forming sequence readily forms G-quadruplex 
structure after the denaturing or unwinding processes. Therefore, the two species, G4’ 
substrates and single-stranded unwinding products could not be separated or 
differentiated. The Raney lab has shown the displacement of streptavidin from 
biotinylated oligonucleotides by DNA helicases, gp1, Dda,5, 6  hepatitis C virus NS3 
and SV 40 T-ag.7 Translocation of T-ag along the streptavidin-bound 5’-biotinylated 
oligonucleotides demonstrated the unloading of streptavidin from bound 5’-
biotinylated oligonucleotides. A gel mobility shift assay was successfully utilized to 
separate biotinylated oligonucleotides bound by streptavidin from free biotinylated 
oligonucleotides. Thus, streptavidin-bound 5’-biotinylated G4’ could be used as a 
substrate for SV 40 T-ag helicase. Determination of unwinding products could rely on 
the analysis of streptavidin-free 5’-biotinylated oligonucleotides using the same 
mobility shift assay. However, further details of assay conditions need to be 
investigated. Of utmost concern is the need to establish that the displacement of 
streptavidin from biotinylated G4’ is really a representation of helicase activity. 
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The other interesting question to be asked is what the role of G-quadruplex 
DNA structure in DNA replication of SV40 is. Based on the data presented in this 
dissertation, we have certain tools, such as the selective G-quadruplex interactive 
agents, like Tel11, which is a specific inhibitor and other inhibitors of SV40 T-ag 
unwinding of G-quadruplex DNA structures. Preliminary investigations may be 
performed by using well-established SV 40 based in vitro replication models,8, 9 and 
the DNA synthesome, a recently described in vitro model system to study replication 
in S-phase.10, 11   
In conclusion, this dissertation deals with the field of medicinal chemistry 
focused on DNA-Drug interaction. One of the aims is to damage DNA by designed 
agents, which is a part of the process of developing DNA cleavage agent for anti-
cancer drug discovery. The other goal is to search for potent and specific interacting 
agents for G-quadruplex DNA which could serve as tools for understanding the 
specific roles of G-quadruplex DNA structures and G-quadruplex interacting proteins. 
They could also be used to inhibit certain cellular processes which involve G-
quadruplex DNA. It is hoped that the studies presented herein will have made some 
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reaction of 3-Phenyl-2-propyn-1-ol. To a solution of  3-Phenyl-2-propyn-1-ol  in 30 
mL dry THF was added triphenyl phosphine (0.66 g, 2.5 mmol) and 2-
bromobenzimidazole (0.48 g, 2.5 mmol). The mixture cooled to 0 º C was added 
dropwise diethyl azodicarboxylate (0.44 g, 2.5 mmol). The reaction mixture was 
stirred at 0 º C for 3 h, the solvent was removed by distillation and the product was 
purified by flash chromatography over silica gel eluting with 1% MeOH in CH2Cl2   
and the product was recrystallized from ethyl acetate/hexane to afford analytically 
pure material (0.75 g, 95% yield). 1H NMR δ: 5.21 (s, 2 H), 7.29-7.44 (m, 7 H), 7.58 
(d, 1 H, J = 6.6 Hz), 7.77 (d, 1 H, J = 8.4 Hz). 13C NMR δ: 35.9, 80.9, 85.5 109.8, 
119.5, 121.6, 122.9, 123.5, 128.3, 128.9, 129.4, 131.8, 135.1, 143.1. MS (CI) m/z: 


















































Sonogashira Couplings with 2-Bromo-1-(3-phenyl-prop-2-ynyl)-1H-benzoimidazole. 
A 25 mL three-necked flask equipped with a condenser was purged with argon and 
quickly fitted with a U-shaped adapter connected to a 5 mL round-bottomed flask 
charged with Pd(PPh3)2Cl2 (0.015 g, 0.02 mmol). CuI (0.003 g, 0.02 mmol), 
triethylamine (5 mL), phenyl acetylene-2-13C (0.05 g, 0.54 mmol), and 2-Bromo-1-
(3-phenyl-prop-2-ynyl)-1H-benzoimidazole (0.13 g, 0.40 mmol) were placed into the 
reaction flask. The reaction was initiated by the addition of the palladium catalyst, 
and the reaction mixture was heated under reflux for 10 h. The reaction mixture was 
filtered through activated alumina, which was subsequently washed with EtOAc. The 
combined filtrate was washed with saturated NaHCO3, water, and brine. The solvent 
was dried (Na2SO4) and evaporated, and the product was purified by flash 
                                                 
1 1H and 13 C spectra: David, W. M. Studies of a new class of aza-enediynes: aza-
bergman cyclization and the potential use of aza-enediynes as antitumor agents. 
2000.; David, W. M.; Kumar, D.; Kerwin, S. M., Synthesis of a heterocyclic aza-




chromatography (siliga gel, 30% EtOAc in hexane) afforded 0.07 g (50% yield) of 












































1-ium Triflate.ii Methylation of benzimidazole with methyl triflate was followed 
general procedure of alkylation of pyridine, obtained as an off white solid (0.06 g, 















                                                 
ii 1H and 13 C spectra : David, W. M. Studies of a new class of aza-enediynes: aza-
bergman cyclization and the potential use of aza-enediynes as antitumor agents. 
2000.; David, W. M.; Kumar, D.; Kerwin, S. M., Synthesis of a heterocyclic aza-
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1 gcctcggcct ctgcataaat aaaaaaaatt agtcagccat ggggcggaga atgggcggaa 
61 ctgggcggag ttaggggcgg gatgggcgga gttaggggcg ggactatggt tgctgactaa 
121 ttgagatgca tgctttgcat acttctgcct gctggggagc ctggggactt tccacacctg 
181 gttgctgact aattgagatg catgctttgc atacttctgc ctgctgggga gcctggggac 
241 tttccacacc ctaactgaca cacattccac agctggttct ttccgcctca gaaggtacct 
301 aaccaagttc ctctttcaga ggttatttca ggccatggtg ctgcgccggc tgtcacgcca 
361 ggcctccgtt aaggttcgta ggtcatggac tgaaagtaaa aaaacagctc aacgcctttt 
421 tgtgtttgtt ttagagcttt tgctgcaatt ttgtgaaggg gaagatactg ttgacgggaa 
481 acgcaaaaaa ccagaaaggt taactgaaaa accagaaagt taactggtaa gtttagtctt 
541 tttgtctttt atttcaggtc catgggtgct gctttaacac tgttggggga cctaattgct 
601 actgtgtctg aagctgctgc tgctactgga ttttcagtag ctgaaattgc tgctggagag 
661 gccgctgctg caattgaagt gcaacttgca tctgttgcta ctgttgaagg cctaacaacc 
721 tctgaggcaa ttgctgctat aggcctcact ccacaggcct atgctgtgat atctggggct 
781 cctgctgcta tagctggatt tgcagcttta ctgcaaactg tgactggtgt gagcgctgtt 
841 gctcaagtgg ggtatagatt ttttagtgac tgggatcaca aagtttctac tgttggttta 
901 tatcaacaac caggaatggc tgtagatttg tataggccag atgattacta tgatatttta 
961 tttcctggag tacaaacctt tgttcacagt gttcagtatc ttgaccccag acattggggt 
1021 ccaacacttt ttaatgccat ttctcaagct ttttggcgtg taatacaaaa tgacattcct 
1081 aggctcacct cacaggagct tgaaagaaga acccaaagat atttaaggga cagtttggca 
1141 aggtttttag aggaaactac ttggacagta attaatgctc ctgttaattg gtataactct 
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1201 ttacaagatt actactctac tttgtctccc attaggccta caatggtgag acaagtagcc 
1261 aacagggaag ggttgcaaat atcatttggg cacacctatg ataatattga tgaagcagac 
1321 agtattcagc aagtaactga gaggtgggaa gctcaaagcc aaagtcctaa tgtgcagtca 
1381 ggtgaattta ttgaaaaatt tgaggctcct ggtggtgcaa atcaaagaac tgctcctcag 
1441 tggatgttgc ctttacttct aggcctgtac ggaagtgtta cttctgctct aaaagcttat 
1501 gaagatggcc ccaacaaaaa gaaaaggaag ttgtccaggg gcagctccca aaaaaccaaa 
1561 ggaaccagtg caagtgccaa agctcgtcat aaaaggagga atagaagttc taggagttaa 
1621 aactggagta gacagcttca ctgaggtgga gtgcttttta aatcctcaaa tgggcaatcc 
1681 tgatgaacat caaaaaggct taagtaaaag cttagcagct gaaaaacagt ttacagatga 
1741 ctctccagac aaagaacaac tgccttgcta cagtgtggct agaattcctt tgcctaattt 
1801 aaatgaggac ttaacctgtg gaaatatttt gatgtgggaa gctgttactg ttaaaactga 
1861 ggttattggg gtaactgcta tgttaaactt gcattcaggg acacaaaaaa ctcatgaaaa 
1921 tggtgctgga aaacccattc aagggtcaaa ttttcatttt tttgctgttg gtggggaacc 
1981 tttggagctg cagggtgtgt tagcaaacta caggaccaaa tatcctgctc aaactgtaac 
2041 cccaaaaaat gctacagttg acagtcagca gatgaacact gaccacaagg ctgttttgga 
2101 taaggataat gcttatccag tggagtgctg ggttcctgat ccaagtaaaa atgaaaacac 
2161 tagatatttt ggaacctaca caggtgggga aaatgtgcct cctgttttgc acattactaa 
2221 cacagcaacc acagtgcttc ttgatgagca gggtgttggg cccttgtgca aagctgacag 
2281 cttgtatgtt tctgctgttg acatttgtgg gctgtttacc aacacttctg gaacacagca 
2341 gtggaaggga cttcccagat attttaaaat tacccttaga aagcggtctg tgaaaaaccc 
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2401 ctacccaatt tcctttttgt taagtgacct aattaacagg aggacacaga gggtggatgg 
2461 gcagcctatg attggaatgt cctctcaagt agaggaggtt agggtttatg aggacacaga 
2521 ggagcttcct ggggatccag acatgataag atacattgat gagtttggac aaaccacaac 
2581 tagaatgcag tgaaaaaaat gctttatttg tgaaatttgt gatgctattg ctttatttgt 
2641 aaccattata agctgcaata aacaagttaa caacaacaat tgcattcatt ttatgtttca 
2701 ggttcagggg gaggtgtggg aggtttttta aagcaagtaa aacctctaca aatgtggtat 
2761 ggctgattat gatcatgaac agactgtgag gactgagggg cctgaaatga gccttgggac 
2821 tgtgaatcaa tgcctgtttc atgccctgag tcttccatgt tcttctcccc accatcttca 
2881 tttttatcag cattttcctg gctgtcttca tcatcatcat cactgtttct tagccaatct 
2941 aaaactccaa ttcccatagc cacattaaac ttcatttttt gatacactga caaactaaac 
3001 tctttgtcca atctctcttt ccactccaca attctgctct gaatactttg agcaaactca 
3061 gccacaggtc tgtaccaaat taacataaga agcaaagcaa tgccactttg aattattctc 
3121 ttttctaaca aaaactcact gcgttccagg caatgcttta aataatcttt gggcctaaaa 
3181 tctatttgtt ttacaaatct ggcctgcagt gttttaggca cactgtactc attcatggtg 
3241 actattccag ggggaaatat ttgagttctt ttatttaggt gtttcttttc taagtttacc 
3301 ttaacactgc catccaaata atcccttaaa ttgtccaggt tattaattcc ctgacctgaa 
3361 ggcaaatctc tggactcccc tccagtgccc tttacatcct caaaaactac taaaaactgg 
3421 tcaatagcta ctcctagctc aaagttcagc ctgtccaagg gcaaattaac atttaaagct 
3481 ttccccccac ataattcaag caaagcagct gctaatgtag ttttaccact atcaattggt 
3541 cctttaaaca gccagtatct ttttttagga atgttgtaca ccatgcattt taaaaagtca 
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3601 tacaccactg aatccatttt gggcaacaaa cagtgtagcc aagcaactcc agccatccat 
3661 tcttctatgt cagcagagcc tgtagaacca aacattatat ccatcctatc caaaagatca 
3721 ttaaatctgt ttgttaacat ttgttctcta gttaattgta ggctatcaac ccgcttttta 
3781 gctaaaacag tatcaacagc ctgttggcat atggtttttt ggtttttgct gtcagcaaat 
3841 atagcagcat ttgcataatg cttttcatgg tacttatagt ggctgggctg ttctttttta 
3901 atacatttta aacacatttc aaaactgtac tgaaattcca agtacatccc aagcaataac 
3961 aacacatcat cacattttgt ttccattgca tactctgtta caagcttcca ggacacttgt 
4021 ttagtttcct ctgcttcttc tggattaaaa tcatgctcct ttaacccacc tggcaaactt 
4081 tcctcaataa cagaaaatgg atctctagtc aaggcactat acatcaaata ttccttatta 
4141 acccctttac aaattaaaaa gctaaaggta cacaattttt gagcatagtt attaatagca 
4201 gacactctat gcctgtgtgg agtaagaaaa aacagtatgt tatgattata actgttatgc 
4261 ctacttataa aggttacaga atatttttcc ataattttct tgtatagcag tgcagctttt 
4321 tcctttgtgg tgtaaatagc aaagcaagca agagttctat tactaaacac agcatgactc 
4381 aaaaaactta gcaattctga aggaaagtcc ttggggtctt ctacctttct cttctttttt 
4441 ggaggagtag aatgttgaga gtcagcagta gcctcatcat cactagatgg catttcttct 
4501 gagcaaaaca ggttttcctc attaaaggca ttccaccact gctcccattc atcagttcca 
4561 taggttggaa tctaaaatac acaaacaatt agaatcagta gtttaacaca ttatacactt 
4621 aaaaatttta tatttacctt agagctttaa atctctgtag gtagtttgtc caattatgtc 
4681 acaccacaga agtaaggttc cttcacaaag atcaagtcca aaccacattc taaagcaatc 
4741 gaagcagtag caatcaaccc acacaagtgg atctttcctg tataattttc tattttcatg 
 349
4801 cttcatcctc agtaagcaca gcaagcatat gcagttagca gacattttct ttgcacactc 
4861 aggccattgt ttgcagtaca ttgcatcaac accaggattt aaggaagaag caaatacctc 
4921 agttgcatcc cagaagcctc caaagtcagg ttgatgagca tattttactc catcttccat 
4981 tttcttgtac agagtattca ttttcttcat tttttcttca tctcctcctt tatcaggatg 
5041 aaactccttg cattttttta aatatgcctt tctcatcaga ggaatattcc cccaggcact 
5101 cctttcaaga cctagaaggt ccattagctg caaagattcc tctctgttta aaactttatc 
5161 catctttgca aagctttttg caaaagccta ggcctccaaa aaagcctcct cactacttct 
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